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SUMMPR( 
The main purposes of this work is to search, on an empirical and 
semiempirical M. 0 basis for quantitative structure / activity 
relationships (QSAR's) relating the drug activity of agiven type of 
molecule to indices of its biochemical reactivity. Ibe utility of such 
study lies in its ability both to ellucidate the mechanism of drug 
action, and to predict the drug activity of an untested molecule of the 
Same type. Most of the reactivity indices used in this, work are 
electronic properties of the molecule, obtained from CNDO/2 and INDO MO 
calculations. 
In chapter one, the basis for using the form of QSAR known as the linear 
free energy relationship ( LFER ) to explain in vivo and in vitro drug 
activities is discussed. 
Chapter two introduces SCF MO theory and the ZDO approximation. The 
types of indices which may be calculated from SCF wavefunctions are 
explained, along with their pharmacological applications. The 
electrostatic potential of a drug molecule, relevant to its interaction 
with the receptor, is introduced. 
MO calculations and regressions on a series of antitumour platinum(II) 
complexs are described in chapter three. The Dihydrofolate reductase 
inhibitors and some irreversible enzyme inhibitions are considered in 
chapters four and five. The mutagenic and antitumour activities of 
acridine and some diacridines are disscused in chapter six. Chapter 
sevEn is a discussion of the implications of the present work to drug 
iii 
design and scope for future work. 
The numerical ccmputations are carried out on the ICL 1905 F machine at 
the university of Surrey computing unit, and on the CDC 7600 ccmputer of 
the university of Manchester Regional Computing Centre (UMRCC). 
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CHAPrER CNE 
1 
PHYSICOCHEMICAL PROPERTIES OF MOLECULES IN RELATION TO DRUG DESIGN 
1.1 Introduction 
The relationship between the physiological action anJ chemical 
constitution of a compound is referrel to as the structure activity 
relationship (sAR). 
Most early attempts to correlate changes in molecular structure with 
changes in drug activities were empirical ani qualitative. 
Ideally, a quantitative Jescription of the SAR should shed light on the 
mechanism of Jrug action at the molecular level and be able to pre3ict 
the drug activity of an unteste-i molecule. 
The r3rug activity of a compound is suitably expressed as the negative 
logarithm of the concentration C of Irug requireJ to elicit a defined 
response in a given biological system. 
drug activity =- log C= pC (1.1) 
Here C is the average concentration in moles or millimoles per kilogram 
of biological system required to elicit the defined response. 
Quantities commonly represented by C are : 
Lethal dose concentrations LDn, where n is the percentage of animals 
killed at that dose. Similarly, effective or inhibitory concentrations 
are denoted EDm or ID.., respectively, where m is a given percentage of 
2 
enzyme inhibition or increase in life span produced by the drug. The 
therapeutic index (T. I) is the ratio of a lethal Jose (such as LD§O) to 
an inhibitory Jose (such as ID 
90 
), and this inlicates the selectivity of 
the Jrug. The higher the T. I, the greater the therapeutic value of the 
dr ug. 
Crum-Brown and Fraser's (1) studies on molecules of pharmacological 
interest, showed that the gradual chemical modification in molecular 
struture of a series of poisons produced some important differences in 
toxicity. They postulated that the physiological action ( 0), as 
measured by the observed biological response (BR), of a molecule is some 
function of its chemical structure. 
BR = 
1.2 Drug-receptor interaction 
(1.2) 
For every drug there is a target substance or "receptor" in a given 
biological system. The concept of the receptor was developed by Ehrlich 
(2), who uttered the famous phrase "Corpora non agunt nisi fixata" 
(Drugs do not act unless they bind). Meaning that a drug molecule must 
bind to the protoplasm in order to produce a response in the organism. 
In view of the great structural specificity required of a drug molecule 
associated with a certain biological response, Ehrlich assLrne3 that the 
protoplasm has certain specific side chains each capable of binding a 
particular type of molecule. 
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According to the wdern theory of molecular pharmacology (3) the 
receptor is envisaged as a region of an indigenous macromolecule, such 
as enzyme protein or nucleic acid, with special binding properties. 
most drugs combine reversibly with the receptor, and act at the 
molecular level by one of the following mechanisms: activation or 
inhibition of enzymes, suppression of gene function, chelation. Drugs 
acting on enzymes can either activate or inhibit them. There are two 
main types of inhibition: competitive and non-competitive. In the case 
Of Competitive inhibition of a natural enzyme catalysed process, this 
binding alone is enough to produce the biological response. In other 
cases the macromolecule containing the receptor undergoes a 
configurational change as a result of the binding, and this elicits a 
chain reaction of conformational changes which eventually leads to the 
"effect". The stereospecificity of the drug molecule is commonly 
rationalised solely in terms of its interactioa with the receptor, this 
being sufficient to elicit the response. 
In order to understand the mode and mechanism of drug action, it is 
important to know the types of interaction that bind drugs to their 
receptors. Reversible interactions between the drug and receptor are 
usually Possible only when the molecular surfaces have complementary 
structures, i. e when a positive charge on one surface corresponds to a 
negative charge on the other surface. The majority of drug-receptor 
interactions are expected to be charge controlled (4). Bond strength 
depends on the distance that separates two particular atoms. At the 
optimal distance, the strongest bond is formed. The greater the 
reduction in free energy, the higher the proportion of receptor-bonded 
drug. This can be deduced from the free energy changes of the reaction, 
using the following equation : 
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K= ex p-A G/RT (1.3) 
where AG is the free energy of reaction, K the equilibriLin constant, 
R the universal gas constant, and T the absolute temperature. 
Clark (5) and Gaddum (6) advanced the simplest theoretical model of drug 
receptor interactions. They gave a quantitative model of the 
drug-receptor concept, and introduceJ the occupancy theory, which states 
that the intensity of a pharmacological effect is directly proportional 
to the number of receptors occupiel by the drug. This may be 
represented by the following equation : 
ki 
D+ R-DR -E 
k2 
where R is a receptor, Da molecule of the drug, DR the drug-receptor 
complex, E the pharmacological effect, ani k, and k2 are the rate 
constants of adsorption and desorption respectively. 
The effect of pharmacological action is proportional to the 
concentration of DR, so that: 
k3 [DR] (1.5) 
where k3 is the factor of proportionality. In the state of equilibriun: 
[R] [D] / [DR] = k2 / k, (1.6) 
where Kd is the dissociation constant of the drug-receptor c(xnplex, 
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[DI represents the molar concentration of free ]rug in equilibriun with 
the receptors, [RI is the molar concentration of free receptors, anJ [DR] 
is the molar concentration of Irug-receptor complex. 
The total concentration of the receptor is : 
[R 
tot 
I= [RI + [DR] (1.7) 
When all receptors are occupiel the biological effect is maximal 
Em= k3[R bot 1 
Dividing equation (1.5) by equation (1.8) we obtain : 
E/ Em = [DR] / [R tot 
I=1/ (1 +kd/ 
Hence 
Em [D] /(+ (1 " 10) 
This equation is ilentical to the classical equation of Michaelis and 
Menten 
Vm IS] /( IS] +km) (1.11) 
wtiich gives the rate V of an enzyme catalyzed reaction as a function of 
the concentration Of the substrate [S], of the maximal rate Vm , ani the 
dissociation constant k. of the enzyme substrate complex. At 50% 
response, E/ Em = 0.5 and equation (1.9) becomes: 
0 
0.5 =1/ (1 +kd/ [DISO ) (1.12) 
so that 
kd ý- [D]5 0 
Two quantites are used to specify the activity of a drug on its 
receptors : 
1. The affinity of the drug for these receptors, which may be 
identified with the equilibrium constant kd for a given drug-receptor 
combination. 
2. The ability of the drug to inJuce in the receptor the changes 
required to produce the observed biological effect, termed "intrinsic 
activity" by Ariens (8) and "efficacy" by Stephenson (9). 
The in vitro systems of lirect interest in this thesis contain either 
mammalian or bacterial tissue. Fbr a simple enzyme-substrate reaction 
(observed in vitro) , the quantity pC is usually linearly related to the 
logarithm of one or two equilibrium or rate constait. 3. For example, the 
ability of a given competitive enzyme inhibitor (D) to compete with a 
prime substrate (S) of enzyme (E), is likely to depen] on the relative 
equilibrium constants for binding to the enzyme. 
ES 
E+S+D 
k 'dýý ED 
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[ED] / [ES] =kd [DI /ks IS] (1.14) 
where [ED] is the molar concentration of enzyme-drug complex, [ESI is 
the molar concentration of enzyme-substrate complex, kd and ks are the 
equilibrium constants for enzyme-drug and enzyme-substrate interactions 
respectively, and [D] and [S) are the concentrations of free drug and 
substrate, respectively. 
For 50% inhibition [ED] = [ES) and equation (1.14) beccxnes : 
[D501 =ks (S] / (1.15) 
Here [D501 is the molar concentration of drug required to produce 50% 
inhibition of the enzyme-substrate reaction. Taking logaritkins of both 
sides of equation (1.15) , we obtain : 
-10g[D501 = logk d- 
log (k 
s 
[S] ) 
where kd is dependent on given drug properties, ani relates to the free 
energy changes of the reaction (equation 1.3). Substituting this 
equation into equation (1.16), the relationship becomes : 
-109[D. 5o] = -2.303 AG d/ RT - 
log (k 
s 
[S]) (1.17) 
In the in vivo stLAy i. e the stLAy of the effect of the drug on a living 
organism, it is necessary to consider, in addition to drug-receptor 
interaction, "absorption", "distribution" and "elimination". These 
three processes influence the drug concentration within the body fluids. 
They constitute the f ield of pharmacokinetics. 
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Conversely, the resultant effect of the drug on the organism is the 
object of pharmacodynainics. Because the pharmacokinetics of a drug 
determine its concentration at the receptor site, the pharmacodynamics 
of a drug in vivo are largely determined by its pharmacokinetics. 
Whether Jealing with in vitro drug activities, or more complex in vivo 
activities, a more general equation may be used in place of equation 
(1.17) 
PC AGt + a. AG. 
133 
where i and j are taken over all the rate anJ equilibriun processes 
involved. AG*' is the ith activation free energy, AGk. is the ith free 13 
energy of reaction. ai p, a and b are system parameters. 
Equation (1.18) is not exact for every biological pathway. In going 
from the parent drug to a substituted derivative, changes 6(AG. ) and 
1 
6( AG ) occur in the pertinent free energies. The drug activity, which 
goes from pCoto pC upon substitution, may be expressed using a Taylor 
expansion. Truncated after the first or3er term, this expression is: 
PC ý-- PCO +6 (A G*j J (PC)/ a( A G*) +6 (ýG. ) a (pQ/JIýQ 
Hence the general definitions of the system parameters appearing in 
equation (1.18) are : 
3(PC) /3 (AG* 
il 
aj =a (PC) /a (A Gi) 
9 
b= pC ai (A G *i)p - i, (AG i) i 
where the subscript "p" specifies the parent Compouni. 
Note, in equation (1.18) that any change in units of concentration will 
be reflected in a change in b, whereas any change in energy units will 
be reflected in changes in the ai and aj . 
Many attempts to clarify the active region of a receptor and its 
chemical nature have remained incomplete. The receptor is probably a 
limited portion of a macromolecule, usually protein, probably similar to 
an enzyme or antibody. Sometimes it is described as a lipoprotein 
component of a membrane of high molecular weight. Some drugs react with 
nucleic acids in ways thatmake the nucleic acid their receptor. 
The receptors are assumed to lie in a compartnent c. il-Led the "biophase", 
as distinguished from the "exobiophasell which is a bath fluid separated 
from the biophase by soate form of barrier (10). The penetration of drug 
into a biological system involves the crossing of lipophilic barriers 
between aqueous exo- and endo-biophases. 
In early works Mayer (11) and Cverton (12) use] the partitioning of a 
drug between oil and water to represent the partioning between the 
biophase and exobiophase. Hence, parallels between the narcotic 
activity and the oil/water partition coefficient were observed for 
various series of compounds. 
In studies of narcotic agents, Traube (13) observed a relationship 
between the surface tension of compounds an. 3 the-Lr narcotic activity. 
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Moore (14) usel another physiochemical parameter in structure activity 
studies. He observed that the toxicity to insects of the vapour of an 
organic compound is directly related to its boiling point. 
Ferguson (15-17) rationalized the interlationship of the early structure 
activity studies using a simple thermodynamic principle. The addition 
of CH 2 units 
in passing along a series produces a regular change in many 
physical properties. He suggested a general form for the relationship 
which could be used to correlate a large portion of the data on toxic 
action of different sets of congeners under equilibrium conditions. 
K Am 
i 
wher e: Ci is the concentration of the ith member of a series required 
to elicit a defined response; A. is the physical property used as a 
descriptive paraneter for the compound, such as solubility,, - vapour 
pressure or partition coefficient; K and m are constants for the 
series. Ferguson was able to calculate the toxic concentration C of a 
series of compounds from solubility and vapour presure Jata. Taking the 
negative logarithm of equation (1.19) yields : 
-109 C= alogA+b (1.20) 
where a= -m, and b= -log K. If A is a physicochemical parameter for 
the compound, such as partition coefficient, solubility, or an 
equilibrium constant for a reaction in a particular phase, then equation 
(1.20) becomes a linear free energy relationship (LFER). After 
replacing A by the equilibrium constant K, and employing equation 
(1.3), we get : 
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-109 C=(a/2.303 RT )AG0+b (1.21) 
In other circumstances it might be appropriate to identify A with a 
particular rate constant k. The rate constant is logaritýmically 
related to the free energy of activation, AG* , for the reaction (18): 
k= k- Rr / No h exp -A G*/RT (1.22) 
where k is the trananission coefficient for the reaction, AG* is the 
activation energy of the reaction, No is Avogairo's number, and h is 
Planck's constant. 
log k=-2.303 A ORT + 1019 K FG / No h 
Hence, the empirical relationship of Ferguson is consistent with 
equation (1.18). 
1.3 De Novo approach to biological SAR's 
The chemical reactivity of a substance may be quantitatively related to 
its drug activity on an empirical basis. For a given series of 
molecules of known drug activity, with a common sfeletal structure anJ a 
range of different substituents, it is possible to predict the activity 
of a molecule with the same skeleton, anJ a new combination of the 
substituents in this range. This method of drug design was first used 
by Bruice et al (19) and appliel to the correlation of thyroxine-like 
activities of a series of congeners with the sm of constants assigned 
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to different molecular substituents. In a similar approach, Free and 
Wilson (20) definel the biological response as being equal to the sum of 
contributions to the activity of the substituent groups plus the overall 
average activity (@), which might be attributed to the activity of the 
parent structure. 
BR = (substituent group contribution )+ 
The major limitation of the Free-Wilson method is that the activity 
contributions of the substituent must be additive. 
Kopecky, Becek and Vlachova (21) introduced a similar mathematical QSAR 
based upon a multiplicative as well as an additive model. 
The De Novo method may be useful for predictive purposes but sheds no 
light on the mechanism of drug action. In order to relate effect to 
cause, the substituent constants used in QSAR's may have a wider 
physical significance. The substituent constants used in the LFER 
approach are defined accoriing to the effect of a given substituent on a 
standard equilibriLm or rate process. 
1.4 Substituent constants usei in linear free energy relationships 
To explain the differences in reactivity within a series of closely 
related compounds, physical organic chemists use the LFER approach 
(21-23). Accordingly, the rate constant or equilibriun constant for a 
reaction involving a substituted compound Rx , is predicted relative to 
that of the unsubstitutei parent, RH , by the formula : 
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log f K(RX )/ K(R H) 1= Pcý (1.23) 
wher e: p is the reactim constant depenlent an the type and conJ it ion of 
the reaction as well as the nature of R. a is a constant which is 
lependent on the nature anJ position of the substitution. 
In the Hammett equation (1.23), a represents the electronic effect of 
placing substituent X in a position meta or para to the reactive centre 
on the phenyl ring (24,25). It is Jefined, by the effect of X on the 
dissociation constant KA, of benzoic acid. 
ax= log [KA (X-C 6 H4CCOH) 
/KA (C 
6 H4 
COOH) 1 (1.24) 
It is eviJent that the larger a, the greater the electron withdrawing 
x 
influence of x. 
Taft (26) extended Hamett's approach by separating the electronic and 
steric effects of substituents in aliphatic compounds. The electronic 
substituent constant, a* , is Jefined by : 
1/2.48 [ log (KX /KH )B - lcýg (K X/KH 
)A (1.25) 
where: KX and KH are rates of hydrolysis of esters of the type 
X-CH2COD-Et and H-CH2COD-Et respectively, and the sLbscripts "B" and "A" 
indicate hydrolyses in basic and acidic solutions respectively. The 
term log(KX / KH )Bcontains both electronic and steric effects of the 
substituent, while log(K 
x/KH)A 
contains only the steric: effect. The 
difference between these two terms yields the electronic effect. The 
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factor 1/2.48 in equation (1.25) is simply to place a* on the same 
scale as a (26). 
The Taft steric substituent constant Es j which may be used as a measure 
of the steric impact of a given substitution, is defined by : 
ES(x) = log (KX/KH)A (1.26) 
Charton (27) has shown by reference to a simple series of substituents 
that Es is linearly related to the Van der Waals radius (r v and 
iniepenient of the electronic effect. Three types of Van der Waals 
radii are considered. rv(min), rv(max) and rv, these being appropriate 
to different orientations of the given group. All three give similar 
relationships with Es , but rv(min) is preferred, because groups favour 
orientations which minimize the degree of steric interactions. 
Antiparasital activity (28,29) , antibacterial activity (30), 
insecticidal activity (31), and antitmour activity (32), have all been 
successfully correlatel with a 
Most drugs cross body meabranes by simple Jiffusion. The speed of 
passing depen: Js on the relative solubilities of the : Jrug in the aqueous 
and lipid phases. In cases when the drug is a weak acid or base, cell 
membranes are preferentially permeable to the lipid soluble, unionized 
form. The fraction of the total drug concentration which is. present in 
the unprotonated form (i. e ionized in the case of a weak acid and 
unionized in the case of a weak base), is proportional to the 
dissocoation constant (Ka. ). The negative logaritým pKa is proportional 
to the free energy of protonation. 
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If active transport is not involved, then diffusion through the membrane 
barrier is controlled by thermodynamic factors, in particular the free 
energy change on passing from one phase to another. If P is the 
partition coefficient of the drug between the lipid xnA aqueous phases, 
then this free energy change is proportional to log P. It has been 
observed (33-37) that log P is an additive-constitutive molecular 
property. Accordingly, it is possible to assign a fraction of log P 
denoted7T 
x, 
to a given portion x of the molecular structure. Tr x 
remains fairly constant throughout a series of species containing x. 
The value of 7T associated with a chloro group might be calculated thus: 
Tf C, ý 
log P(chlorobenzene) - log P(benzene) (1.27) 
Trcl = 2.84 - 2.13 = 0.71 (1 " 28) 
The sLbstituent constant iT is Ienote3 PI in subsequent chapters, to 
avoide the confusion with TT-electrons. The 7T valu, -%s are very useful 
when examining a series of molecules with the same skeletal structure 
but different substituents, since the log P value of each is then simply 
a constant plus the value of its substituent. 
Swain ard Lupton (38) suggest two electronic substituent effects, 
defining field (f ) arvi resonance (R ) components, to be measures of the 
inductive and resonance effects respectively. Coats, Glave and Hansch 
(39) use these paraneters in their study of sLbstituted uracils as 
thymidine phosphorylase inhibitors. 
With a view to explaining the variation in C within a given series of 
Irug molecules, Hansch et al (40-42) have expandei the Hammett LFER 
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expression such that account is taken of three types of substituent 
properties : 
1. Electronic properties, described by a constants or other electronic 
substituent parameters. 
2. HyJrophobic properties, described by using a substituent partitioning 
paraneter Tr 
3. Steric properties which are described by the linear free energy 
paraneter Es. 
In some cases, the inclusion of E is not statistically justified, the 
s 
to p- a- iT " equation being appropriate 
log 1/C=kl 7T + PC + k2 (1.29) 
where C is the molar concentration necessary to elicit a defined 
biological response. ki and k2 are constants generated by regression 
analyses of the data. 
In other works, Hansch (43) has employed all three relevant substituent 
constants in the following model : 
log l/C =a 7T 
2+b Tr +pa+ c Es+ d (1.30) 
The 7T2 term is not a linear free energy term, but it has been justified 
by numerical experiments which determine the rate of passage of a drug 
through a multilayer system, with alternate water and lipid layers, as a 
function of log P (44). 
The passage of a drug between compartments of a biological system may be 
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impeded by its bulk. Size indices which have been useI in relationships 
with biological activity include the Van ier Waals radius (45,46) , its 
square root, molecular volume and cavity surface area. 
As well as using physicochemical properties to explain the variation in 
biological activity within a series of molecules, indices obtained from 
quantum chemical calculations may also be employeJ. A. Pullman and B. 
Pullman (48,49) have pioneered this approach, using MO calculations to 
interpret the properties of many biomolecules, and even to propose a 
mechaniEm for chemical carcinogenesis. 
Lowdin (50) has proposed a mechanism of Jeoxyribonucleic acid (DNA) 
replications baseJ on theoretical calculations. Kier (51-54) has 
postulated the nature of several biological receptors through quantum 
chemical calculations. The preferred conformation of a biologically 
active molecule, taken in isolation, is predicted and the minimum energy 
conformation is used to make JeJuctions about the complementary 
structure of its receptor. Kier's calculation of the preferred 
conformation of cortisol (55) has been confirmed experimentally by using 
infrared anJ nuclear magnetic resonance (rinr) techniques (56). These 
techniques are used in studies of Irug-receptor interactions at the 
molecular level. The changes in the cheatical shift observed in the nmr 
spectrum of the small molecule have been usel to investigate 
enzyme-substrate interactions (57) and enzyme-inhibitor interactions 
(58). 
in the present study, a broad view of molecular features relevant to 
drug design is taken. Quantities obtained from MO studies are used for 
the electronic characterization of molecules. Specifically, an 
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approximate ground state wlecular wavefunction is obtained for each 
molecule in the series. This permits the calculation of all ground 
state electronic properties considered to be of relevance to the drug 
activity, as well as the crude estimation of certain excited state 
properties. 
In addition, hydrophobic and steric features have been taken into 
account, the former by using tabulated values of the substituent 
constant 7T (59) . Steric properties are obtained by numer ical 
computation of the mean radius, surface area and volume of a solid 
representation of the molecule suggested by Bondi ý60). This 
representation is a conglomeration of spheres, each centred, on a given 
atom and with the observed Van der Waal's radius of that atom. 
The MO method and various reactivity indices used in this work are 
described in the next chapter. 
CHAPrER TWO 
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REACTIVITY INDICES AND THEIR USE IN PHARMACOLOGICAL SAR'S 
2.1 Introduction 
A quantitative description of the electronic structure of a molecule, 
deduce-] from MO calculations, is sufficient to obtain the neccessary 
information in many chemical ani physical problems. Currently there is 
considerable interest in the develop-nent of a good approximate MO theory 
of chemical reactivity anJ its application in pharmacological SAR's. 
The HGckel approximation (61) for conjugated molecules was one of the 
first to be used in the calculation of chemical reactivity indices. In 
this approximation only 7T electrons are consi-lerel explicitly anJ their 
mutual interaction is ignoreJ. The linear combination of a tom ic 
orbitals (LCAO) is chosen to be an approximation to the molecular 
orbitals of the system. The n 7T - MO's of a molecule are each expressed 
as a lifferent linear combination of n PZ atomic orbitals The 
molecular orbitals ip 1 
can be represented as : 
n 
where the C. (ji= 1 to n) are the coefficients associated with MO'i. 
pi 
The coefficients may be of either sign anJ may be real or complex 
nunbers. Using the variation principle to Jetermine the best values for 
the C 
.., we obtain 
the secular equations 
Pi 
(H 
Ijv - 
Ei S 
11V 
)c0 for all p and i. (2.2) 
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where S,,, represents the overlap of with With the neglect 
overlap, these reduce to : 
HC F- iC Vi 
for all P and i (2.3) 
Separation of valence orbitals into a anJ TT orbitals is only 
possible for planar systems. For non planar systems it is essential to 
treat all valence electrons in the same way. 
The "Extended H(ickel" (EH) method of Hoffmann (62) implies the 
equivalent treatment of all valence electrons, i. e all atomic orbitals 
of the valence shell of each atom are included in the LCAO. The method 
still ignores interelectronic interactions, but overlap is retained 
in the secular equation. 
The diagonal elements of the one electron Hamiltonian are assigned 
empirical values, while the off diagonal elements are calculated froin 
the corresponding elements of the overlap matrix by a Mulliken. type 
approximation (63). 
The retention of overlap means that a Mulliken population analysis (64) 
is used to define the valence electrons associated with a particular 
centre A in the molecule. 
n 
OV (A) IP 
pv 
S 
liv 
(2.4) 
p (A) v--l 
where P., is an element of the bond order matrix, Jefined by : 
00C 
P 
pv 
2C 
pi 
c 
vi 
(2.5) 
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and the elementsof the overlap matrix S,,, v are 
lefineJ by : 
pv = -cc pIv> 
(2.6) 
The symbols "p" and "v" refer to atomic orbitals, and the symbol "i" 
refers to the MO . 
The HCickel molecular orbital (HMO) and Extended Hi3ckel (EH) methods are 
of value in comparing series of closely related compounds, and are 
attractive because of their simplicity. Appropriate redefinitions of 
other simple Wickel reactivity indices, compatible with EH theory are 
given by by Lukov its et al (65) . 
The reactivity indices have been used in attempts to explain biological 
SAR's. Perault and Pullman (66) observed parallelism between the Hilckel 
charge and free valence of the amine nitrogen in some aryl amines, and 
the rate of enzymatic acetylation of these compounds. Bell and Roblin 
,. ko pta. (67) observed that the changes, %on the amide nitrogen of some 
sulphonamides effects the ordering of the bacterostatic activity. 
Encouraging correlations have been obtained from HUckel calculations 
with antitumour activity (68), hallucinogenic activity (69), 
antibacterial activity (70,71), and acety1cholinesterase inhibiting 
activity (72). 
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2.2 SCF MO theory and its application to pharmacological SAR's 
The neglect of interelectronic repulsion in the Hijckel method results in 
many practical defects (73). The calculated polarities in molecular 
charge distributions are exaggerated. This is apparent when the 
calculated dipole moments of molecules using Hdckel charge distributions 
are compared with the observed values (74). The H5ckel dipole moments 
of fulvene and azulene are 4.7 Debyes(D) and 6.9 D respectively, 
wheareas the observed values are 1.2 D and 1.0 D respectively. The EH 
method is similar to the H5ckel method in this respect (75). These 
defects mainly arise from the neglect of interelectronic interactions, 
a(A the assumption that a is the same for every atom. However, as an 
atom gathers a high electron density, it becomes less attractive to 
further electrons, so a becomes more no5btive. The first'and simplest 
method used to take this effect into account, within the HUckel 
framework, is an iterative method called the ". W-technique" (76). Using 
the w-technique the calculated dipole moment of azulene is reduced from 
6.9D to 3.8D (77). 
Ballhausen and Gray (79) first introduced all valence electron 
calculations with charge self-consistency. Iterative extended H6ckel 
(IEH) techniques, characterised by the charge Jepenience of the liagonal 
elements of the Hamiltonian, have also been used in SAR 
calculations (78). 
If interelectronic interactions are taken properly into account in the 
Schr6dinger formulation and the totalmolecular wavefunction is taken to 
be a closed shell Slater determinant i. e an antisymmetrized product of 
single electron states, in which pairs of spin states with oppsite spins 
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are represented by the swe spatial imolecular orbital, then the sun of 
electron-nuclear and interelectronic interactions is given by : 
E=2H+ (2 J K (2.7) 
where H (P) [-iv2 ZA /RAP) ýj (P) dT (p) (2.8) p A 
i ij 
ff (P) (q) 
p 
(P) (q) dT (p) dT (q) (2.9) 
q 
K (P) (q) ij 
ffi 1 
pq i 
(q) (P) dT (p) dT (q) (2.10) 
where i and j are each sumed over the nurber of the spatial MD's. 
_V2 p/2 is the kinetic energy operator for electron p. ZA is the charge 
on nucleus A. RAP is the distance between centre A and electron P and 
rpq is the distance between a pair of electrons p anJ q. 
The integrals J.. and K.. are referred to as the "coulomb" ani 
1] 1] 
"exchange" integrals respectively. 
It is usual in MO studies to obtain approximate solutions by expressing 
each MO as a LCAO (equation 2.1). Substituting for ý, in equation 
(2.7), we obtain : 
C* CH+j1 C*r -C C* -C [2 (, ov 
1 ýCO - (IJIJ 1 ý'» 1 
.i prv 
lii vi liv ij pvxö pl vi x] 
aj 
wbere i and j are each sumed over the nunber of occupiel ýU's. ii rV, ý 
ani a are each summed over all A. 0's in the basis set n. H., is an 
element of the core Hamiltonian matrix : 
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H (p) V2+ýZA R7L 3 ýX) (P) d -u (p) (2.12) pA 
and 
(pv lka) =* (P) ý (P) r- 1 ý* (q) ý (q) dT (p) dT (q) (2.13) f1 11 v pq Xa 
which is to be interpreted physically as the repulsion between an 
electron distributed in space accoriing to the function (p) and a 
second electron having a distribution (q) 
In applying the variation theorem to equation (2.11), and varying the 
components of each eigenvector, it is necessary to impose the condition 
that the MO's remain an orthonormal set. Ibe expression for the 
resultant optimum eigenvector has been Jerived by Halý (80) and 
Roothaan (81) : 
n 
IC (F -6 S)=0 (2.14) 
(for all p and all i 
where Fpv is the Fock Hamiltonian operator. 
FV, 
j =H liv 
+ 
.1P xcy 
(2.15) 
XG 
where P XU is the bond orJer which is JefineJ in equation (2.5). 
The necessity for the Mo's to form an orthonormal. set is explained by 
Roothaan (81). 
It is clear from equations (2.14) and (2.15) that no single coefficient, 
C 
Pi , can 
be expressel in3ependently of the others. It is therefore 
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necessary to determine them by an iterative process. The achievement of 
self-consistency in the element F pv 
indicates that the SCF situation has 
been reached. The set of atomic orbitals (A. 0's) used to constitute the 
MO's, via equation (2.1), is referred to as the "basis set". The 
smallest basis set which can be used in obtaining a solution to the 
Hall-Roothaan equations is referred to as a "minimal basis", to which 
each atom contributes all the A. 0's in each subshell which is occupied 
in the ground state of the atom. Such calculations are referred to as 
"ab-initio" calculations, and usually require a large amount of 
computing time. 
To reduce computational cost, all valence basis sets may be used. In 
such approximations, those electrons not explicity considered are 
grouped with the nuclei t3 form the atomic cores. The repulsive effects 
of these core electrons with the outer electrons are absorbed into the 
elements, H11v j, of the "core Hamiltonian" matrix. The exchange 
interaction between core and valence electrons on the sane centre are 
included in the H 
P11 0A 
large number of two-electron integrals remain to 
be evaluated. If Slater type atomic orbitals are used, the two electron 
integrals involving atomic orbitals on three or four lifferent centres 
are difficult to evaluate. To eliminate these, a "zero differential 
overlap" (ZDO) approximation (82) can be used, by which the product 
0 
11 
(p) ý (p) is taken to be zero everywhere unless P=V 
By applying the ZDO assumption we get : 
( 11 XI cy )=( ýj pIvv)6 -px 
6 
va 
6 
px 
6 
va Ypv 
(2.16) 
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where is kronecker Jelta 
liv 
anJ 
Y11V 
1 if =v 
30 v 
(2.17) 
The off-diagonal one electron integrals may also be eliminated with the 
ZDO approximation : 
s 
liv =6 pv 
III 
-pv =6 11V 
H 
11 p 
(2.19) 
Using equation (2.18), the Hall-Roothaan equation (2.14) can be reducej 
to the eigenvalue equation 
n 
F 
liv 
C\) E: 
Ic 
(2.20) 
Applying equation (2.19) to equation (2.20), we obtain : 
lip ill I pi 
Hence H 111, 
Therefore molecular orbital eigenvalues are identified with atomic 
orbital energies. For this reason the approximation expressed by 
equation (2.19) is not applicable. The resonance integrals, H,,, ) , which 
are the off-diagonal elements, carry the essence of covalent bonding 
into the formulation. 
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With approximation (2.16), equation (2.15) becomes : 
F 
lip 
H 
pil 
+jP Pil y Pil 
+ý Pvv YVV (2.22) 
VAI 
PlIv = ljv 
j 
liv Y liv (2.23) 
An SCF treatment of iT -MO systems based on equations (2.22) and (2.23) 
was first used by Pople (83), though a closely related formulation with 
a non-iterative method of solution, had been given earlier by Pariser 
ani Parr (84). The so called lePariser-Parr-Pople" (PPP) method is 
characterised by the use of experimental atomic lata in the estimation 
of H lip and y pil , and 
the use of values for H 11V which are contrived 
to 
give sensible solutions (85). The PPP method is the first of the 
"semieimpirical" SCF KO techniques. 
The drug molecules of interest in the present work Jo not have electron 
systems which can be partitioned into a and 7T electrons. For this 
reason all valence methods are used. The two approximate SCF MO methods 
appliel in the present work Jiffer mainly in the extent to which the ZDO 
approximation is usel for electron repulsion integrals. 
The CNDO/2 method has its theoretical basis in equations (2.22) anJ 
(2.23). Coulomb integrals are spherically averaged to maintain 
rotational invariance, and the off-diagonal elements, Hpv , are taken as 
zero if orbitals p and v are centred on the sane atam. The 
approximations and the details of the empirical parameterization, are 
described in reference (86). 
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More advanced than CNDO (Ccmplete Neglect Of Differetial Overlap) is the 
INDO (Intermediate Neglect Of Differential Overlap) method of Pople, 
Beveridge and Dobosh (87). In this method, mbnoatomic differential 
overlap is retained in one-centre two-electron integrals. Prior to the 
introduction of the spherical averaging approximation for the coulomb 
integrals, y 11V , 
the Roothaan equations take the following form : 
F 
Illi =H iiii 
+11 Pxcr [ (II1A 1 Xcy) -ý (A 1 lici) 1+ýý lý'(liv 
X (A) a (A) WA v (B) 
for all p on atom A (2.24) 
Y' pXaý("I ý(I) -ý (Ijý 1 ")(3) 3 
ci (A) 
for all ji and v on atom A, 0 76 v (2.25) 
F 
ljv =H pv 
P 
11V 
Ypv 
for p anJ v on different atoms (2.26) 
The the INDO parameterization closely resembles that of CNDO/2, as 
explained in reference (36). For the INDO/5R program, the details of 
the parameterization of platinum ani chlorine are given in reference 
(88) . 
It appears that DiDD may have advantages over CNDO/2, with regard to 
structure-activity work, particularly if geometry optimizations are 
required. In the original "CNINDO" program (39), the INDO option is 
only available for elements up to fluxine, whereas CNDO/2 is 
parametrized up to chlorine. Even in the later "CNDO/2 -3R" program 
(90) which puts non-metallic thirJ row elements insi-le the range of 
CNDO/2 calculations, the INDO parameterization is still only up to 
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fluorine. This is because of lack of sufficient spectral data to obtain 
the Slater Condon parameters necessary for estimating all the 
one-centre, two- electron integrals involving d orbitals. In the 
INDO/5R program, routines are inserted to calculate all necessary one 
centre, two electron integrals from the Slater A. 0's. This facility is 
lacking in the optimization progran "GEOMIN". The CNDO/2 method has 
been used to optimize most of the geometries for the series studied in 
the present work. Consequently the author used the CNW/2 wavefunctions 
in the chemical indices calculations, except for platinum complexes, 
where INM SCF wavefunctions are used. 
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2.3 Indices used in the present work 
A wile range of calculateI inJices are useJ in the present work. A 
variety of electronic properties are calculated from CNDO/2 or INDO 
wavefunctions. Electronic properties may be subdiqided into those 
associatel with : 
1. A single atomic centre X in the molecule : 
Q(X) , FE(X) , FN(X) , EBINDW , ALPHAW 
2. A pair of atomic centres X and Y (bond properties) 
ALPHA(X-Y) , QX + QY , E(X-Y) 
3. The molecule as a whole 
EHOMO, ELEMO, MU, ESTAT, mol, a -IP, B. E, Mum, I/DELTA, E cav 
Edis , Epoll, EP012 
A-Mitional routines are employed to calculate the mean molecular Van Jer 
Waals radius, surface area and volume. 
The following descriptions define the chemical reactivity indices 
mentioned above : 
1. Net charge ( 
Q(A) = Z(A) -Qv (A) 
where 
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QV (A) =211 C2 pi (2.26) 
ýi (A) iocc 
Cpi is the contribution of atoi-nic orbital to MO i. 
2. Frontier electron lensities ( FE, FN ) 
FE (A) =21(, 2 11h 
(2.27) 
(A) 
r2 FN (A) =2 7L C0k 
(2.28) 
p (A) 
wbere FE(A) and FN(A) indicating the susceptibity of site A to 
electrophilic ani nucleophilic attack respectively. h lenotes the HOMO 
and X denotes the LEMO. 
3. Atomic polarizability ( ALPHA ) 
This is a secon: 3 orJer quantity similar to the self atom polarizability 
of Coulson and LongLet-Higgins (91). The expression used is basel on 
the energy obtained from Hartree-Fock perturbation theory for a limited 
basis set (92). The only type of perturbation of interest here is a 
real first or-ler change, H' in the one electron Hamiltonian, with a 
potential energy component ( -V ). In this case, the first order 
perturbation energy is given by : 
Eý= I H' 
PV 
P 
liv 
+IV (1ý0 ZA (2.29) 
PV A 
where Wpv is a first order core Hamiltonian matrix element, ZA is the 
core charge on the centre A, and P.. ) is the bond orJer matrix element. 
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Lan#off et al (93) have described a simple uncoupling proce-Jure 
originating from the work of Dalgarno et al (94). Using the simple 
uncoupling procedure, the second order energy change, E", obtainei when 
a perturbation H' is appliel to the molecule is given by 
occ ur I 
H' j12 
(Ci - E: j)-1 2 
(2.30) 
where H<iI H'I j> 
and E: denotes an eigenvalue of the ground state Fock Hamiltonian. 
i and j refer to occupiel and unoccupied MO's respectively. 
Assming the MO's to be real, and expanding each as a WAO we obtain : 
EAA 2 
occ unocc 
ccIc Ir Ir XyI CIA 
vj xi aj -pv 
PVXU ij 
where ji, v, Xandj each run over the n atomic orbitals. 
The space occupiel by any molecule is Jivided into zones, each 
containing one of the atoms of the molecule. Zero differetial overlap 
(ZDD), between the atomic orbitals of the CNDQ/2 basis, implies that it 
is possible to Jefine each zone such that the at(xnic orbital functions 
of only the enclosed atom are non zero. If we apply a hypothetical 
probe to a molecule, in the form of an electrostatic potential which 
takes a constant value, VA , in the zone of atom A, but which is zero in 
all other atomic zones, then equation (2.31) becomes : 
A occ unocc -1 
211c 
ýd 
c 
vi 
cxiC Gj VA <v> 
VA <XI cr > (E: i-E: j) 
(2.32 
33 
If a valence only atomic orbital basis is usel we -get : 
A occ unocr- 
E'4ý- 2VAII cpi ýj Ai Aj 
IIX ii 
since the valence orbitals on A are mutually orthogonal. Introducing 
the atomic polarizability ALPHA(A) , we get : 
VAa 
where 
A occ unocc 
a (A) 4C 'Pi 
C 
PI 
C 
vi 
c 
vj 
(F- i-C i (2.33) 
pv ii 
A part from a factor -1, this reduces to the expression of Coulson and 
Longue-t-Higgins of self atom polarizability in the Hijckel frarnwork, when 
only one atomic orbital is contributed by each atom. ALPRA(A) may 
therefore be regarled as an extension of self atom polarizability to all 
valence electron systems. 
For the bond polarizability ALPHA(A-B), the expression can be obtained 
by applying a constant potential of unit magnitude over zones A and B. 
The second or-3er interaction energy is given by: 
AB occ uTiocc 
Er, =F (V 
(IB -8C Vi 
C 
Vi 
C 
ýIj 
C 
Vj 
(E: 
1 -C 
(2.34) 
= -1/2 (x (A-B) 
while the first orler energy is given by the sm of two charges: 
Q(A-B) = Q(A) + Q(B) (2.35) 
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4. Bond energy E(A-B) 
The ZDO total molecular energy, E toe may 
be broken down into 
monocentric anJ bicentric contributions : 
Etot = E(A) + E(A-B) (2.36) 
where for the CNDQ/2 approxt-nations (86). 
AA 
E (A) P 
1111 
U 
lip 
+ '. YAA XIp 141 
P 
vv _jP2 pv 
(2.37) 
pv 
anl 
AB 
E (A-B) 
ý2HVJV 
ýAB 
)p 
pv 
+ YAB 
[PeB 
- ZAPB - ZBPA + 
ZAZB R AB 
where :U P11 IY AA anJ yABare 
define] elsewhere (86) , ani 
A 
PA PlIp ppli 
For the INDD/5R program the formulae for E(A) a n-J E (A-B) take more 
general forms, which exclude the assLmption that every valence A. 0 of a 
given atom has the same ra3ial function : 
AA 
E (A Pwl Upp +p 
P11 
p 
vv 
P, Y11V (2.39) ]IV 
ov 
AA 
E (A)INDO P 
pp 
U 
Wl 
+IP 
ýlv 
P Xa (PV 
I XCF) (IIX I VC) (2.40) 
pvXG 
pp p2 F. (A-B) 
PV 
p 
IIV 
+I 
pp vV PV -NpP VV -NVP 1111) 
YlIVI 
(2.38) 
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+ ZAZB R71 (2.41) AB 
where Nv is the occupancy of A. 0 tj , in the neutral grounJ state atom. 
5. Energy of binding ( EBIND ) 
The energy of binJing of atom A to the rest of the molecule, is 
formulated as : 
EBIND(A) =I E(A-B) 
BýA 
(2.42) 
Note that the sumnation is taken over all other atoms B, in the 
molecule, so that interactions other than lirect covalent bonjing are 
taken into account. EBIND(A) is similar quantity to the free valence 
(74) of HMO theory i. e the larger EBIND(A) the higher reserve binling 
capability of A. 
6. Molecular binling energy ( B. E ) 
The binJing energy (B. E) is used as a measure of overall molecular 
stability. It is lefined by : 
A 
B. E =E tot -I atcmic 
(2.43) 
Here E tot is the total molecular energy incluling core repulsion, and 
EA is the valence electron energy of the isolated neutral atom A atcmic 
calculated in a manner consistent with the CNDQ/2 an] INDO procedures. 
It is taken as the average energy for the grouni state configuration of 
a given atom. Fbr a valence electron configuration, EA can be atmic 
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expresse-I as : 
A 
atanic = 
ZU 
ss 
+ mu 
pp 
+ nU dd +j9, 
( Z-1) -Y 
ss 
+jm (M-1) y pp 
n (n-1) -ydd + ýun TSP + 9, n Ysd + mn YPd (2.44) 
where 1, m and n are the populations of s, p and J subshells 
respectively. The core integrals U are obtained as described in 
reference (86). Fbr the CNDO/2 procedure, the average two electron 
integrals y are all simply equated to y the excharvge part being 
ignored in all cases. Flor INDO calculations, these average integrals 
are calculated accoriing to the formulae given by Slater (95). The B. E 
represents the heat of atxxnization of the molecule at OOK. 
7. Frontier orbital energies ( EHOMO an] ELE140 ) 
These are simply the eigenvalues associatel with the highest occupiel 
an] lowest empty MO's respectively. EHCMO mearsures the electron 
donating ability, ELEMO measures the electron accepting ability. These 
. p-nergy levels are very important in determining tha ease of formation of 
charge transfer complexes between the drug anJ receptor. 
8. Transition energy ( DELTA ) 
The difference between the HOMO and LEMO energy levels is relevent to 
reactivity, if the molecule reacts in its first excited state 
(activation energy for the reaction). It has further physical 
significance in that its reciprocal (EHOMO - ELEMO)-1 is a factor in the 
term likely to be Jominant in any second orler perturbation expansion, 
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this term being obtained in the expansion of equation (2.31) , when i an, ] 
represent the HOMO an] LEMO respectively. 
9. Dipole moment ( MU 
The dipole moment (MU) calculation is performed accor3ing to the Pople 
formulation (96), in which monocentric Jifferetial overlap is retained 
but bicentric differetial overlap is taken to beý zero. The Iipole 
moment vector is given by 
AA 
ZA ri -ý Pýlv < ýj I ri Iv> (2.45) 
A[ pv 
I 
where r1 is the x, y, or z component of r, as i=1,2 or 3 respectively. 
The usefulness of MU lies in its appearance in formulae for clý-? oLar 
interaction terms. 
10. Square of Jipole moment ( MU 
2) 
The ability of a neutral molecule to polarize its surrounding molecules, 
e. g those of receptors or solvents is largely determined by MU. 
However, the resulting stabilization is Jetermined by the components of 
the tensor MU ( MU) T, the trace of which is MU2 The case of 
stabilization due to polarization of solvent molecule by a solute 
molecule is that considered by Onsager. The "Onsager" term is one of 
two Debye terms in solute/solvent interactions. The other being the 
polarization of a solute molecule by solvent molecules. A more ; Jetailed 
explanation of these terms is given later in this chapter. 
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11. Electrostatic energy ( ESTAT ) 
The total electrostatic energy of the molecule ESTAT, is of interest for 
calculating solvation energies accorling to the Born model (97). The 
Born model was originally applieJ to the solvation of ions. The ion is 
treated as a conducting or non-conJucting sphere, of radius R and charge 
q. If this charge is assumed to have been produced by bringing 
infinitessimal elements of charge from infinity, the change in 
electrostatic energy on immersion of this sphere in a medium of 
dielectric constant D, is given by : 
AE 
solv 
q/2R (1/D 1) (2.46) 
where q2 /2R is the elctrostatic energy of the systeiR in free space. 
When an electric charge Jistribution, of potential energy ESTAT in free 
space, is immersed in the Jielectric medim, the change in energy 
E 
801v 
(assuming no reJistribution of charge) is simply given by : 
A E, 
solv 
=(1/ D-1 ) ESTNr 
where D is the lielectric constant of the mediLn. 
12. Molecular polarizability ( (ýmol) 
The mean molecular polarizability ( Otmol) is calculated by an empirical 
additive method. Even though molecular polarizabilities are calculable 
by MO methods, in the present study the environment inlepenJent atomic 
partial polarizabilites (98) are usel for elements up to Br. For 
platinum, the atomic polarizability is calculated using the equation : 
39 
6(x = 0.9754 ( +/-0.4) OtH. F - 0.175 (+/-0.1) 
Substituting the value of 11.5 for OýH. F which is obtaine-i from (99) in 
the above equation we get : 
(platinun) = 11.04 
A3 
. 
A detailed description of how the above equation is obtainei is given 
(98) . 
Ctmol values are calculatel by simple summation of the above 
value for each atom in the molecule. W)lecular polarizability is 
related to molecular refraction R Mol 
(100) by the fo I lowing 
relationship : 
R 
mol = 
4/3 TT No ot mol 
where N is Avogadro's number. R may be estimated as a sun Of 0 nul , 
tabulatel "refractivities", each one being characteristic of a 
particular fragment of the molecule. 
The usefulness of cc., comes from its appearance in several formulae 
relating to Van der Waals interactions. Fbr a London dispersion 
interaction of each of a series of substrates with an unknown receptor, 
the product of ionization potential and polarizability for each 
substrate approximately characterizes the interaction energy (101). Fbr 
this reason the product of -EHOMO and a mol has also been used as an 
index in the present work. -EHOMO represents the ionization potential 
of the molecule. The product is denoted a. IP in the present work. 
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13. ribe size in3ices 
The size indices used in this work are all based on the nodel of Bondi, 
where the Van Jer Waals radii for first and second row elements are 
0 
reported (102). Values of 1.7A to IA are obtain,? i from (103) for the 
Van Jer Waals radius of platinum. This radius is substantially smaller 
than predicted from ionization potentials. A Van Jer Waals radius for 
0 platinum of 2.048 A, calculated using the Ie Broglie w-ave length of the 
outermost valence electron (102), is used in the present work. 
The Van Jer Waals radius (R), Van der Waals surface area (S. A) ani Van 
der Waals molecular volume (M. V) are the three parameters determined for 
003 
each molecule in this study, the units being A,, W and A 
respectively. 
R and S. A are letermined by dividing the surface of each atomic sphere 
0 
into segments of area not greater than 0.1 A. It is then determ3. ned 
which of these segments lie on the molecular profile, the area of these 
segments being includeJ into the surface area summations. The distance 
of the segment from the centre of mass of the molecule is used in the 
mean radius calculation. 
In the molecular volume calculation, a rectangular solid is defined such 
that all of its faces touch the molecular profile. The solid is 
segmented into cubes of side 0.1 A. It is then determined which of these 
0 
cubes lie within the molecular profile, and a simple counting procedure 
is used to obtain the molecular volume. 
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14. Quantities in the molecular envirorment 
The electrostatic potential (Vj) at a point rI with respect to the basic 
structure, i. e drug molecule, determines the coulombic interaction 
energy with a charged entity placel at r If the drug actility 
correlates with Vir then it might be deduceJ that rI is the position 
of centre of charge of the receptor, in the drug-receptor complex. 
Other fields arising from the drug molecule also determine the 
Irug-receptor interaction energy. The square of Vj(r determines the 
stabilization Jue to any polarization of the receptor charge 
distribution produced by Vl(r i. e the second order interaction energy 
of Vl(r with the receptor. 
The components of the electric field E(r determine the energy of 
II 
interaction with a point lipole at point-r", . and its square [E(r i )12 
determines the interaction energy with the induced dipole at point r 
The second order interaction energy V2(ri) arising from the polarization 
of the drug molecule by a point charge placed at (ri), is also 
using equation (2.31). 
15. Hylrophobic constant (PI) 
An empirical hydrophobic substituent constant PI (104) is. include the 
regression analysis as an aJditional variable. 
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16. Solvent interaction energies 
A useful study in quantun pharmacology is the calculation of solvent 
interaction energies. These can be decisive in the distributive 
properties of the drug, and its stability in the environment of water 
molecules. Solubility can play a fundamental role in the biological 
action of some drugs. There are many ways to model and calculate the 
effect of solvent on solute. A brief description of those methods 
relevant to the present study is given below : 
(i) Discrete method 
The supermolecule approach (105) is well established as a Jiscrete 
method, in which solute ani solvent are taken as a single species in the 
ýO calculation. It concentrates on water molecules which are likely to 
be tightly bound by hy-3rogen bonds to the solute. The most stable 
positions for water molecule in the environinent of the solute are founJ, 
their effect on the solute molecule conformation and overall interaction 
energy being deduceJ. The more water molecules included in the 
supermolecule calculation, the more relevant it becomes to the state of 
infinite Jilution. 
(ii) Continuum model 
The total energy (Etot) of a molecule in a given geometry, under the 
influence of solvent effects described by the continuum model, is 
considered to be of the form 
E tot E solute +E solvation 
43 
where E solute is the total quantum mechanical energy of a solute 
molecule in free space, and can be calculated by using equation (2.36) , 
and Esolvation is the solute-solvent interaction energy. 
The present method takes into account the form of the molecule (solute) 
which is deduced from the Van Ier Waals radii of the atoms. The solvent 
molecules are represented by spheres of appropriate radius which are 
packed around the solute molecular profile. 
Using a dipole approximation (106), E solvation may 
be expressed as the 
sun of four terms : 
E solvation =E Pli +E PCL +E dis +E cav 
(2.47) 
where E 1111 
is the dipole-dipole interaction energy (Keesom energy), which 
averages to zero if all possible water conforimations are taken into 
account. 
ElIct is the lipole-iniucel dipole interaction energy (Debye term) - 
E dis is the London or Jispersion interaction energy, and E cav 
is the 
energy requirel to form a cavity in the solvent to accommodate the 
solute molecule. The expressions for tiiese terms are given in reference 
(106). The definitions given below are used herein : 
Using the microscopic surface tension of water (which is evaluated from 
an empirical expression (106) ) the following expression is obtained for 
cav : 
E 
cav = 
0.00145 x S. A (2.48) 
44 
For E 
dis the 
following expression is used : 
E dis ý- 3/2; t otAoLB /R 
6xA IB /(, A + B) 
(2.49) 
wher ea and oL. are the polarizability for solute and solvent 7ý 
respectively. IA and IB are the ionization potentials for the solute 
and solvent respectively. and R is the separation between the solute 
and solvent. The value of 1.5 AO is usel for the Van ler Waals radius of 
the water molecule. 
The Debye interaction term (E 
pa 
) is subdivided into Epol, ancl Epo12 . 
where : 
Epol, is the interaction energy Jue to the polarization Of solvent 
molecule (H20) by the permanent Iipole of the solute molecule. 
Epo12 is the interaction energy due to the polarization of solute 
molecule by permanent dipoles of the solvent mol&:: ules (H20). 
A solvation cavity surface for the solute, asdefined by Hermann (107) 
is generated. This surface is partitioned into small elements. The 
method then requires one to go round each element and calculate the 
energy of polarization, by poles of the solute molecule, of an H20 
molecule centred at that element, whose orientaticn is averaged over all 
possible orientations. At the sane time, polarization of the molecule 
by the H 20 dipole, the orientation of which is similarly averaged, is 
calculated. Hence the solute molecule sees an isotropic polarizability 
tensor. 
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For a given point, P on the cavity surface, the electric field due to 
solute molecule is E: (p), and the energy of polarization is : 
Epol 1/2 C: 2 (p) H20 (2.50) 
The components of the fiel-3 vector P- (p) are calculated by a simple 
point charge approximation of the molecular charge distribution : 
QA* XAp lrýp 
A 
where the summation is over all atoms of the solute molecule, Ex (P) is 
the x component of the field, and XAP is the Jistx-ica between solvent 
and solute along the X axis. A similar expression exist for cy ýp) anJ 
EZý (p) . 
For the calculation of EP012 . the H20 molecule is represented as a point 
T 
lipole. The field due to the point iipole is 
Ex=-P /r -3 +3x -lj* J x/r5 
Averaging over all possible orientations of the H20 molecule, the 
squared electric field at a Jistance r is given by : 
e: 2 >=2ý, 2/r6 
ani the energy of interaction with an isotropic polarizability tensor 
I ct , is : 
112 a r-6 
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In the present stuly, each atom is taken as a separate isotropic 
polarizability tensor, so that the total interaction energy is given by: 
EPO' 21ý, 
2 &Y, R-6 (2.52) 
AA AP 
where 6a A is the partial polarizability as used in the calculation of 
the mean molecular polarizability and is the dipole moment of 
water. The value of 1.84 Debyes is used (108). 
An encouraging correlation has been obtained in a multiple regression of 
the heat of solution, at infinite dilution as the Iepenlent variable for 
some small molecules (109) , with the interaction energy contributions as 
independent variable. StandarJ bonJ lengths anJ bond angles are used 
(110). The relevant 13ata are given in table (2.1). Simple regression 
equations are obtained between the heat of hydration ani inJividual 
terms of the energy. The significance level is above 99.9% : 
AH 
soln = -22.378 (±, 3.08) E cav 
+ 3.206(±1.3) (2.53) 
and r=0.895 ;s=1.6 ; F(1,13) = 52.77 . 
'"soln = 3.11(±2.2) Epoll - 5.641(±1.01) (2.54) 
and r=0.355 ;s3.3 ; F(1,13) = 1.88 
AH 
soln = 
2.714(±0.43) Epo12 - 0.512(±1.03) (2.55) 
ani r=0.868 ;s=1.78 ; F(1,13) = 39.84 
A Hsoln 2-» 0.747 r-, 0.15) E dis + 2.752 (±1.9) (2.56) 
and r=0.805 ;s=2.13 ; F(1,13) = 24.01 . 
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The negative coefficient in equation (2.53) in3icates that the larger 
molecule, the more negative is the heat of hy-Iration, which is 
reasonable provide that E cav 
is surrogate for other terms in the 
interaction, with which it is strongly covariant. Without this 
covariance, we woull expect a positive coefficient. However, even when 
all four terms are included in a multiple regression the coefficient 
associated with E 
cav 
is still negative : 
AH 
soln "ý -2.305(±-13.7) 
E 
cav 
+ 3.25(±1.05) Epoll + 2.985(±1.7) 
Epc)12 0.164(: ý0.2) E dis - 0.2(±2.4) (2.57) 
and r=0.949 s=1.28 ; F(4,10) = 22.95 . 
The regression obtained without Ecav term is : 
AH 
soln 
3.35(±. 83) Epoll + 3.24(±. 86) Epo12 
0.15(±. 2) E dis - 0.506(±1.5) (2.58) 
and r=0.95 ;s=1.23 ; F(3,11) = 3.36 
The negative coefficients of E dis are unimportant, because of the low 
statistical significance (as expressed by the t-test) of its 
contribution. There is a large covariance between Epo12 anJ Edis ' 
which makes E dis statistically redundant. Omitting this term from the 
regression we get : 
AH+0.32 (±J) (2.59) 
soln 
3.31(±. 8) Epoll + 2.75(±2.9) EPO12 
and r=0.948 ;s= . 89 ; F(2,12) = 52.90 . 
This regression is statistically and physically inore significant than 
those given above. The ratio of the coefficient of Epol, anJ EP012 
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yiells an estimate of the polarizability of water (a factor ommited in 
the calculation of Epol, ) 
eff 03 
H20 = 3.31/2.75 = 1.205 A 
In fact, this value is smaller than expectei. An experimental value of 
0 1.48 A is obtained for the electronic contributions alone. This 
discrepancy may be explain by : 
(i) The damping effect on polarization proJuceJ by the mutual repulsion 
of polarized H20 molecules surrounding the solute molecule 
The fact that EP012 is surrogate for the dispersion term which 
makes its coefficient larger than it would be. 
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TABLE 2.1 Calculated interaction energies and observed heat of 
hydration. All values are in kcal/mole. 
NO. Molecule E (Cav) -E(Poll) -E(PO12) -E(dis) -H(g-soln) 
1 H2 0.20 0.00 0.50 5.870 1.03 
2 N' 2 0.29 0.00 1.35 14.53 2.62 
3 CH 4 0.31 0.0 1.36 16.26 3.11 
4 CF 4 0.41 0.12 1.41 15.88 3.70 
5 Co 0.29 0.03 1.3 13.34 3.10 
6 C02 0.32 0.38 1.25 13.94 4.91 
7 C 2H 4 0.38 0.00 1.87 18.75 4.17 
8 CH 3 NH 2 0.39 0.06 1.76 16.16 5.36 
9 CH 3 NOZ 0.44 
1.75 1.88 16.91 8.54 
10 c5 HSN 0.56 0.12 3.43 24.28 11.94 
11 (CH 3)2CO 0.51 0.80 2.57 21.01 9.85 
12 C6H5 0.58 0.03 3.55 26.99 7.67 
13 CA NH2 0.64 0.13 3.96 22.8 11.43 
14 C6 HSCH3 0.67 0.64 4.11 26.19 9.82 
15 CH 3 CHO 0.42 0.66 1.99 17.55 
8.08 
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2.4 Molecular electrostatic potential 
Much interest has been given in quantun pharmacology to the 
electrostatic potential (e. p) due to a molecule. The e. p determines the 
first order interaction energy of the molecule with any given charge 
distribution. This charge distribution may represent the drug's 
receptor, or any other biomolecule with which the drug molecule 
interacts. Neglecting bicentric Jifferetial overlap, the e. p at point 
-0. rP is given by 
rp)='1ZA R7ýp -ijAp liv 
V 
liv 
(2.60) 
AA liv 
where V< pl I/r liv ip 
Equation (2.60) considers each atoinic centre A at the molecule'as fixed 
points at position RA and charge ZA surrounded by an electron cloud of 
density P (r (ri). Improvement of the estimation of the 11V 11 V 
electrostatic potential at any point may beinaie by including three 
centre integrals V 11V 
into the calculation. This would necessitate the 
prior Jeorthogonalization of the CNDO/2 wavefunction to satisfy the 
conservation of electronic charge (111). 
The electrostatic portion of the interaction energy between two 
proximate molecules is simply equal to the classical coulombic 
interaction between the two static molecular charge distributions. 
Eelec ": 
ffP G"' 
A 
/r 
12 p, 3 
ý2 (3ý2) dT 
1 
dT (2.61) 
where is the PPI) charge density at point 1 in the species A, 
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PB (r2 ) is the charge lensity at point 2 in the species B, ani 
rl 2 r2 - r1l. 
The electrostatic potential due to A is : 
p A (cL) (l/Cl 2 dT, ý- VA (C2 
Hence 
AE PB (2.62) 
elec=fVA(C2) 
(C2) d T2 
This equation is very useful in Jrug-receptor interactions. Everything 
is known about the Irug molecule, proviled it Joes not act in the form 
of a metabolite, but usually very little is known about the receptor, 
and much less about the configuration of the Jrug-receptor complex. 
Equation (2.62) is the relationship between electrostatic interaction 
energy (A E) and electrostatic potential (\ý ). The latter is Jefined 
whatever the nature of species B. For the special case when speices B 
is a unit charge, placed at -r* BE 
is nLmer ically equal to VA(r B 
The value of knowing the e. p for the drug molecule, even without knowing 
the receptor charge listribution, is that it rnight give an idea about 
the protonation sites ani the sites of probable attack in a molecule. 
If each drug molecule in a series reaches the receptor site without 
being metabolized, then the variation in electrostatic binding energy 
within the series is determined by the differences in the electrostatic 
potentials in the regions occupieJ by the receptor charge Jistribution. 
The e. p surrounding a given molecule may be represented in the form of a 
map. These maps consist of contours connecting points at which the 
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energy is identical or "isopotential". Semlempirical ani ab initio 
methods can be employed in the e. p calCulation. 
To check the valAity of serniempirical maps, Giessner-Prettre and 
Pullman (112) have compared four . -nethods for calculating e. p's for 
CNDQ/2 or INDO wavefuntions . Method III of reference (112) is used in 
the present work, monocentric lifferetial overlap being retained. 
Petrongolo, and Tbmasi (113) report e. p's for a series of three member 
rings which are calculated using CNDO/2 deorthogonalized wavefunctions 
(here denoted CNDOR), and compare these with ab initio calculations 
(STO). The deorthogonalization of CNDO/2 wavefunction permits bicentric 
differential overlap to be retained in calculation of e. p In the 
present work the same potentials are calculated using CNW/2 
wavefunctions, but according toirnethod 111 (112) (here denoted CNDO 
The calculated anJ reported values are given in table (2.2). 
Regressions of the reported potentials VCNDDR and VSTO on the calculated 
potential VCNDO are given below. The significance levels are above 
99.9% as is observed from the F-values. StandarJ errors of the slope 
and the intercepts are given in parentheses : 
Linear regression equation relating VCNDOR to VCNDO 
VCNDOR = 0.685(+/-. 82) VC9DO + 6.173(+/-2.3) (2.63) 
and r=0.992 ;s=3.4 ;F (1,9) = 582.05 
Here r is the correlation coefficient, s is the standard deviation and F 
is the var iance ratio. 
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TAKE 2.2 Calculated and reported electrostatic potentials for some 
three menbered ring molecules. All values are in kcal/mole. 
NO. Molecule 
1 Cyclopropane (C-C) 
2 Cyclopropene (C-C) 
3 Cyclopropene (C=C) 
NýN 
4 Diazirine (N) 
"I'll 
0 
5 Oxirane (0) 
N 
6 Aziridine (N) 
7 Aziridine (C-C) 
'11ý , 
8 Trans-diaziridine (N) 
9 Cis-diaziridine (N) 
N 
10 Oxaziridine (0) 
11 Oxaziridine (N) 
12 Oxaziridine (N, symm) 
ýýs 
13 2H-azirene (N) 
-V (CNDO) -V (CNDOR) -V (STO) 
4.00 11.1 15.1 
13.0 13.4 13.6 
- 5.70 12.0 
42.0 38.5 
84.0 58.5 44.8 
112 83.8 76.9 
-0.1 10.1 
89.0 67.5 66.8 
101 74.2 75.5 
64.0 51.1 43.3 
85.0 64.6 65.1 
76.4 53.4 54.5 
119 92.9 
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Linear regression equation relating VSrO to VCNDO : 
VSM = 0.611(+/-. 06) VCNDO + 7.928(+/-. 09) (2.64) 
and r=0.962 ;s=6.89 ; F(1,7) = 88.05 . 
The correlation between VSTO anJ VCNDD is worse than that of the linear 
regression equation relating VSTO to VCNDOR : 
VSM = 0.902(+/-. 06) VCNDOR + 2.71(+/-3.4) (2.65) 
and r=0.976 ;s=6.19 ; F(1,9) = 186.75 . 
Contour, and solid maps of VCNW for these molecules are given in 
figures (2.1) and (2.2) respectively. These maps are plotted by using 
the "SIMPLEPLOV routines ( this routine is avalable at UMRCC ). The 
calulations an-] plottings were acheived by using the CDC 7600 and ICL 
1900 computers of the University of Manchester. 
In solil maps three colours can be listinguished. For positive 
potentials, the green colour is observed if the viewer looks at the top 
of the surface while red is observed from the undersiJe. For negative 
potentials, the red zone is observe-1 from the top of surface and black 
from the underside. The angles are specified in degrees between the 
viewing direction and the XY plane, which is the base plane of the e. p 
surface. The X and Y directions are as inJicated in the liagrams. All 
the positive potentials are artificially choppei at 50 kcal/mole to 
prevent then going to infinity at the nuclear sites. Artificial 
potential wells are produced at the nuclear sites, so that their 
positions are clear. 
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The molecular orbital and regression program "MORBG" is used in the 
present work to calculate the chemical indices described in this 
chapter. The input data are the cartesian atomic coordinates and drug 
activity of each series of molecules stuJied. After performing a CNDO/2 
or INDO MO calculation, the program calculates and stores on a disc file 
all of the electronic and steric indices. Hydrophobic constants are 
input to constitute an additional independent variable. Then a 
systematic regression analysis is performed on the stored variables in a 
search for correlations with drug activity, which is taken as the 
independent variable. The relevant details of the regressions, which 
constitutes the final output from the calculation, include the 
regression coefficients and their standard errors, the intercept and its 
standard error, the correlation coefficient (r), the standard error of 
the estimate (s) and the variance ratio (F). Details of the regression 
analysis are given in appendix (A) Regressions linking single and 
pairs of indices with drug activity are printed. 
Provided the receptor points have been specified, the variables E. F(r), 
E. F2(*r) , V, j V, 
2 and V2 associated with each point in the molecular 
environment are calculated and stored on the disc. A multiple 
regression of drug activity on all these variables is performed. 
The following chapters deal with the use of the MORE)G program to produce 
QSAR's for some enzyme inhibitors and antitumour agents, using the 
indices described above in the drug activity stuJy. 
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FIGURE 2.2 e. p solil maps for some three membered ring molecules. 
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61 
ANTITUMOUR ACrIVITY OF SOME PLATINUM(II) COMPLEXES 
3.1 Introduction 
Platinun (Pt) occurs in *nature with the rare metals of group VIII. it 
is reported to be present in normal tissue. Platinum is used 
extensively in industrial and chemical laboratories. The therapeutic 
use of platinum was known as early as 1841, when it was used against 
syphilis and rheunatim. Since then platinm compounds have been found 
to be potent antitmour agents. 
Rosenberg and coworkers (114) found that, the passage of a- low 
alternating current via platinun electrodes immersed -in a nutrient 
medium containing Eschrichia coli bacteria, resulted in the formation of 
long bacterial filaments. It was leduced that bacterial cell division 
was being inhibited, but cell growth was not affected., Antitunour 
activity was therefore suspectel, although some compounds which cause 
this effect are not antitmour active. 
Filamentous growth in bacteria is almost certainly iniicative of the 
ability of -. an agent to react with DNA, lealing- to inhibition of DNA 
synthesis with no effect on other biosynthesis such as RNA or protein 
synthesis., A variety, of agents such as U. V, X-ray irradiation and 
cytotoxic alkylating agents can also elicit this response. because of 
their ability to dwage DNN (115). 
The cis species of platinun cOMPlexes are biologically active while the 
correspon-Jing trans iý; omers have relatively little , effect.. on cell 
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division. only neutral platinum complexes are active, while the charged 
complexes show no antitmour activity (116,117). This may be connected 
with the problem of drug transport through cell membranes. The neutral 
species pass through the cell membrane more easily than charged species. 
Aowever,, the platinun blue complexes (i. e complexes of various platinum 
diammine dichloriJes with pyrimidine) are an exception to this trend. 
They are a new class of platinun containing antitumour agents. 
The antitumour activity of cis-platinum complexes is well established 
(118,119) . This activity has been related to the, interaction. of 
platinum complexes with DNA in vitro (120) and in'vivo (121). 
Friedman and Teggins (122,123) have observed the inhibition of malate 
dehydrogenase (mr)H), lactate dehydrogenase (LDH) and horse liver alcohol 
dehydrogenase. (ADH) by cis and trans dichlorodiammine platinLn(II) 
They have determined the relationship of the charge on platinum 
complexes to their ability to inhibit MDH. It appears '. that the 
electrostatic charge on the platinun complexes is ýthe most important 
factor in enzyme inhibition. 
The greatest antitumour , activity has been evident for the 
cis-dichlorodiammine platinLm(II) complex. Rosenberg and Van Camp (124) 
have shown this. complex to ýbe capable of-regressing eight day, solid 
S180 tumours, complete regression having been observed in 60% of the 
cases studied. 
Cis-dichlorodiainine platinum(II) (cis-DDP) , has proven to be valuable 
in the treatment of certain human tumours, especially. ovarian 
adenocarcinoma (125),, squamous cell carcinoma (126), testicular tumour 
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(127), and being active against a wide variety of animal tumours (128). 
il 
Since the discovery of the antitumour activity of cis-DDPr a large 
nurber of new platinum complexes have been synthesised and tested. 
Among those synthesised. an: 3 tested, dichloro 1,2-diamino cyclohexane 
platinum has a high antitumour activity against various tumour systems 
(129-131). 
Most of the active species are square planar platinun(II) complexes of 
the form cis-Pt(Am )2 XV, where Am is an N-donor ligand and X is either 
Cl or Br. Others differ from this specification by the introduction of 
bidentate ligands. 
The ability of certain, platinum coordination compounds to cause 
regression of tumours depends on the chemical structure of the 
complexes. The active complexes can be represented by 
AX 
Pt 
ýX 
where A is the carrier ligand(s) monodentate or bidentate and X is the 
anionic leaving monodentate (usually. Cl). The correlation between the 
nature of leaving groups and their Antitumour activity can be 
established from their rate of substitution. Kinetic studies show that 
the order of their rates of leaving for a series of X ligands is 
NO'3 >H2, () >Cl >Br >I >N3 > SCN >N02 XN 
highly active inactive 
toxic 
II 
relatively non toxic 
This order reflects the changes of activity in the animal test results 
(132). 
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3.2 The mechanism of action of antitumour platinum complexes 
Most of the stuJies of action of antitwour platinun complexes have been 
carried out using the best known cmpound, cis-DDP, the only one which 
has been put into clinical trial so far. However, a nunber of organic 
analogues of cis-DDP have been synthesized (133,134)f which show higher 
activity (against AW/PC6A plasma cell tumour in mice) than the original 
inorganic complex. 
Platinm complexes offer advantages as biological reagents. They are 
moderately soluble in water, are kinetically stable, and unlike. some 
complexes with earlier third row transition metals? do not 
. 
form 
insoluble hydrated oxides at neutral pH (135). The known chemistry of 
platinum in the +2 and +4 oxidation states is extensive arid it is now 
relatively easy to design and synthesize complexes having desired 
properties. 
The impcýrtance of metal ions in the biochemistry of nucleic acid has led 
several workers to investigate metal complexes with nucleic acids and 
their components (136) Most of the earlier studies have been carried 
out in solution. using ror and other spectroscopic methods (137) 
Attempts have also beem made towards understanding metal binding sites. 
A number of specific questions concerning antitumour platinum drugs can 
be raised. %bat is the mode of binding to DNA,. 
. 
covalent, - 
intercalative ?. What are the binding sites on DNA ?. My is the cis 
isomer active and trans isomer relatively less active ?., 
The mode of binding of inetal to nucleotide can be classified as one of 
the following : 
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(i) base-bincling. (ii) phosphate binJing. (iii) sugar -binJing. Most 
of the transition metals come'under the first two categories, However, 
there is no example of a metal binSing to both the base anJ phosphate, 
base and sugar, or phosphate and sugar groups of 
"the 
same mononucleotide 
molecule. 
Mansy, Fosenberg and Thomson (138) have used U. V spectroscopy to 
investigate the mode of interaction of the platinum drugs'with nucleic: 
acid components. Cis-MP forms a bidentate 'Chelate with either 6-NH2 
and N-7, or 6-NH2 and N-1 of adenosine, and 4-NH2 and N-3 of cytijihe, 
while trans-DDP interacts monofunctionally at'N-1 and N-1 of adenosine 
and N-3 of cytidine. Both isomers bind monofunctionally. to N-7 of 
guanosine and inosine. 'No evidence has been found to suggest binling of 
either isomer to uridine or thymidine. 
Theophanides et al (139) have attemptel to stuly the stereoppecificity 
of the platinun drug actions, viz, cis configurations are active while 
trans configuration are not, -by exanining the possible in teractions of 
the platinun complexes with bases of MA. Guanine is thought to be the 
most likely base for this interaction. 
Platinua complexes exhibit both covalent and intercalative modes of 
binling. The covalent birding of cis-DDP with DHN takes place through 
the chelation of Pt with the N-7 (Gua) and 06 (Gua) sites (140) 
Trans-DDP does not interact with the 06(Gua) site, It is specifically 
the binding of the 0. (Gua) site which prevents MA replication. This is 
because there is usually a hydrogen bond between 06(Gua) and NH2(CYt) in 
the Guanine-Cytosine base pairing arrangements. In. making the 06(Gua) 
site unavailable for hydrogen bonding, the complex prevents the 
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recognition of Guanine by Cytosine, BinJing by cis-DDP has no similar 
effect 6n the Adenine-Thymine base pair. 
It is currently believed that cross linking of Guanine bases in 
complementary strands of DM is responsible for the cytotoxic action of 
bifunctional alkylating agents (141). The alkylating centres require 
the chloride leaving groups to be about 5.7 AS apart in order to show 
marked antitunour activity. This is presuned to be due to the similar 
spacing between N-7 groups of the guanine bases on opposite strands of 
the Watson-Crick structure, which are the bridging sites.. The two 
chloride leaving groups of the cis-DDP compound are only 3. *27 
X apart 
which is very close to the 3.4 AO of the stacking spacing of the bases in 
the Watson-Crick model (142). 
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3ý3 Strategy of the present study 
In the absence of a confirmeJ mechanism of antitumour activity for 
cis-DDP and its analogues, one is left with trying to explain the 
variation in activity of such series in terms of the properties of the 
isolated complexes. 
Ground state and second order properties of these complexes may be 
directly relevant to relative drug activity if the ccmplexes are 
essentially unreacted at the stage in which discrimination between the 
molecules of the series is evident e. g if an intermediary loose 
association between the complex and guanine a critical to relative 
activity -. 
Gua 
cl **ýý 
ptol"***ý 
NH 3 
""ýýNH'3 
In such a case the electrostatic potential around the drug molecule is 
important, as determined by the Q values at Cl's and Pt as well as 
N7 (Gua) and 06 (Gua) 
The first and second order properties of the isolated complexes may 
carry over to the biologically reacted species, and hence determine the 
drug activity. The reacted species might be PtAm 2 (Gua),, whose structure 
expected to be : 
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i 
H 
H 
With these point in mini, a search for correlation between antitumour 
activity and properties of the complexes,, such as bond polar izability,, 
might lead to an understanding of the mechanism of drug activity. In 
addition, the first and second order properties of receptor groups in 
the environment of a given complex which may be determine the possibile 
drug-receptor interaction, are of great interest. Tb assist with the 
choice of the most likely biochemical reagent sites, -the electrostatic 
potential in the enviromental of cis-DDP has been extensively mapped. 
Electrostatic potential contour maps and electrostatic potential solid 
maps are plotted for cis-DDP and are given in figures (3.1) and (3.2). 
The main features revealed by these maps are a positive region. extending 
round the relatively electropositive ammine groups, and the negative 
potential attractive to cations, near the two chlorine atoms. The 
potential well in the vicinity of the chlorines is shown in figure 
(3.1). This well is resolved into two minim'a, each of depth -56 
kcal/mole, as shown in figure (3.1b). (bntours are placed at intervals 
of 5 kcal/moler though confined to the electronegative region', Figure 
(3.2) shows these min: L-na in three dimensions, as looked at f rom three 
directions indicated by the cartesian. frame. The viewing directions are 
10 and 15 degrees downwards from the horizontal. 
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21N 
H 
b. Potentials in the range -25 to -56 kcal/mole 
-3 lý 
0 
:41 X 
HX AXIS 
3-1 
20 
_4 
-20 
-1 0 
a. Potentials in the range +20 to -50 kcal/mole 
FIGURE 3.1 INDO-e. p contour maps (kcal/mole) for cis-dichlorodiammine 
I. platinan(II) complexes - 
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-V 
x 
x___ "---Y 
FIGURE 3.2a INDO e. p soliJ maps for cis-dichlorodiaiwnine platinum (II) 
(all viewing directions are 10 degrees downwari from the horizontal) . 
71 
f 11 ýx 
VX 
FIGURE 3.2b INDO e. p solil maps for cis-dichlorodiammine platinum (II) 
(all viewing directions are 15 degrees JownwarJ from the horizontal). 
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It is interesting to probe the whole mesh of points around the molecule 
and find out which point is vital in the interaction with DNA. Th 
, acheive this we needimuch more computing time than 
is availble. For 
reasons of economy of computing time receptor'points have been limited 
to nine possible reaction sites in the environment of atoms in the 
complex. Only four points are included in the calculation and 
correlated with antittmour activity, the remaining five being symmetry 
related. The precise positions are given in Angstroms below 
No Point x y z 
1. P, 2 1.6 2.8 0.00 
2. 2.8 1.6 0.00 
3. P2 1.1 2.1 1.690 
4. 2.9 1.1 1.690 
5. 1.1 2.9 -1.69 
6. 2.9 1.1 -1.69 
7. Pa. 0.0 0.0 1.690 
B. 0.0 0.0 -1.69 
9. P4 1.04 -8.5 5.240 
The coorJinate system is indicated in figure (3.1), the Z axis is out if 
the plane, Points 1 and 2 are minima near the chlorine atoms. The 
points 3-6 are minima in Z 1.69 A planes (relevant to 
intercalation). Points 7 and 8 are positions directly above and below 
the platinun atom, in Z= +/- 1.69 X planes. Point 9 is a position 
calculated by superimposing the substituents in. the whole. series. ' and 
hence choosing the closest point to avoid steric-interaction with any 
bulky substituent in the series. 
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3.4 Method 
The RM SCF method has been used iný calculations on some. platinum (II) 
complexes, seeking relationships between activity, toxicity and 
structure. Connors and coworkers (133,134) have reported the ' ID90 
(minimum dose required to produce 90% tumour regression in mice bearing 
fstablished AW/PC6A tumours) , and LD50 ( minimum dose required to kill 
50% of mice )- for some platinum complexes, mostly of the form cis-Pt 
(NH 2 R)2 C12 * These studies show the 
dranitic effect which small 
structural changes can have on ID9, anJ LD50. The second study (134) 
reveals that the therapeutic ir0ex, i. e the ratio LD50 / ID90 is not 
simply related either to the aqueous solubility or to the 
water-chloroform partition coefficient. 
The "INDO/5R! ' program (INDO program extended to fifth row elements) , 
with platinum and chlorine parameters (88) has been combined with the 
"MOREG" program (143) and extended to produce the "MOREG/5R! program by. 
the author. Using MOREG/5R, calculation are performed on the series of 
platinun complexes for which drug activity data (133,144) are available,, 
the inactive compounds and those with large bidentate substituents are 
excluded from the present calculations. Specifically, MOREG/5R 
calculations have been performed on 26 substituted cis-dichlorodi&n3ne 
platinun(II) complexes. The observed toxicity, antitumour. and 
therapeutic index for each of these compounds is given in ta ble (3.1). 
All ccmplexes are considered to be square planar. Substituent 
coordinates are determined using standard bond paraneters (110,145) 
Wherever conformational degrees of freedom exist, an, attempt has been 
made to choose the most stable conformation. Ibtation of a CH3NH2 group 
about its bond with Pt in CiS-CH3NH2 NH3 Pt(II) C12 has given an energy 
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minimum at the torsional angle at which the CH3 group is-raised by 90 
degrees out of the plane of the complex. The calculated torsion angles 
in (degrees) ard the corresponding energies in (a. u. ) are given. in 
table (3.2). Accorlingly,, all single substituents on the mono-Jentate 
ammine ligands are given this conformation. Complexes of the type 
Pt(ATý2 C12 ar. e taken as square planar, with Pt-Cl boni distance of 
2.309 ý, as in Pt C14 (146). and a Pt-Am bond distance of 2.052 
R as in 
Pt(NH3)4 (147). These bond parameters are very close to the bond 
lengths determined by X-ray structure studies of cis-DDP (148), Flor the 
structures in which the two ammine ligands are joined to form a single 
bidentate ligand (numbers 20-24 in table 3.1),, geometries are chosen 
which compromise the known bonding characteristics of the moeities 
involved as little as possible. In these cases it is necessary to 
increase the N-Pt-Cl bond angles, symmetrically,, from 90 degrees in 
order that the group brilging the two nitrogens can retain (as closely 
as possible) its normal geometry. 
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TABLE3.1 Observed toxicity, 
index of complexes 
cis- Pt(LQCL2 and 
antitumour activity and therapeutic 
of the type cis-Pt(L)2C12, 
ci--, -Pt(LLI)Cl2-. 
No L LD50 ID90 T. I, 
mg/kg mg/kg 
1 NH3 13.0 1.6 8.1 
2 CH3NH2 18.5 18.5 1.0 
3 C1C2H4NH2 4S. 0 17. S 2.6' 
4 n-C2HsNH2 26. S 12.0 2.2 
5 n-C3H7NH2 26. S 12.0 2.2 
6 n-C4H9NH2 110.0 10.0 11.0 
7 n-C5H, INH2 92.0 37.0 2. S 
8 NH2 33.5 0.9 37.2 
isopropylamine 
NH2 
9 83.0 6.2 13.3 
isbbutylaminie 
NH2 
1150.0 5.8 
isoamylamine 
11 NH2 730.0 27. 'ýS 26. e'5'. ' 
2-aminohexane 
12 H 57.0 2.6 21.9. 
ethyleneimine 
13 NH2 57.0 2.3 24.7 
cyclopropylamine 
14 <C>-NH2 90.0 2.9 31.0 
cyclobutylamine 
is 
CNN 
240.0 17.5 13.7 
pyrrolidimine 
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TABLE 3.1 (cont. ) 
No L LDso IDgo T. L 
mg/kg mg/kg 
16 NH2 480.0 2.4 200.0 
cyclopentylamine 
17 -NH2 > 3200 12,0 >267 
-cycýlo>exylamine 
NH2 
18 89.0 34.0 2.6 
cyclohexyl- 
methylamine 
19 H3C-0-NH2 990.0 1180.0 0.8, 
4-methylhexylamine 
No LC LDso ID90 T. I 
mg/kg mg/kg 
20 
NH2 22.5 10.0 2.25 
IýH2 
ethyl enedi amine 
21 
NH2 a 
14.1 2.1 -9 6* 
NH2 
1,2-diamine cyclo- 
hexane 
NH2 
22 
(ýK 48.0 2.4 20.0 
Ný2 
o-phenylenediamine 
23 22.5 3.7 6.0 
NH2 
4-mqhyl-o-phenylene- 
diamine 
24 283.0 2.5 113.2 
4 5-dimethyl-o- 
pAenylenediamine 
No L Ll LDso I Dq o T. I 
mg/kg mg/kg 
25 Nfi3 28.0 4.0 7.0 
26 NN MH3 11.0 0.5 22.0 
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TABLE 3.2 THe results of calculation of the total energy br 
CiS-CH3NH2NH3 Pt(II) CL2 at different dihedral angles (Tau).. 
NO, Tau Energy NO. * Tau Energy 
(deg) (a. u. ) (deg) (a. u. ) 
1. 0 -92.6783 19. 180 -92.6459 
2. 10 -92.6820 20. 190 -92*6705 
3. 20 -92.6904 21. 200 -92.6881 
4. 30 -92.6988 22. 210 -92.6987 
5. 40 -92.7052 23, 220 -92.7053 
6. 50 -92.7096 24. ' 230 -92.7097 
7. 60 -92.7126 25. 240 -92.7126 
B. 70 -92.7145 26. 250 -92.7145 
9. 80 -92.7156 27. 260 -92.7155 
10. 90 -92.7159 28. 270 -92,71415P, 
11. 100 
--92.7156 
29. 280 -92.7155 
12. 110 -92.7145 30. 290 -92.7144 
13. 120 -92,7124 -31. 300 -! -92.7126 
14. 130 -92.7082 32. 310 -92.7079 
15. 140 -92.6992 33. 320 -92.7053 
16. 150 -92.6804 34. 330 -92.6989 
17. 160 -92.6504 35. 340 -92.6905 
18. 170 -92.6319 36. 350 -92.6821 
a. u. = 627.5245 kcal/mole 
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3.5 Results ani discussion 
Regressions are obtained for the series of cis-platinLn(II) complexes. 
The drug activities used in the regression are expressed as p(LD,, ) 
where p is the negative logarithm ani IDsO is the dose in mole/kgm 
required to kill 50% of the animals, p(ID90) the negative logarithrn of 
lose in mole/kgm required to produce 90% tumour regression and log(T. I) 
is the logarith-a of LD50/ ID90 in mice. establisher] AW/PC6A tumours, all 
are given in table (3.3). The calculated indices relevant to the 
regression are given in table (3.4). The following quantities from 
statistical tables (149) are required below as significance criteria 
f (1,, 24,0'010%) = 14.028 
f (1,24,0.25%) = 11.398 
f (1,24,0.50%) = 9.551 
f (2,23,0.10%)*= 9.468 . 
f (2p23,0.25%) 7.862 . 
f (2,23,0.50%). = 6.730 . 
f (1,24,1.00%) = 7.822 
f (1,24l2.50%) = 5.716 
f (1,24,10.0%) = 2.927 . 
f (2o23,1.00%) = 5.663 . 
f (2p230,2.50%) = 4.349 
f (2,23,5.00%) = 3.422 
where f is used throughout to represent any tabulated value of the F 
probability distribution ( the "FII is the variance ratio obtained from, 
the regression, which is to be compared with the tabulated 'If"). Flor a 
given fla, b, c), a is the number of independent variables, b is the 
number of degrees of freedom retained by the data and c is the 
probability of the observation being made by chance. 
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TABLE 3.3 Observed toxicity, antitumour activity and therapeutic 
index of complexes of the type cis-Pt(L)2Cl2, 
cis- Pt(LC)CL2 and cis-Pt(LL')Cl?.. 
No L p(LD50) p(ID, 30) log T. I 
1 NEi 3 4.3632 5.2730 0.9098 
2 CH3NH2 4.2488 4.2488 0.0 
3 ClC2li4NH2 3.9731 4.3833 0.4101 
4 n'C2HSNH2 4.1284 4.4724 0.3440 
5 n.: C3H7NH2 4.1613 4.5053 0.3440 
6 n: C4H9NHz 3.5737 4.6151 1.0414 
T n-: CsH, INH2 3.6799 4.0755 0.3956 
8 NH2 4.0595 5.6303 1.5708 
isopropylamine 
NH2 - 9 4 3.6961 4.8227 1.1266. 
isobutylamine 
10 
NH2 
2.5830 4.8803 2.2972 
isoamylamine 
11 NH2 2.8072 4.2312 1.4239 
2-aminohexane 
12 H 3.7908 5.1317 1.3409 
ethyleneimine 
13 NH2 3.8241 5.2182 1.3941 
cyclopropylamine 
14 
<>-NN2 
3.6566 5.1485 1.4918 
cyclobutylamine 
15 NH 3.2307 4. ý678 1.1371- 
pyrrolidimine 
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TABIE 3.3 (cont. ) 
No Lp (LD5 0) p(IDga) log T. I 
16 (D--NH2 2.9585 5.2595 2. 
. 
3010 
cyclopentylamine 
17 -NH2 ý'2.1617 4.5876 > 2.4265 
cycýloe>xylamine 
18 c 
ý142 
3.7429 4.1608 0.41 79 
cyclohexyl- 
methylamine 
19 H3C-<: 
>-NH2 2.6966 2.6204 -. 0762 
4-methylhexylamine 
No LC p(LDso) p (ID9 o) log T. I 
20 
NH2 F 4.1611 4.5133 0.3ý22 
19H2 . ethylenediarnine 
21 
NH2 a 
4.4284 5.2ý54 0.8270 
NH2 
1,2-diaminecyclo- 
hexane 
NH2 
22 
(ýý 3.8917 5.1928 1.3010 
NH2 
o-phenylenediamine 
43C'%. 
ooOýý-.., eNH2 
23 tSjý 4.2368 5.0208 0.7839 
. 
NH2 
4-methyl-o-phenylene- 
diamine 
24 
H3C NH2 
3 . 1526 5. . 2064 . 
2.0538. 
442 
4 5-dimethyl-o- 
pAenylenediamine 
No L p(LDso) p(ID90) log T. I 
25 NH3 
ýN 
H 4.0661 4.9112 0.8450 
26 NN NH3 4.5246 5.8671 1.3424 
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TABLE 3A Calculated indices for cis-platinan(II) complexes 
NO s FN (Pt) ALPHA (Pt-N. ELEMO B. E S. A M. V 
(-e) (e%F (ev) (ev) 
02 
(A 
0 
(A3 
1. 1.33364 0.23582 -1.66800 -65.96607 141.21875 103.698 
2. 1.31820 0.23897 -1.46058 -138.4315 181.59962 137.312 
3. 1.31705 0.24051 -1.63080 -189.9053 257.56951 198.372 
4. 1.32439 0.23885 -1.36804 -206.0480 226.49924 171.171 
5. 1.32677 0.23910 -1.32099 -273.8774 269.21399 204.612 
6. 1.32768 0.23894 -1.29536 -341.5070 312.36322 238.157 
7. 1.32810 0.23893 -1.28052 -409.0356 355.52200 271.704 
8. 1.32860 0.23491 -1.38551 -276.3841 248.25564 200.408 
9. 1.32829 0.23906 -1.29290 -341.4548 300.66033 236.390 
10. 1.32766 0.23896 -1.29341 -408.8274 343.51295 269 . 902 
11. 1.32315 0.23983 -1.12638 -479.0759 370.41130 298.973 
12. 1.31176 0.24256 -1.21490 -192.1164 193.63140 155.714 
13. 1.32344 0.23899 -1.35590 -256.9814 243.06536 189.190 
14, 1.32675 0.23882 -1.30283 -328.6314 273.86092 218.244 
15. 1.33170 0.24235 -1.20518 -334.1588 245.53472 212.164. 
16.. 1.32896 0.23865 -1.24946 -401.0907 305.77453 248.082 
17. 1.32494 0.23775 -1.19393 -471.9271 339.53755 280.308 
18. 1.32799 0.23912 -1.26309 -536.3134 389.84672 315.294 
19. 1.32574 0.23773 -1.16699 -538.9946 379,53908 313.559 
20. 1.32835 0.23976 -1.65491 -131.7619 164.06017 127.049 
21. 1.33355 0.24042 -1.51771 -263.3191 222.77793 182.071 
22. 1.33312 0.23783 -1,38851 -229.8914 202.82641 164.640 
23. 1.33437 0.23766 -1,35680 -263.9351 224.27426 181.632 
24. 1.33498 0.23761 -1.33765 -297.9718 242.37281 197.712 
25. 1.32186 0.24045 -1.42843 -129.0678 165.30104 129.343 
26. 1.33088 0.23650 -1.44787 -233.5466 223.50944 175.855 
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TABLE 3.4 Cont. 
NO. VI(p2) V2(P2) E (P 2 x 
V2 (p 
12 
v (P 
23 
E (P3) 
y 
(volts) (ev/e2 VoltS/R (VoltS2)- (ev/e2 volts/R 
1 -1.740B9 -1.01868 -. 19516 3.03069 -. 857732 0.387790 
2 -1.88854 -1.03329 -. 19555 3.56666 *-. 976230 0.573029 
3 -1.73647 -1.05061 -. 17952 3.01535 -1.00430 0.528162 
4 -1&92022 -1.03751 -. 20224 3.68726 -. 950184 0.486267 
5 -1.93925 -1.04065 -. 20553 3.76072 -. 961238 0.494645 
6- -1.95104 -1.04179 -. 20726 3.80656 -. 965106 0.486119 
7 -1.95840 -1.04262 -. 20842 3.83533 -. 967581 0.484870 
8 -1.90990 -1.04877 -. 20827 3.64773 -1,01775 0.583736 
9 -1.94926 -1.04490 -. 20836 3.79965 -. 973375 0.489649 
10 -1.94956 -1.04446 -. 20659 3.80082 -. 973362 . 
0.492387 
11 -2.06202 -1.04945 -. 22062 4.25194 -1.04179 0.632210 
12 -2.01650 -1.05134 -. 22044 4.06628 -. 999430 0,856637 
13 -1.93373 -1.04693 -. 20231 3.73934 -1.02819 0.537873 
14 -1.95007 -1.04992 -. 20470 3.80277 -1.03684 0.511128- 
15 -1.99551 -1.06322 -. 22249 3.98208 -1.00531 0.486780 
16 -1.97483 -1.05365 -. 20872 3.89996 -1.05962 0.507130 
17 -1.99927 -1.07335 -. 21361 3.99710 -1.17509 0.679253 
18 -1.97217 -1,04814 -. 20719 3.88946 -. 987856 0.478264 
19 -2.01109 -1.07480 -. 21595 4.04448 -1,17990 0.671448 
20 -1.72844 -1.03106 -. 18333 2.98753 -. 905706 0.324691 
21 -1.77717 -1.03950 -. 18929 3.15833 -. 944805 0.337377 
22 -1.91221 -1,04517 -. 21117 3.65656 -. 976751 0.436274 
23 -1.92687 -1.04588 -. 21328 3.71282 -. 981520 0.431820 
24 -1.93878 -1.04708' -. 21537 3.75886 -. 986461 0,429807 
25 -1.82536 -1.03626 -. 19787 3.33193 -. 934236 0.845797 
26 -1.88546 -1.03566 -. 20470 3.55496 -. 897889 0.396412 
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TABLE 3A Cont, 
NO. E. F(PO E. F2 (P ) v2 (P4 ) E (P 4) E (P 4) E. F(P 4) 3 Y z 
volts/R volts2/R2 (ev/e 2) volts/R volts/R volts/R. 
1 2.846067 8.100150 -. 005014 -. 020719 0.029555 . 002008. 
2 2.882205 8.307107 -. 007037 -. 024369 0.033318 . 002535 
3 2.879276 8.290230 -. 023903 -. 015504, 0.025822 . 000931 
4 2.838211 8.055441 -. 009790 -, 026165 00"033192 . 002614 
5 2.831473 8.017240 -. 016956 -. 024288 0.036231 . 002701 
6 2.829635 8.006833 -. 039701 -. 028900 0.025912 . 002212 
7 2.827956 7.997334 -. 198022 -. 171906 0.157501 . 056828 
8 2.833441 8.028385 -. 011492 -. 026697 0.031249 . 002371 
9 2.836380 8.045051 -. 019800 -. 024854 0.038236 . 002891 
10 2.827806 7.996486 -. 046752 -. 032659 0.025479 . 002479 
11 2.795115 7.812669 -. 199612 -. 174829 0.158255 . 058448 
12 2.990666 8.944085 -. 008753 -. 029215 0.036716 . 003138 
13 2.850251 8.123933 -. 012331 -. 027620 0.032290 . 002673 
14 2.885780 8.327727 -. 016885 -. 028085 0.033504 . 002762. 
15 2.834788 8.036025 -. 013736 -. 027602 0.036084 . 002928 
16 2.891676ý 8.361789 -. 021461 -. 029527 0.035911 . 003081 
17 2.776840 7.710840 -. 031282 -. 028020 0.034596 . 002535 
18 2.834518 8.034493 -. 065918 -. 017836 0.034453 . 002227 
19 2.773727 7.693564 -, 043569 -. 031730 0.043759 . 003386 
20 2.902236 8.422976 -. 006280 -. 020026 0.028923 . 002017 
21 2.886121 8.329693 -. 010567 -. 021687 0.029582 . 002369 
22 2.843325' 8.084495 -. 010119 -. 021669 0.032685 . 002637 
23 2.840321 8.067424 -. 010506 -. 020984 0.032250 . 002637 
24 2.835136 8.037995 -. 012004 -. 021456 0.033788 . 002855 
25 2.961139 8.768343 -. 008299 -. 034542 0.038301 . 003514 
26 2.860202 8.180757 -. 005896 -. 017298 0.028562 . 001905 
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1ý4 
Three sets of regressions are obtained from the data given for 26 
molecules in table (3.3), according to the type of biological activity : 
(1) Lethal dose (LD50) 
The best simple regression is with p(LD,, ) as the depenlent variable ar4L 
given below. Significance levels are above 99.9% 
p(LD50) = 6.685(il. 1) V2(p3) + 10.31(±1.16) (3.1) 
and r= . 758 ;s= . 41 ; F(1,24) - 32.50 
p(LDSO) = 0.0037(t, 0006) B. E, + 4.786(t. 21) (3.2) 
ard r= . 749 ;s= . 42 ; F(1,24) = 30.73 
p(EDSO) = 39.19(±-7.1) V2(P2) + 44.67(±7.4) (3.3) 
ani r= . 746 ;s= . 42 ; F(1,24) = 30.12 
p(LD'50) - -. 0078(±. 001) M. V + 5.317(i-3.2) (3.4) 
ard r= . 731 ;s= . 43 ;. ' F(1,24) = 27.60 
The best four two variable regressions have significance levels above 
99.9% : 
P(LDSO) = 0.0021(±. 0008) B. E + 4.06(±1.4) V2(P. 3) + 8.34(±1.2) '(3.5) 
and r- . 820 ;s= . 37- ; F(2,23) = 23.65 
P(LDso) = -. 0043(±oOO1) M. V + 4,3(±1.4) V2(p3) + 8.86(±1.1) (3.6) 
arO r= . 817 ;s= . 37 ; F(2,23) = 23.19 .* 
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P(LDso) = . 002(±. 0008) B. E + 22.6(±9) V2(P2) + 28(±9.4) (3,7) 
and r= . 808 ;s= . 38 ; F(2,23) =. 21.63 . 
p (LD so) 0044 001) M. V + 24.3 8) V2 (P2 + 30.07 (±-8) (3.8) 
and r= . 807 s . 38 ; F(2,23) 21.47 
The coefficients of the second order quantities V2 in the above 
equations have a sign which is difficult to explain i. e which Lndicates 
that the lower the reactivity at the given site, the higher the drug 
activity. ribe positive coefficient of- the B, E indicates that the, less 
stable the molecule,, the higher its toxicity. The negative coefficient 
of the M. V indicates that as the molecular size increases, it becomes 
less toxic. Since B, E and M. V have a substantial . negative 
intercorrelation, it is difficult'to decide which, if either, of these 
is a causal quantity. 
(2) Inhibition dose (ID9, ) 
The best four simple regressions with p(IDd) as the depenient variables 
are given below, the significance levels lie between 99.5% and 99.0%. 
They are therefore fairly significant regressions,, however low the r 
value. 
p(ID90) = 7.186(±2.4) Ez (P3) - 15.2(±, 6,8) (3.9) 
and r= . 512 ;s =ý . 56 ; F(1#24) = 8.54 
p(ID90) = -. 0046(i,. 001) S. A + 5.973(t. 4) (3.10) 
aneJ r . 512 ;s= . 56 ; F(1,24) - 8.53 
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p(ID90) = -. 0055(±. 001) M. V + 5.91(: f. 41) (3.11) 
ard r= . 508 ;s= . 56 F(1,24) = 8.36 
p(ID90) = 0.0023(±. 0009) B. E + 5.464(±. 3) (3.12) 
and r= . 471 ;s= . 57 ; F(1,24) = 6.85 
The cartesian axes to which the electric field vector is referredr 
are indicated in figur*e (3.1), The Z component of the electric field at 
the receptor point (P3) has a significant correlation with drug activity 
indicating the possible approach of a dipolar species along the line 
normal to the plane of the molecule,, passing through platinua. It is 
apparent from equations (3.10) and (3.11) that the waller the complext 
the more active it tends to be. EquAion (3.12) has the same trend as 
with the U)ýO regressions and might be reinterpreted as indicating that 
the less stable the complex, the more active it becomes. 
Four of the two independent variable regression have 'a significances 
between the 99.75% and 99.9% levels : 
p(ID90) = -160(±61) ALPHA(Pt-N, ) t 8.8(±2) Ez (p3) + 18.5(114) (3.13) 
and r . 656 ;s= . 503 ; F(2,23) = 8.69 
p(IDg) = -217(458) ALPHA(Pt-NS) + 8.9(: t2) E. F(P3) + 31.1(±14) (3.14) 
ard r= . 646' ;s= . 509 F(2,23) = 8.24 
P(ID90) 61.53(±20) FN(Pt) + 8.26(±2.3 
,)E. 
F(p3) - 100.5 (±30) (3.15) 
and r . 626 ;s= . 52 ; F(2,23) = 7.42 . 
P(IDqo) = 61.9(-±20) EN(Pt) + 1.43(. ±. 4) E, F 
I 
(P3) - 89.1(±29) (3.16) 
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and r= . 624 ;s= . 521 ; F(2,23) - 7.35 . 
All the above regressions confirm the observation that the higher the 
electric field at point 3, the higher the drug activity. The biological 
species which interact at P3 is probably not a DNA base lying parallel 
to the complex, however, since such a species would have little or no 
dipole moment in the Z direction. The component of electric field at 
point 3 is in the Z direction, for the complexes considered. 
It is interesting that FN(Pt) appears in regressions (3.15) ard (3.16). 
It is possible that a species lisplacel along, the Z axis from the 
platinum pasition, interacts with the complex both electrostatically and 
through transfer of electrons to platinun. In equations (3.13) and 
(3-14),, the negative coefficients of ALPRA(Pt-N. ) makes - these 
regressions less attractivep despite the higher correlation. Negative 
coefficients indicate that the more polarizable the Pt-N. bond, the 
lower the drug activity. 
(3) Therapeutic inlex (T. I) 
The best simple regressions with log(T, I) as dependent variable are 
significant, but they have low correlation coefficients. Their 
significance-levels are between 90.0% and 95.0% : 
log(T. I) = -25.81(: U2.2) E (P2) - 4.239(: t2.5) (3.17) x 
ard r= . 394 . 65 ; F(1,24) = 4.42 
log(T. I) = -2.6(±1.5) VI (P 2 
3.926(±. 2.9) (3.18) 
and r= . 329 ;s= . 67 ; F(1,24) = 2.91 
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log(T. I) = 0.69(±. 4) V2 (P2) - 1.475(±1.5) (3.19) 1 
and r= . 327 ;s= . 67 ; F(1,24) - 2.88 
log(T. I) = 1.598(±*. 44) ELEMO + 3.233(±1.2) (3.20) 
and r= . 327 ;s= . 67 ; F(1,24) = 2.87 . 
Despite the low correlation coefficients,, all of these regressions are 
readily given physical interpretations. Equations (3.17), (3.18) and 
(3.19) are relevant to the ease of interactions with a species situated 
0 
at the electrostatic minimum point in the Z-1.69 A plane. Equation 
(3.20) indicates that the more ready is the complex to accept electrons 
in a charge transfer process, the greater the drug activity. Since 
p(ID, ý and p(LD50) are . hopefully determined by different molecular 
characteristics, it is not surprising that single independent variables 
give poor correlations with log(T. I) 
The best two variable regressions have significance levels between 95.0% 
and 97.5% : 
log(T, I) = -124(++-46) EZ(P4) + 81.2(±30) E. F(P4) + 1.09(±. 2) (3.21) 
and r= . 489 ;s= . 63 ; F(2,23) = 3.62 . 
log(T. I) = -30.2(tl2) Ex (P2) - 4.6(t. 4) Ez (PO - 4.96 (±2.5) (3.22) 
ard r= . 448 ;s= . 65 ; F(2,23) = 2.90 
I 
locl(T. I) = -29.2(±12) E x(P2) + 
2.5(±2.6) V2(p4) - 4.87(±2.6) (3.23) 
and r- . 431 ;s= . 65 ; P(2,23) = 2.63 .I 
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log (T. I) = -553 (±25) Ex (PO - 66.4(±29) Ez (P4 + 1.89 (±. 3) (3.24) 
and r= . 423 ;s= 66 F(2,23) = 2.51 
In the above two vakable regressions, the improvement in correlation is 
disappointing. However, they still provide some interest from a 
mechanistic stanipoint, in involvement of the electric field components 
at P4 and P2 . The electric field at the point (PO is involved in 
regressions (3.21), (3.22) and (3.24), this point takes into 
consi-Jeration of closest possible approach of a species in the vicinity 
of the ammine ligands, without steric interference. 
The identification of the point (p4) 'with a receptor is not certain. It 
is expected that there is one receptor for the antitunour 'activity and 
another for the toxic action. Hence'r regressions (3.22) and (3.23) are 
perhaps more attractive, but the identification of either P2 : )f P4 with, 
either antitunour or toxic activity is not convincing. It is noticeable 
that the size iMices which appear in both the p(LD,,, ) and p(ID9, ) 
regressions are absent from the log(T. I) regressions. As the molecular 
size increases, p(LD,, ) and p(ID,, ) decrease by similar &nountsl so the 
change has a negligiable effect on lbg(T. I) 
In conclusion, the above regressions with p(ID,, ) and log(T. I) as 
depenJent variables are disappointing, since they can scarcely be relied 
upon to predict more active 'compounds, However j many of the regressions 
with p(LD50) as dependent variable have a high a correlation and are 
highly significant. These might therefore be used to predict less toxic 
compounds. The high toxicity of 'cis-DDP proves to be a major problem in 
clinical trials (150). A less toxic but equally active compound might 
therefore represent a major clinical advancement. 
CHAPrER FOUR 
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DIHYDROFCLATE REDUCTASE INHIBITION BY QUINAZOLINES AND PYRIMIDINES 
4.1 Introduction 
This chapter covers a wide range of dihydrofolate reductase inhibitorst 
including quinazolines and pyrimidine compounds,, due to their importance 
as antineoplastic agents, Folate antagonists continue to be useful 
drugs in the treatment of certain neoplastic diseases. The design of 
antimetabolites for the treatment of cancer has been focused on 
inhibition of enzymes involved in the synthesis of nucleic ac id 
precursors, Dihydrofolate reductase is the target . for the 
therapeutically important "anti-folate" drugs. The enzyme dihydrofolate 
reductase catalyzes the Nicotinamide Adenine Dinucleotide Phosphate 
(NADPH) dependent reduction of dihydrofolate (FH2) to tetrahydrofolate 
(FH4) (151,152), This enzyme is of considerable chemotherapeutic, 
interest, because of its role in the cellular biosynthesis of purines,, 
pyrimidines and certain amino acids. 
Dihydrofolate reductase inhibitors have already proved to be of value as 
antibacterial (153,154), and antitumour agents (155), W11 known 
exanples are amothopterint trimethoprim and cycloguanil hydrochloride, 
In the biosynthesis of amino acids, thymidylate and purinesl 
tetrahydrofolate acts as a carrier of one carbon fragments such as the 
formate unit (156). In most of the one-carbon transfers, the folate 
enzyme remains at the tetrahydro oxidation level,, but in the synthesis 
of thynidylate from deoxyuridylate (catalysed thymidylate synthetase) 
the product is dihydrofolate. This must then be reduced by 
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dihydrofolate reductase to maintain the cellular pool of 
tetrahydrofolate derivatives. Inhibition of dihydýofolate reductase 
will thus lead to a depletion of this pool and to inhibition of DNA 
synthesist owing to a lack of thymidylate and purines. 
folate + NAWH +H ------ >, FH' + NADP 
FH2 + NADPH +H FH + NADP 
Folic acid is composed of three parts: pteridine, P-amino benzoic acid 
(P-AB) and glutamic acid. The determination of the structure of folic 
acid (157) confirms the presence of P-AB as an integral part of the 
folic acid. 
In an attempt to understand the mechanism by which antifolate agents 
bind to dihydrofolate reductasep it beccmes necessary to examine 
existing inhibitors in great detail. 
A series of dihydrofolate reductases (DHFR) from various mammalian and 
bacterial sources have been reported (158). 7he individual enzymes do 
not differ among themselves in pH optimal dissociation constant (Km) 
values for dihydrofolater or other properties usually measured. 
However, bacterial and mammalian enzymes perhaps differ in the binding 
of various inhibitors (151) . The observed differences in some of the 
physical and kinetic properties of the enzymes (159) has led to the 
development of inhibitors that are toxic to bacteria but not to mammals 
(153). 7he activity may also vary toward the enzymes obtained from 
different mamalian sources. Some differences in the level of 
inhibition may exist between the enzymes of normal and neoplastic 
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tissms (160). 
A relevant enzyme inhibitory assay has been- performed by the method 
described in reference (161,162). This assay is based on a decrease in 
optical density at 340 nm due to the conversion of dihýdrofolate and 
+0 
NADPH to tetrahydrofolate and NADP . All assays are performed at 37. C 
using a Gilford multiple sample absorbance recorder By this meanso, 
the- C.., and ID so values have been measured -for many series of 
dihydrofolate reductase inhibitors (all clinically useful, folate 
antagonists are inhibitors of this enzyme) . 
A large number of compounds have been synthesized and tested -in vitro 
for biological activity in order to, find more potent and less toxic 
anticancer agents (163). Hansch and coworkers (164-167), have analysed 
these data on the inhibition of dihydrofolate reductase to find 
correlations between structure and activity, and to "map" the receptor 
space of DHFR from rat liver, bacteria and malarial parasites, for a 
series of quinazoline derivatives (168). Their relationships involve 
various physicochemical properties and also dummy variables. 
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4.2 Mechanism of action 
The folate antagonists, in particular amethopterin (methotrexate)r 
continue to be useful drugs for the treatment of certain neoplastic 
diseases in man. The effectiveness of. amethopterin in preventing DNA 
synthesis and cellular replication appears to be a consequence of 
inhibition of the enzyme DHFR. In an attempt to understand the 
mechanism by which antifolate agents bind to DHFR, the X-ray structure 
of methotrexate (MTX) bound DHFR has been determined (170). MTX is a 
powerful inhibitor of the enzyme, binding up to 10,000 times more 
tightly than the structually similar folate. The only differences 
between folate and MTX are that the hydroxyl group at C4 in folate is 
replaced by an amino group in RrX and N,,,, is'methylated, It is thought 
that protonation of the ring occurs most readily at N18 which interacts 
strongly with the side chain of ASP-27 (Aspartate)., 
In the present work, several series of DHFR inhibitory agentsp from 
various sources have been studied. The effects of structural changes on 
the electronic environnent are determined,, correlation between 
calculated electronic propertiepand inhibitory activity within a given 
series being sought. Any observed correlation might shed some light on 
the mechanism of enzyme inhibition, or assist in the design of more 
potent inhibitors, The e. p contour and solid maps, which are plotted 
for quinazoline and 2j4-diamino 5-benzylamino pyrimidine are given in 
figures (4.1) and (4.2) and (4.3) respectively. The maps indicate that 
electrophilic attack might also occur readily at N3 as well as at N, 
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b. 2,4-diamino 5-benzylamino pyrimidine 
-6 
as Quinazoline 
-41 
FIGURE 4.1 CNDO/2 e. p contour maps for quinazoline and 2,4-diamino 
5-benzylamino pyrimidine (all values are in kcal/mole). 
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d. 
ce 
b. 
a. 
FIGURE 4.2 CNDO/2 e. p solid maps for quinazoline (a and b, c and d are 
viewed from directions with angles of 10 and 15 degress, respectively, 
to the hor 1 zon t al) . 
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FIGURE 4.3a CNDO/2 e. p solid maps for 2,4-diamino 5-benzylamino 
pyrimidine viewed in directions (indicated by cartesian frames) 10 
degrees to the horizontal. 
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FIGURE 4.3b CNDO/2 e. p solid maps for 2,4-diamino 5-benzylamino 
pyrimidine viewed in directions (indicated by cartesian frames) 15 
degrees to the horizontal. 
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4.3 Inhibition of DHFR in vitro by 2,4,5,6 and 7 substituted quinazoline 
A large number of quinazoline series are studied. Other comon names of 
quinazoline are phemiazine, benzyl''. ene amidine, benzo-1,3-diazine, 
5,6-benzopyrimidine and 1,3-diazanaphthalene. 
From the chemical point of view, quinazolines can be divided into two 
main groups according to their characteristic properties. The first 
group is that in which the two rings are fully aromatic, These do not 
behave entirely as pyrimidines. The benzene ring has a profound effect 
on the properties of the pyrimidine ring. It delocalizes the 7r 
electrons of the 3,4-double bond making its reactivity like'that of an 
isolated double bond (170). As a consequence of this? quinazoline is 
very reactive towards nucleophiles,, which readily add across the 314 
double bond. Evidence that the electron distribution in the vicinity of 
this bond is critical to inhibitory activity is, provided by the 
observation that substitution in positions C2 and C4 has. a dramatic 
effect on the activity. 
The second- group includes the quinazolines which lack the full 
complement of six iT electrons in either the pyrimidine or the benzene 
ring. All the quinazolines studied in this chapter belong to the first 
group, 
Using the CNDO/2 option, MORBG calculations have been performed on a 
series of 2,4,5,6 and 7 substituted quinazolines. An X-ray structure of 
quinazoline has been obtained from reference (171). This geometry has 
been optimized by usýng prograrn "GEOMIN" (QCPE 312) (172), to obtain a 
more reliable estimate of the geometry in solution. Fed with eitý er a 
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geometry estimated using standard bond lengths and bond angles (110) or 
an x-ray structure,, "GEOMIN" adjusts the atomic coordinates to minimize 
the total energy of ýhe molecule as ca lculated by the CNDO/2 or INDO 
method. A variable metric. (or quasi-Newton) minimization routine is 
employed in the program, this being based on the method of Murtagh and 
Sargent (173). The minimum point obtained is not# in general, the 
"global" (absolute) minimum energy point,, but merely the "local" minimum 
which terminates the curve of steepest descent in energy from the 
starting coordinates. The minimization is terminated' as soon as a 
point# giving all derivitives of energy with respect to atomic 
coordinates to be less than 0.0001 a. u. is found. This point 
approximates the local minimum. In order to find the global minimume it 
is necessary to perform the whole calculation for every possible 
starting point arrangement of the atoms, The distinct local minima 
obtained with lowest energy is the so called global minimum. 
"GEOMIN" has been used presently with the CNDO option to get a minimum 
energy geometry, which is completely consistent with the use of CNDO/2 
in the calculation of electronic properties. The optimized bond lengths 
and bond angles for quinazoline are given in table (4.1). 
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TABLE 4.1 The optimized bond lengths and bond angles for-quinazoline. 
14 
I 
Bond lengths(g) 
NI-C2 1.320 CS-C6 m C7-CS 1.365 
C2-NS 1.357 CS-C 10 =C B-C 9 1.413 
N3-C4 1.325 C2-H 25 =C 4-H 16 
1.111 
C6-C7 1.403 C6-H 14 
c7 -H 11 
1.117 
c -C 78 1.365 c -C 19 1.372 
C4-CIO 1,409 C5-H 13 1.118 
C9-clo 1.413 CS-H 12 1.113 
Bond angles (deg) 
C3-C2 -NI 129.26 Hl5-C2-Na 114.85- 
C4-N3-C2 113.41 Hl6-C4-N3 114,44 
C9-Cl-C2 115.16 Hj3-C57C6 119.87 
CO-Cg-N, 118,88 H24-C6-C7 119.25 
c7 -CO-Cg 121.35 Hll-C7-CB 120.51 
C6-C7-CB- 120.01 H22-C8-C9 117,08 
c5 -C 6 -C 7 119.94 
CS-CIO-C4 127.45 
Cl 
0 -C4 -C3 125.83 N, -Cg-Clo 122.38 
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The 25 substituted quinazolines were chosen as having reliable drug 
activity estimates given in reference (174). Saturated compounds and 
compounds with extrapolated drug activity have been excluded from the 
study. The drug activity and the electronic and molecular parameters 
which correlate most significantly with the drug activity are given in 
table (4.2). The drug activity is expressed as p(C,, ), where C,, is the 
molar c oncentration which causes 50% inhibition of rat liver DHFR under 
a given set of conditions. 
The best four single variable regressions with p(C so 
) as the dependent 
variable (where p is the negative logarithn),, have significance levels 
above 99.9%: 
p(C5Q) = -19.62(±2.2) FN(NI) + 8.05(±. 38) (4.1) 
and r= . 875 ;s= . 54 ; F(li23) = 75.28 
P(Cso) = 1.556(±. 18) ALPHA(Clo) -, 181.4(±22.7) (4.2) 
and r= . 863 ;s= . 56 ; F(1,23) = 67.12 ., 
P(Cso) = . 484(±. 06) Omol - 4.32(±1.29) (4.3) 
and r= . 830 -; s= 62 ; F(1,23) 50.99 
P(C. 
50) = 1.275(±. 18)ýE (CS-Cd + 55.2(±7.2) (4.4) 
and r= . 824 ;s= . 63 ; F(1,23) = 48.72 
Ihe best four two variable regression with- p(C,,, ) as the dependent 
variable also have significance levels above 99.9% 
P(Cso) = L23(±l-el)AU4iA(Cjo) - 3.3(±. 5)E(NI-Cg) - 258(±18) (4.5) 
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and r= . 956 ;s= . 33 ; F(2,22) = 116.57 . 
P(Cso) = 1.06(±1.6) ALPHA(Clo) + 1.17(±. 2) E(NI-C 80.6(±26) (4.6) I 
and r= . 935 ;s= .4; F(2,22) = 77.37 
p(Cso) = 2.35(+-. 4) EBIND(Clo) + 0.31(±. 05) ctmol + 242(-+47) (4.7) 
and r= . 927 ;s= . 43 ; F(2,22) 68.05 
p(Csg) = 9.71(±1.9) ALPHA(C,, ) + 0.26(-+. 06) Clmol - 120(±23) (4.8) 
and r= . 924 ;s= . 43 ; F(2,22) = 64.99 
The most attractive regressions represented contain atomic and molecular 
polarizabilty as independent variablesi, the positive coefficients always* 
associated with these variables may be taken to indicate that a second 
order interaction is critical in drug-enzyme binding. 
Cn the other hand, negative cofficients are associated with E(N, -C. ) and 
FN(NI), The former suggests that the stronger the bond between atom NI 
and C9, the greater the drug activity. It seems unlikely that there is 
a direct physical link between the stability of this bond and enzyme 
inhibition. The latter suggests that the more resistant is N, to 
nucleophilic attack, the greater the enzyme inhibition, which is equally 
unlikely. On the other hand, positive coefficients appear with. E(C, -C6) 
and E(N, -C, ) in equations (4.4) and (4.6) respectively. it is 
concievable that an increase in reactivity in either of these positions 
might have some direct bearing on enzyme inhibition. 
The two types of polarizability are correlated with the drug activitY. 
The atomic and molecular polarizabilities, taken together, may be used 
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to characterize second order interactions at intermediate 
molecule-reagent separation (99). TAbenever enzyme-substrate binding is 
reversible, it probably , arises from fairly weak Van der Waals 
interactions rather than covalent bonding. In this casep if one of the 
poles of the enzyme charge distribution were closer to atom C1, of the 
quinazoline substrate than to any other quinazoline atomsj then 
ALPHA(C,, ) might be expected to be of special relevance. However,, the 
field of the enzyme over the rest of the quinazoline environment would 
still be substantial, this could account for the relevance of (Y'Mol, 
which determines the second order interaction energy in the presence of 
a uniform electric field. I.. I.. 
The appearence of EBIND(CIO) in equation (4.7) might arise through the 
high correlation of this quantity with ALPHA(CIO) . 
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TABM 4.2 Calculated indices and observed biological activity of 
R4 R5 
some substituted quinazolines. I 
NO. Substituent 
R2 R4 R5 R6 
HHHH 
2H NH 2HH 
3H OH HH 
4 OH OH H -' H 
5 OH NH2 HH 
6 ACNH OH HH 
7 'NH2 OH HH 
8 NH2 OH H 7-CF 3 
9 NH 2 SH HH 
10 NH 2 OH H CHS 
11 NH2 NH2 H NH2 
12 NH 2 NH 2HH 
13 NH 2 OH H, Cl 
14 NH 2 OH CH 3H 
15 NH 2 NH 2H 
CN 
16 NH 
2 
NH 
2H 
CHO 
17 N% NH 
2H 
CH2 NH2 
18 NH NH H Cl 
22 
19 NH2 NH 
2H 
Br 
20 NH 
2 NH 2H 
CH3 
21 NH 
2 NH 2 
CH 
3 
H' 
22 NH2 NH 2 ci NH2 
23 NH 
2 NH 2 
Cl H 
24 NH2 NH 2 
ci ci 
25 NH 
2 
NH2 Cl Br 
P(Cso) 
R. 1 iv, 
2.2596 
3.0861 
3*6197 
3.8860 
4.0177 
4.2839 
4.3098 
4.3467 
4.3665 
4.4436 
4.5686 
4.6575 
4.6575 
4.7958 
4.9208 
5.0000 
5.0268 
5.3971 
5.6020 
5.6575 
6.0861 
6.1804 
6.2518 
6.6989 
7.0000 
'I) R2 
FN (N1) 
er (-e) 
0.2974 
0.2067 
0.2355 
0.1958 
0.1708 
0.2012 
0.1825 
0.1644ý 
0.2439 
0.1820' 
0.1630 
0,1601 
0.1438 
0.1751 
0.1427 
0.0957 
0.1589 
0.1439 
0.1358 
0.1242 
0.1397 
0.1273 
0.1152 
0.0932 
0.0855 
H 
E(NI-CgXLPHA(Clo) (Xmol 
(e. v) (KeT 1) ( ý3) 
-33.2386 121.809 15.04 
-33.1474 123.222 16.23 
-33.1688 122.691 15.72 
-33.4633 122.680 16.41 
-33.4332 123.183 16.92 
-33.4616 122.773 20.98 
-33.5235 122.715 16.92 
-33.5534 123.110 19.33 
-33.5819 122.949 19.61 
-33.5080 122.886 18.82 
-33.3270 123.582 18.62 
-33.4993 *123.227 17.43 
-33.5637 123.657 18.98 
-33.5338 123.393 18.82 
-33.5981 123.281 19.68 
-33.6664 123.103 19.58 
-33.4914 123.420 20.52 
-33.6168 123.243 19.49 
-33.6451 123.302 20.63 
-33.6294 123.360 19.32 
-33.5297 123.958 19.32 
-33.3820 124.694 20.69 
-33.5482 124.261 19.49 
-733.6569 124.277 21.56 
-33.6799 124.355 22.70 
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TABLE 4.2 Calculated indices and observed biological activity of 
R4 RS 
some substituted quinazolines. I 
R6 
NO. Substituent 
R2 R4 R, 5 R6 
1HHHH 
2H NH2 HH 
3H OH HH 
4 OH OH H 'H 
5 OH NH 2HH 
6 ANH OH HH 
7 NH2 OH HH 
8 NH2 OH H 7-CF 
9 NH 2 SH HH 
10 NH 2 OH H 
CHS 
11 NH2 NH2 H NH2 
12 NH 2 NH2 HH 
13 NH 2 OH H Cl 
14 NH 2 OH CH, H 
15 NH 2 NH 2H CN 
16 NH 
2 NH 2H 
CHO 
17 NH 
2 
NH 
2H 
CH2NH2 
18 NH NH H Cl 
22 
19 NH 
2 
NH 2H Br 
20 NH 2 NH2 H CH 3 
21 NH 2 NH 2 
CH3 H 
22 NH2 NH 2 Cl NH2 
23 NH 2 NH 2 Cl H 
24 NH 2 NH 2 ci ci 
P(CSO) 
R. 1 ive 
2.2596 
3.0861 
3.6197 
3.8860 
4.0177 
4.2839 
4.3098 
4,3467 
4.3665 
4.4436 
4.5686 
4.6575 
4.6575 
4.7958 
4.9208 
5.0000 
5.0268 
5.3971 
5.6020 
5.6575 
6.0861 
6.1804 
6,2518 
6.6989 
'11ý 
R2 
EN(Ni) 
r (-e) 
0.2974 
0o2067 
0.2355 
0.1958 
0.1708 
0.2012 
0.1825 
0.1644 
0.2439 
0.1820' 
0.1630 
0.1601 
0.1438 
0.1751 
0.1427 
0.0957 
0.1589 
0.1439 
0.1358 
0.1242 
0.1397 
0.1273 
0.1152 
0.0932 
H 
E (N I -C 9)AI 
(e. v) 
-33.2386 
-33.1474 
-33.1688 
-33.4633 
-33.4332 
-33.4616 
-33.5235 
-33.5534 
-33.5819 
-33.5080 
-33.3270 
-33.4993 
-33.5637 
-33.5338 
-33.5981 
-33.6664 
-33.4914 
-33.6168 
-33.6451 
-33.6294 
-33.5297 
-33.3820 
-33.5482 
-33.6569 
PHA(Clo) 
(KeNr 1) 
121.809 
123.222 
122.691 
122.680 
123.183 
122.773 
122.715 
123.110 
122.949 
122.886 
123.582 
123.227 
123.657 
123.393 
123.281 
123.103 
123,420 
123.243 
123.302 
123.360 
123.938 
124.694 
124.261 
124.277 
mol 
(91) 
15.04 
16.23 
15.72 
16.41 
16.92 
20.98 
16.92 
19.33 
19.61 
18.82 
18.62 
17.43 
18.98 
18,82 
19.68 
19.58 
20.52 
19.49 
20.63 
19.32 
19.32 
20.69 
19.49 
21.56 
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4.4 Inhibition of DHFR in vitro by 2,4-diamino 6-(benzylamino) 
quinazoline 
A series of 2,4-diamino 6-(benzylamino) quinazolines and 2F4-diamino 
6-( anilinomethyl ) quinazolines report , ed in reference (175) are 
inhibitors of DHFR from rat liver and L1210 mouse leukemia cells. The 
calculated electronic and molecular indices are correlated with both 
drug activities. , 
The optimized geometry of isolated quinazoline is carried over to this 
series, The conformations of the benzylamino and anilincmethyl 
substituents in position C are also optimized using program "GBOMIN" 6 
All electronic indices are obtained by using CNDO/2 wavefunctions. The 
calculated indices and observed drug activities are given in table 
(4.3). libe results are subdivided according to the enzyme source : 
Rat liver I 
The best simple regressions with p(ID, 50) as 
the dependent variable have 
significance levels above 99.9% : 
p(ID so -28.93(±-3.7) E(C 2 -N 3)-. 
1008(±132.6) (4,9) 
and r- . 868 ; ýs = . 37 F(1,19) = 58.46 
p(ID50) = -93-91(±13.3) FE(C 2) + 16,. 84 (±1.5) (4.10) 
and r= . 849 ; ;s= . 40 ; F(lpl9) = 49.30 . 
P(ID50) = 1.733(-±. 2) ALPHA(Clo) - 208.4(±. 31.3) (4.11) 
and r= . 843 ;s- . 41 ; F(1,19) = 46.75 
106 
p(ID 50) = 
200.8(±29.4) Q(C4) - 516.2(±8.4) (4.12) 
and r= . 842 ;s= . 41 ;- F(ltl9) = 46.42 
as have the best four two variable regressions : 
p(IDSO) = -25.30(±-2.7) E(C 2 -N 3 0.261(±. 
05) MU-Y -880(±97) (4.13) 
and r= . 940 ;s= . 26 ; F(2,18) = 68.68 
p(ID50) = -81.25(±10) FE(C 2 . 
225(±. 06). MU-Y + 15.4(±-1.2) (4.14) 
and r= . 918 ;s= . 31 ; F(2,18) = 48.62 
p(IDSO) = 310.6(±34) Q(C 4) + . 23(±. 06) MU-Y - 80.9(±10) (4.15) 
and r= . 915 ;s= . 31 ; F(2,18) = 46.83 
p(ID50) = 1.49(.. +-. 2) ALPHA(Clo) - 0.26(±. 06) MU-Y - 179(±25) (4,16) 
and r= . 915 ;s= . 31 ; F(2,18) = 46055 
In the above equations, E(C2-N, ), FE(C2) j ALPHA(CIO) and Q(C4) appear in 
the two variable as well as the simple regression equations, The 
negative coefficients associated with the first two variables are 
difficult to explain. The appearance of Q(C4) with a positive 
coefficient, is reasonable. A high charge at C4 may be favour'able for 
drug-enzyme interactions, The KJ-Y appears in all two-variable 
regressions, This can be explained on the basis of electrostatic 
interactions between the drug and the. enzyme. 
107 
TABLE 4.3 Cbserved drug activities and calculated indicies for 
inhibition of DHFR by 2.4-diamino 6-11ýqpzylamino) quinazolines. H 
I. 
H 
NH2 yH 
NH 
"2N"ý' 
NO. Substituent p(ID50) p(ID50) 
xyR liver L1210 
1HH5.8239 5.9586 
2 2-CH 3H5.8860 5.7695 
3 3-CH3 H 5.5850 5.3372 
4 4-CH3 H 5.3187 5.5228 
5 2-OH H 5.7212 5.7695. 
6 3-OH H 5.4685 5.5228 
7 4-OH H 5.5376 5.3565 
8 4-CH20H H 5.0362 5.0000 
9 4-F H 5.9586 5.8239 
10 4-C12 H 5.6575 5.8538 
11 4-Br H 5.7212 5.8239 
12 3-Br H 6.2218 6.1938 
13 3,4-C12 H 6.0969 6.2839 
14 4-COOH H 4.8538 5.3467 
15 4-4COOC2Hs H 5.5686 5.3372 
16 2-M2 H 5.6020 5.9586 
17 2-W2 H 6.4814 6.4948 
18 H Cl 7.4202 7,4559 
19 3#, 4-C'2 H 6.9586 7.2518 
20 H 7-CH3 6.3979 5.9586 
21 3,4-C12 Cl 7.9208 8.2365 
*Ani-linomethyl rather than benzylamino 
0 (C4 
(e) 
0.28541 
0.28536 
0.28537 
0.28532 
0.28525 
0.28546 
0.28530 
0.28544 
0.28555 
0.28575 
0.28577 
0.28573 
0.28601 
-0.28572 
0.28580 
0,28526 
0.28598 
0.29182 
0.28877 
0,28720 
0.29857 
4 
E (C2 -N3 
(ev) 
-35.0392 
-35.0392 
-35*0394 
-35.0395 
-35.0400 
-35*0388 
-35.0394 
-35.0387 
-35.0380 
-35.0371 
-35.0371 
-35.0375 
-35.0358 
-35.0374 
-35*0382 
-35.0393 
-35.0392 
-35.0902 
-35.0856 
-35,0624 
-35,1188 
MU-Y 
(D) 
0.7174 
0.9001 
0.8400 
0.6498 
0.9900 
1.1731 
1.9572 
1.0288 
0.7970 
0.8643 
0.8875 
-. 9217 
-. 4322 
1.6541 
-. 1295 
1.5096 
-2.867 
-. 2326 
-. 3172 
0.5874 
-. 5115 
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TABLE 4.3 Cont. 
NO* ALPFA (C 10) FE 
(C 
2) 
(Kev, a) (-e) 
1 123.549 0.118332 
2 123.549 0.110871 
3 123.548 0.118228 
4 123.547 0.118186 
5 123.544 0.118126 
6 123.550 0.118380 
7 123.548 0.118181 
8 123.551 0.118402 
9 123.554 0.118605 
10 123.558 0.118878- 
11 123.558 0.118900 
12 123.557 0.118836 
13 123.564 0.119244 
14 123,557 0.118825 
15 123.557 0.118668 
16 123.550 0.117954 
17 123.546 0.117738 
18 124.700 0.103235 
19 124.394 0.102630 
20 12a632 0.117575 
21 124L575 0.095554 
e 
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(ii) Mouse leukemia (L1210) 
The best four simple regressions with p(IEýo ) as the dependent variable 
have significance levels above 99.9% : 
PUDýO) = 104.2(±-12.1) FE(C2) + 18.08(±1.4) (4.17) 
and r- . 891 ;s= . 37 ; F(1119) = 73.16 
P(IDSO) = -30.89(±3.8) E(C 2 -N 3)- 
1077(tl36.5) (4.18) 
and r= . 876 ;s= . 38 ; F(ljl9) = 62.87 . 
p(ID50) = 1.897(±. 2) ALPHA(Clo) - 228.6(±30.2) (4,19) 
and r= . 872 ;s= . 39 ; F(1,19) = 62.28 . 
PUDýO) = 218.7(±28.9) Q(C4) - 56.69(±6.2) (4.20) 
and r= . 866 ;s= . 40 ; F(lF19) = 57.27 
as do the best four two variable regressions : 
PUDýo = -92.97 (±10) FE(C2) - 0.22(±. 06) MU-Y + 16.8 (-+I,, l) (4.21) 
and r= . 938 ;s= . 28 ; F(2,18) = 66.13 . 
PUDSO) = -27.51(±3.1) E(C2-N3) -0.242(±. 06) MU-Y - 958(±110) (4.22) 
and r= . 931 ;s= . 30 ; F(2,18) = 59.05 . 
PUDSO) = 1.684(±. 2) ALPHA(C,, ) - 0.236(±. 06) MU-Y - 202(±. 25) (4.23) 
and r= . 923 ;s= . 31 ; F(2,18) = 52.48. 
PUDSO) = 193ý±25.5) Q(c4) - 0.22(±. 07) MU-Y - 49.3(±7,3) (4.24) 
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and r= . 914 ;s= . 33 ; F(2,18) = 45.66 . 
The above regressions are very similar to the regressions obtained with 
the rat liver. The same variables appear, with coefficients of the same 
sign. , The similarity is almost certainly a result of the enzymes being 
from simi-lar sources. The results do not provide a basis for 
discriminating between enzymes from normal and neoplastic, tissues. 
4.5 Suppression of malaria by 2,4-diamino quinazolines 
A series of 2,4-diamino 6- (ben zylam ino, phenoxy, (phenylamino) methyl and 
phenylthiol-. quinazolines, with activity against P. berghi in mice, has 
been reported (176-178), 
The investigation of the effect of substitution in the 6-position on the 
quinazoline ring has led to the choice of four types of substituents 
which produce different electronic and molecular characteristics. 
A series of 26 substituted quinazolines were chosen as having reliable 
drug activities, observed under the same dietary conditionst these 
observations are obtained from references (176-179). 
The optimized geometry for quinazoline is used. The substiuents in 
position C6 are also optimized because of their steric effect. The 
6-[benzylamino, (phenylamino)methyl and phenoxyl group conformations are 
Optimized by using "GEOMIN". The CNDO/2 option is used for consistency 
with the MOM calculations. Owing to the inability of the "GEOMIN" 
program to handle second row atcms,, the 6-phenylthio group confor. mation 
ill 
k 
is optimized using a MINDO/3 program (180). The MINDO/3 minimum energy 
I 
point may be quantitatively different from the CNDO/2 minimum point, but 
it is better than geometry obt ained using stand ard bond parameters. 
The drug activities are expressed as p(SD 
90 
), where SD,, represents the 
daily dose in mole/kgm required for 90% suppression against P. berghei 
in mice. All the data are obtained under the sane experimental 
conditions. 
The molecular and electronic properties have been calculated for a 
I series of 26 molecules. The observed biological activities and 
calculated indices relevant to the regression analysis are given in 
table (4.4). 1 
The best four simple regressions with p(SD90) as the, dependent variable 
are all significant at the 99.9% levels : 
p(SD90) = -112.5(±18.4) Q(q) + 1.15(. ±. 6) (4.25) 
and r . 780 s= . 56 ; F'(1,24) = 37.33 
p(SD901 = 116.9(±20.1) FE(N 3) + 3.42(±. 2) 
(4.26) 
and r= . 764 ;s= . 58 ; F(1,24) = 33.70 
p(SD90) = -55.51(±9.9) O(Cio 0.48(±. 9) (4.27) 
and r . 752 ;s= . 59 r F(1,24) = 31.39 
P(SDgg) = -10.30(±2.2) E(NI-Cg) - 339.7(i-75.5) (4.28) 
and r= . 681 ;s= . 66 ; F(1,24) = 20.84 . 
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TABLE 4.4 Observed drug activity and calculated indices of 2.4- 
diamino 6-(benzylarnino, phenoxy, phenylthio) quinazolines. 
H NH2 
NH 
HP-'ýN 
H 
H 
NOe Substituent p(SD90) Q (r. 4 (Q (Ce Q(Clo 
RYz (e) (e) (e) 
1HHS4.5148 0.29490 -. 03603 -. 10810 
2 4-F HS5.9005 0.29513 -. 03656 -. 10824 
3 4-Cl HS6.1387 0.29550 -. 03665 -. 10779 
4 4-Br HS5.4614 0.29547 -*03653 -. 10778 
5 2,5-C12 HS4.8747 0.29596 -. 03593 -. 10755 
6 2-CH3 HS4.8380 0.29461 -. 03624 -. 10835 
7 3-CH' 
3HS4.6584 
0.29475 -. 03570 -. 10815 
8 4-CH3 HS4.5934 0.29461 -. 03591 -. 10828 
9 4-OCH 
3HS5.3955 
0.29458 -. 03630 -. 10836 
10 2-CHS HS5.8673 0.29528 -. 03702 -. 10802 
11 3, A-C 
4H4HS6.5998 
0,29456 -. 03564 -, 10825 
12 3,4-C'2 H 149CH 2 
4.5462 0.28601 -. 02534 -, 08201 
13 2-NO 2H NHCH 2 
3.2613 0.28592 -. 02540 -, 08169 
14 2'14H 2H NHCH 2 
3.0674 0.28527 -. 02602 -. 08202 
15 3-OCH H NHCH 4.1481 0.28545 -. 02587 -. 08199 32 
16 3r4-Cl2 H NHCH 2 4.8343 
0.29098 -. 03325 -. 09863 
17 H CH3 NHCH 2 
5.3322 0.29044 -. 03368 -. 09854 
18 HH04.4287 0.28833 -. 02904 -. 08448 
19 2t4,, 5-Cl3 H04.5732 0,28976 -. 02745 -. 08353 
20 4,5-C12 H04.5155 0.28912 -, 02791 -. 08419 
21 315-C12 H04.1087 0.28921 -. 02786 -. 08409 
22 3,, 5(CF3 )2 H04.4430 0.28966 -. 02749 -. 08366 
23 4-C1 H CH2NH 5.1980 0.29191 -. 04130 -. 09928 
24 4-Cl CH3 CH2NH 6.5521 0.29576 -. 04713 -. 11412 
25 4j5-C12 H CH2NH 5.5602 0.29198 -. 04089 -. 09921 
26 4,, 5-Cl, CHýt CHNH 6.0233 0.29576 -. 04659 -. 11395 
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TABLE 4.4 Cont. 
f 
NO. FE(Ns) B. E E (1ý --Cq mu R, EBIND (C2) 
(-e) (ev) (ev) (D) (a) (ev) 
1 0.01762 -420.826 -33.4650 8.7160 4.1428 -106.3876 
2 0.01761 -422.939 -33.4697 7.0956 4.1860 -106.3690 k 
3 0.01769 -421.201 -33.4744 6.6016 4,2807 -106.3690 
4 0.01766 -423.007 -33.4738 6.3563 4.3574 -106.3703 
5 0.01773 -421.717 -33.4910 8.0892 4.2536 -106.3696 
6 0.01754 -455.091 -33.4563 8.8051 4.1606 -106.3861 
7 0.01760 -454.905 -33.4617 8.9688 4.2813 -106.3898 
8 0.01752 -454.958 -33,4588 9.2854 4.3369 -106.3921 
9 0.01748 -464.613 -33.4573 8.9238 4.4233 -106.3915 
10 0.01763 -455.486 -33.4677 7.9100 4.2646 -106.3701 
11 0.01748 -530.667 -33.4563 9.3478 4*5114 -106.3916, 
12 0.00426 -517.778 -33.3644 2.3775 5.0530 -106.3145 
13 0.00390 -550.064 -33.3562 6.9313 4.7779 -106.3460 
14 0.00371 -536.815 -33.3434 3.0064 4.7667 -106.3366 
15 0.00383 -560.266 -33.3475 4.3662. 5.0630 -106.3390 
16 0.01074 -546.973 -33.3924 2.4241 5.0074 -106.3502 
17 0.00995 -546.031 -33.3740 3.7825 4.7275 -106.3736 
18 0.00833 -427.490 -33.4165 2.8631 4.2138 -106.3298 
19 0.00937 -473.865 -33.4580 1.1720 4.4484 -106.3010 
20 0.00909 -473.438 -33.4465 2.0705 4.4433 -106.2996 
21 0.00908 -473.341 -33.4468 1.0633 4.4118 -106.3030 
22 0.00927 -554.174 -33.4585 1.0652 4.5819 -106.2917 
23 0.01222 -517.545 -33.5182 2.0259 4.8840 -106.3322 
24 0.02277 -545.418 -33,5554 2.0667 4.8667 -106.3529 
25 0.01230 -518.045 -33.5258 3.7659 5.0011 . -106.3206 
26 0.02286 -545.923 -33.5630 3.8189 4.9798 -106.3402 
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Regressions (4.25) and (4.27) indicate the relevance of high electron 
density in the vicinities of atans C9 and CIO respectively, while 
regression (4.26) indicates that the susceptibility" of N3 to 
electropholic attack may be relevant to drug activity. 
The appearance of a negative coefficient for E(NI-C. ) in equation (4.28) 
makes this regression unattractive and difficult to explain,, as 
discussed in section (4.3). 
The best four two variable regression with p(SD90) as dependent variable 
have significance levels above 99.9% 
P(SDSO) = 228(+-+32.6) Q(C4) + 1.09(-±. 3) R. 66.56(±10) (4.29) 
and r . 825 ;s= . 52 ; F(2.23) = 24.59 
P(SD90) = 14.07(±5.1) EBIND(C2) - 84.23(±13) O(Clo) 
+ 1493(+546) (4.30) 
and r= . 820 ;s= . 53 ; F(2.23) = 23.65 
p(SD90) = -74.76(±11) O(Clo) - 0.12(±. 4) MU - 1.75(±. 9) (4.31) 
and r= . 819 ;s= . 53 ; F(2.23) = 23.52 . 
p(SD90) = 234.6(±34) Q(C4 - 0.006(±. 0002) B. E - 66*9(±10) (4.32) 
and r =.. 819 ;s= . 55 ; F(2,23) = 23.44 . 
Regressions (4.29) and (4.32) both indicate that the more 
electropositive C4, the higher the drug activity. The second variable 
appearing in each of these regressions indicates that, within this 
series, molecular size is positively correlated with activity, As the 
Ilb 
size increases, B. E beccmes more negative. This is because B. E is 
roughly equal to the sun of the bond energies, E(A-B)F for all pairs of 
atans A and B. Hence, as the nuTtber of atoms increases, B, E tends to 
increase. 
Regressions (4.30) and (4.31) both indicate that inhibitory potency is 
favoured by high electron density in the vicinity of CIO. The other 
variable in equation (4.30) is EBIND(C2). 7his appears with a positive 
coefficient# indicating that the greater the reserve binding capability 
Of CV, the higher the drug activity. 
The appearance of the dipole moment modulus MUr with a negative 
coefficient in equation (4.31) leads the direct physical interpretation 
that the lower the dipole moment of the molecules, the higher the 
inhibitory activity. It is likely that both EBIND(C2) and MU appear. 
because of covariance with the true causal quantities, which remain 
unidentified. 
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4.6 Inhibition of DHFR in vitro by quinazoline analogues of pterioc,, 
isopterioc acids and pteroylglutamic and isopteroylglutamic acids 
A series of quinazol inyl 6-methylaminobenzoates and quinazonyl 
6-phenylmethyl aminobenzoates substituted in the para position, which 
inhibit DHFR f rom rat liver, S. f aecium and leukemic cell (L1210) , are 
reported in references (181-182), and are given in table (4.5). 
The drug activities are expressed as p(I50),, where I,, is the molar 
concentration required to produce 50% of the enzymatic inhibition under 
a given set of the conditions, The GEOMIN optimized geometries for the 
I 
6-benzylamino and 6- (phenylamino) methyl groups are used. For the 
substituents in positions XjY and COOR, the standard bond parameters are 
used (110,145). 7he electronic and molecular indices relevant to the 
regressions are given in table (4.6). 
The following regression equations are obtained for the inhibition of 
DHFR from rat liver and S. faeclum, 
Rat liver 
The best four simple regression equations linking p(I50) to the 
reactivity indices all have significance levels above 99.9% 
P(I50) = -138.5L+-13.6) Q(NI) - 33.43L+4.0) (4.33) 
and r= . 886 ;s= . 47 ; F(1128) = 102.55 
PUSO) = -13.641.4) E(C2-N3) - 469.5(150.3) (4.34) 
and r= . 873 ;s= 50 t(1? 28) = 89.73 
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P(ýo = -2.933(±. 3) EBIND(C4) - 301.3(±34.1) (4.35) 
and r . 863 ;s= . 51 ; F(1,28) = 82.00 . 
P(ISO) = 2.769(±. 3) E(N3-C4) + 113.9(±11.7) (4.36) 
and r= . 862 ;s= . 51 ; F(1,28) = 81.56 . 
The appearance of Q(N, ) in the regression (4.33) is very interesting, it 
indicates that the higher the electron density at atom N, , the higher 
the inhibitory potency. The appearence of E(C2-N3) with a negative 
coefficient in equation (4.34) has already been observed in other 
series,, and it is difficult to interpret. On the other hand , the 
positive coefficient of E(N3-C4) in the equation (4.36)*- is very 
interesting. Any reduction of the stability of this bond,. is likely to 
be brought about by withdrawal of electrons from this region. This may 
make it more reactive in certain cases by providing an electron 
accepting region for a charge transfer interaction with the enzyme, and. 
it might also increase the susceptibility of the bond to nucleophilic 
attack. The appearence of EBIND(C4) with a negative coefficient in the 
regression (4.35) is probably due to the covariance of this quantity 
with a true causal quantity. 
The best four two variable regressions obtained have significance levels 
above 99.9% : 
P(Iso) = -133(±12) O(NI) 16.8(±-5.4) ESrAT - 33.143.5) (4.37) 
and r= . 917 ;s= . 41 F(2,27) = 71.77 
p(ISO) - -125.9(±-13) Q(NI) + 0,004(±., ool) a, ip - 31.65(±-3.6) (4.38) 
Ilb 
and r= . 912 ;s= . 42 ; F(2,27) = 66.97 
p(Iso) = -145(±12) Q(NI) - 0.25(±. l) MU-Y 35.4(±3.7) (4.39) 
and r= . 908 ;s= . 43 ; F(2,27) = 64.06 
p (1 50 = 
10.1(±-3.2) FE(Clo) - 12.7(±1.2) E(C2-N3) - 438(-+45) (4.40) 
and r . 908 ;s= . 43 ; F(2p27) = 63.39 . 
The appearance of ESTAT with a negative coefficient, in the regression 
(4.37) indicates that the ability of a molecule to favour a medim with 
a low dielectric constant over a mediurn with a high dieletric constant 
has a positive effect on the drug activity. (the dielectric constants 
of substancesvary from 0-80), A positive coefficient associated with 
a. IPr in regression (4.38) indicates that inhibitory potency increases 
as the possible dispersion interaction between the drug and substrate 
increases. The appearance of MU-Y in regression (4.39) can be explained 
in terms of electrostatic interactions. 
(ii) S. faeciurn 
The best four simple regression equations linking p(I,, ) to the 
reactivity indices have significance levels above 99.9% : 
P(Iso) = -4.808(+-3.7) EBIND(CO - 498.9L+39.3) (4.41) 
and r= . 924 ;s= . 59 ; F(1,28) = 165.33 .I 
P(Isc) = 4.487(±. 3) E(N3-C4) + 179.8(±14.5) (4.42) 
and r= *913 ;s= . 63 ; F(1,28) = 141.4 
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p(ýo -21.78(tl. 8). E(q2-N3) - 756.3(-+64.4) (4.43) 
and r . 913 ;s= . 64 ; F(1,28) = 
140.3 
p(IsQ) = -212.2(±20.8) Q(NI) - 55.4(--f-6.1) (4.44) 
and r= . 887 ;s= . 72 ; F(1,28) = 103.54 
The best four two variable regressions are obtained with p(3ý0 ) as 
dependent variable. All regressions are significant at the 99e9% 
levels: 
PUSO) = 4.7(: tl. 4) FN(NI) - 4.08(±. 3) EBIND(C4) - 424 (±41) (4.45) 
and r= . 945 ;s . 52 ; F(2,27) 114.1 
p(Iso) = 38.55(±15) FE(CO - 5.25(±. 3) EBIND(C4) - 548(±40) (4.46) 
and r= . 939 ;s= . 54 ; F(2,27) = 102.18 . 
P(I, 50) = 13.7(-A) FE(Clo) - 
20.5(±1.6) E(C2-N3) - 714(±. 56) (4.47) 
and r= . 939 ;s= . 54 ; F(2,27) = 101.39 . 
P(I, 50) = -4.46(±. 3) EBIND(r,, ) - 3.4(±1,4) E(NI-Cg) - 
577(±49) (4.48) 
and r= . 938 ;s= . 55 ; F(2,27) = 99.29 
It is noticeable that, the statistical significances of the rat liver 
regressions are lower than those obtained from S. faecium regressions. 
The appearance of FE's in the regressions (4.45)-(4.47) can be explained 
by the ease of electrophilic attack at N, t C4 and C, O respectively. The 
negative coefficient of E(C2-Ns) and E(NI-Cs) in equations (4.47) and 
(4.48) is probably due to covariance with other quantities, such as 
electron densities in the vicinity of these bonds. 
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TABLE 4.5 Cbserved drug activities for DHFR inhibition by quinazoline 
analogues of pteroic and isopteroic acids. 
xyH\/H 
Hý 
NO, Substituent 
xyzR 
P(Iso) 
R, I iver 
P(Iso) 
S. feacium 
1 NH2 H 
2 NH, 2 CH 
3 NH2 Cl' 
4 OH H 
5 OH CHs 
6 OH Cl 
7 OH H 
8 OH CH 
9 OH H 
10 OH H 
11 NH 2 Cl 
12 NH 2 CH3 
13, NH 
2 
H 
14 NH2 H 
15 NIi 2 CH 3 
16 NH2 Cl 
17 NH2 H 
18 NH2 Cl 
19 NH2 CH3 
NHCH2 C2, Hs 
NHCH2 C2HS 
NHCH2 C2H5 
NHCH2 C2Hs 
NHCH2 C2H5 
NHCH2 C2H5 
NHCH2 H 
NHCH2 H 
CH2NH H 
CH2NH C2H5 
CH2NH H 
CH2NH H 
CH 2 NH H 
CH 
2 NH 
C2 HS 
CH 
2 NH CH 
CH 
2 NH 
C2 HS 
CH 
2 
NH n-C4H9 
CH2NH n-C4H. 
CH2NH n-C4H. 
7,1366 
8.3467 
7.8860 
5.7695 
5.5086 
6.1079 
5.9586 
5.5850 
6.7695 
6.5228 
8.1739 
8.0809 
7.7212 
8.2006 
8.2441 
7*8538 
7.5850 
7.8538 
7.7695 
7.3372 
8.8538 
802006 
5.5636 
4.5228 
6.0915 
4.5528 
4.0705 
5.7399 
7.0705 
8.2676 
7.9586 
8.7958 
7.6777 
8.2924 
8.6382 
7.5228 
7.6777 
8.1487 
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TABLE 4.5 Cbserved drug activities for DHFR inhibition by quinazoline 
analogues of pteroylglutamic acid (folic acid). HH 
0 COOH 
11 1 
CNHCH 
I 
(CH2)nCOOH 
., 
ý 
NOs 
x 
20 NH2 
21 NH2 
22 NH2 
23 NH2 
24 NH2 
25 NH2 
26 OH 
27 NH2 
28 NH 
2 
29 OH 
30 OH 
H2N 
Substituent 
y z 
H CH2NH 
Cl CH 2 NH 
CH3 CH2NH 
H CH2NH 
Cl CH 2NH 
CH3 CH2NH 
H CHNH 
H NHCH 2 
CH 3 NHCH 2 
H NHCH 2 
CH 3 NHCH 2 
n 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
P(Iso) 
R, liver 
8.7695 
8.1938. 
9.397ý 
8.4685 
8.1249 
8.1611 
7.6382 
7.5850 
8.2518 
6.6777 
6.4089 
P(Iso) 
S. feacim 
8.2076 
8.5578 
8.6020 
8,8538 
9.1549 
8.6575. 
5.7958 
7.4948 
8.0809 
4.6575 
5,2291 
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TABLE 4.6 Calculated indices for inhibition of DHFR by quinazolines. 
NO, Q(N 
1) 
FE(N 
I 
FE(C 
2 
E(C 
2 -N 3 
E(N 
3 -C 4 
EBIND (c 4) 
(e) (-e) (-e) (ev) (ev) (ev) 
1 -. 29688 0.34842 0.11851 -35.03906 -38.29555 -105.4170 
2 -. 30046 0.34594 0.10503 -35.09334 -38.19835 -105.5440 
3 -. 29393 0.33725 0.10432 -35.07921 -38.23879 -105.5253 
4 -. 28634 0.30009 0.12729 -34.96011 -38.88759 -104.8947 
5 -. 28723 0.27520 0.11223 -34.96255 -38.88152 -104.8270 
6 -. 28254 0.27879 0.11084 -34.98169 -38.84960 -104.9823 
7 -. 28514 0.30205 0.12779 -34,95774 -38.88850 -104.8920 
8 -. 28719 0.27624 0.11234 -34.96210 -38.88195 -104.8246 
9 -. 28982 0.44911 0.13822 -34.98693 -38.88484 -104.8964 
10 -. 28887 0.44874 0.13839 -34.98575 -38.88485 -; -104.8992 
11 -. 29887 0,44641 0.09652 -35.11560 -38.21421 -105.5408 
12 -. 30246 0.45385 0.10008 -35.12450 -38.18031 -105.5221 
13 -. 29997 0.49626 0.12194 -35.07296 -38.27936 -105.4101 
14 -. 29893 0,49637 0.12230 -35.07138 -38.27929 -105.4126 
15 -. 30256 0,45200 0.09982 '-35.12527 -38.17948 -105.5255 
16 -. 29892 0.44418 0.09620 -35.11612 -38.21359 -105.5440 
17 -. 29895 0.49601 0.12230 -35.07157 -38.27909 -105.4139 
18 -. 29894 0.44328 0.09608 -35.11636 -38.21335 -105.5454 
19 -. 30259 0.45131 0009973 -35.12553 -38.17917 -105.5270 
20 -. 29897 0.49674 0.12222 -35.07155 -38.27903 -105.4126 
21 -. 29895 0.44432 0.09610 -35.11625 -38.21330 -105.5436 
22 -. 30260 0.45225 0.09973 -35.12549 -38.17918 -105.5253 
23 -. 30007 0.49483 0.12189 -35.07399 -38.27513 -105.4172 
24 -. 29899 0.44237 0.09589 -35.11681 -38.21283 -105.5483 
25 -. 30265 0.45071 0.09960 -35.12605 -38.17855 -105.5301 
26 -. 28991 0.44681 0.13793 -34.98798 -38.88374 -104.9040 
27 -. 29684 0.34743 0.11849 -35.03894 -38.29577 -105.4173 
. 
28 -. 30154 0.34419 0.10468 -35.09563 -38.19822. -105.5449 
29 -. 28630 0.29914 0.12720 -34,96019 -38.88756' -104.8951 
30 -. 28719 0.27438 0.11218 -34.96257 -38.88148 -i04.8274 
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TABLE 4.6 Cont. 
NO, FE(Clo IIU-Y a. IP ESTAT E(N, -CS) FE(NI) 
(-e) (D) 
0 
(ev. R) (Keil) (ev) (-e) 
1 0.13665 -0.1601 354.4991 -61.1638 -33.35301 0.348426 
2 0.10740 -0.1120 365.6376 -63.8025 -33.38392 0.345943 
3 0.11949 -1.0953 380.5525 -86.6188 -33.40419 0.337251 
4 0.11745 -0.7143 357.3393 -62.7020 -33.39207 0.300095 
5 0.07634 -0.0265 369.1291 -64.8756 -33,40487 0,275208 
6 0.09190 -1.1654 382.6071 -87.6828 -33.43857 0.278791 
7 0.11792 -0.0380 320.5431 -58.3555 -33.39582 0.302053 
8 0.07659 0.11213 333.1128 -60.5291 -33.40613 0.276246 
9 0.14782 1.13245 345.5917 -58.3561 -33.54161 0.449114 
10 0.14743 1.03047 385.2126 -62.7026 -33.54243 0.448747 
11 0.12444 -0.1049 366.1961 -82.2714 -33.55795 0.446416 
12 0.11541 1.26892 354.3646 -59.4539 -33.55559 0.453852 
13 0.16385 1.11774 341.7456 -57.2925 -33.51644 0.496263 
14 0.16354 1.01392 380.3113 -61.6391 -33.51750 0.496377 
15 0.11486 1.17112 392.2117 -63.8004 -33.55422 0.452002 
16 0.12377 -0.2060 405.1336 -86.6179 -33.55673 0.444185 
17 0.16347 1.00430 419.1882 -65.9859 -33.51696 0.496018 
18 0.12351 -0.2154 444.3148 -90.9648 -33.55619 0.443284 
19 0.11466 1.16139 430.3032 -68.1473 -33.55368 0.451317 
20 0.16360 -0.3151 444.8507 -81.1340 -33.51810 0.496743, 
21 0.12373 -1.5319 470.2337 -106.112 -33.55726 0.444320 
22 0.11486 -0.1578 455.5280 -83.2953 -33.55487 0.452257' 
23 0.16355 -0.3257 463.6796 -83.3074 -33.51427 0.494839 
24 0.12318 -1.5452 488.9801 -108.286 -33.55575 0.442374 
25 0.11443 -0.1718 473.7298 -85.4687 -33.55331 0.450717 
26 0.14732 -0.3093 470.8187 -84.3709 -33.53959 0.446810 
27 0.13643 -0.7174 432.1924 -83.3068 -33.35227 0.347438 
28 0.10713 -0.6641 441.9022 -85.4705 -33.38030 0.344195 
29 0.11722 -0.7249 436.7219 -84.3704 -33.39141 0.299148 
30 0.07624 -0.5802 447.0598 -86.5440 -33.40419 0.274384 
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4.7 Inhibition of DHFR by quinazoline glutamic acid analogues 
A series of substituted quinazolines reported as DHFR inhibitors from 
Human Acute Lymphocytic Leucemia (ALL) cells (183), are given in table 
(4.7). It would be interesting to find relationships between structure 
and activity from enzymes obtained from human sources. 
The GEOMIN optimized gecmetries with CNDO option for the 6-benzylamino 
and 6-(phenylamino) methyl groups are used. The positions of 
substituents X, Y and R are determined using standard bond parameters 
(110) . The electronic and molecular indices relevant to the regressions 
are given in table (4.8). 
The best four simple regressions with p(IsO ) as the dependent variable 
having significance levels above 99.9% : 
p(Iio) = 4.823(±. 4) E(N3-C4) + 193.1(±19.1) (4.49) 
and r= . 877 ;s= . 60 ; F(1,28) = 93.65 . 
P(Iýo = -5.194(+-. 5) EBIND(C4) - 539.1(-+-57.2) (4.50) 
and r . 874 ;s= . 60 ; F(1,28) = 91.30 . 
P(Iso) = 7.524(+-. B) EBINDA) + 544.2L+61.9) (4.51) 
and r= . 853 ;s= . 65 ; F(1,28) = 74.88 . 
P(Iso) = -211.8(±28.2) Q(NI) - 55.02(±8.4) (4.52) 
and r= . 816 ;sm .7; F(1,28) = 56.15 . 
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TABLE 4.6 Cont. 
ND, FE(C 
10 
KI-Y 
(-e) (D) 
1 0.13665 -0.1601 
2 0.10740 -0.1120 
3 0.11949 -1.0953 
4 0.11745 -0.7143 
5 0.07634 -0.0265 
6 0.09190 -1.1654 
7 0.11792 -0.0380 
8 0,07659 0.11213 
9 0,14782 1.13245 
10 0.14743 1.03047 
11 0.12444 -0.1049 
12 0.11541 1.26892 
13 0.16385 1.11774 
14 0.16354 1.01392 
15 0.11486 1.17112 
16 0.12377 -0.2060 
17 0.16347 1.00430 
18 0.12351 -0.2154 
19 0.11466 1.16139 
20 0.16360 -0.3151 
21 0.12373 -1.5319 
22 0,11486 -0.1578 
23 0.16355 -0.3257 
24 0.12318 -1.5452 
25 0.11443 -0.1718 
26 0.14732 -0.3093 
27 0.13643 -0.7174 
28 0.10713 -0.6641 
29 0.11722 -0.7249 
a. IP 
(ev. Rj 
354.4991 
365.6376 
380.5525 
357.3393 
369.1291 
382.6071 
320.5431 
333.1128 
345.5917 
385.2126 
366.1961 
354.3646 
341.7456 
380.3113 
392.2117 
405.1336 
419.1882 
444.3148 
430.3032 
444.8507 
470.2337 
455.5280 
463.6796 
488.9801 
473.7298 
470.8187 
432.1924 
441ý90; 2 
436.7219 
ESTAT 
(Kev 
-61.1638 
-63.8025 
-86.6188 
-62.7020 
-64,8756 
-87.6828 
-58.3555 
-60.5291 
-58.3561 
-62.7026 
-82.2714 
-59.4539 
-57.2925 
. -61.6391 
-63.8004 
-86.6179 
-65.9859 
-90.9648 
-68.1473 
-81.1340 
-106.112 
-83.2953 
-83.3074 
-108.286 
-85.4687 
-84.3709 
-83.3068 
-85.4705 
-84.3704 
E(N, -Cg) FE(NI) 
(ev) (-e) 
-33.35301 0.348426 
-33.38392 0.345943 
-33.40419 0.337251 
-33.39207 0.300095 
-33.40487 0.275208 
-r33.43857 0.278791 
-33.39582 0.302053 
-33.40613 0.276246 
-33.54161 0.449114 
-33.54243 0.448747 
-33.55795 0.446416 
-33.55559 0.453852 
-33.51644 0.496263 
-33.51750 0.496377 
-33.55422 0.452002 
-33.55673 0.444185 
-33.51696 0.496018 
-33.55619.0.443284 
-33.55368 0.451317 
-33.51810 0.496743 
-33.55726 0.444320 
-33.55487 0.452257 
-33.51427 0.494839 
-33.55575 0.442374 
-33.55331 0.450717 
-33.53959' 0.446810 
-33.35227 0.347438 
-33.38030 0.344195 
-33.39141 0.299148 
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TABLE 4.7 Cbserved biological activity for inhibition of DHFR by 
quinazoline. 
H2N 
No Substituents 
x y Z R 
1 NH2 H CH2NH 3-Cl 
2 NH2 H CH2NH 4-Cl 
3 NH2 H CH2NH 3,4-C12 
4 NH2 ci CH2NH 3,4-C12 
5 NH2 CH 3 CH2NH 3,4-C12 
6 NH2 H CH2NH 3-Br 
7 NH2 CH3 CH2NH 3-Br 
8 NH2 H CH2NH 3-CF$#4-Cl 
9 NH2 H CH2NH 3r4f5(OCHI), k 10 CH H CH2NH 4-COX2H5- 
11 NH2 H CH2NH 4-CCNHCH(COOH), 
12 NH2 CH3 CH2NH 3,4,5 (CCH3) 3 13 b1H2 H CH2NH 4-CONÜCH(CO2H)CH2CO2H 
14 NH2 H CH2NH 4-CONHCH (CH2 COOH)2 
15 NH2 H CH2NH 4-CONHCH(CO2H)(CH2)2CO2H 
16 Mt H CH2NH 4-CONHCH(CO2H)(CH2)2CM2 
17 NH2 CHS CH2NH 4-CONHCH(CO 
2H)CH2CO2H 18 NH2 CH3 CH2NH 4-CONHCH(CO2H)(CH 
2)2CO2H 19 
20 
NH2 
NH2 
CHS 
CH, 
CH2NH 
NHCH2 
4-CONHCH(CH CO H) 
4-CCNHCH(CO 2 H) JCH2) CO H 2 21 NH2 cl CH2NH 2-C1,4: ýýH(CO 2H )8H 2 
8ý 
2H 22 NIlý cl CH2NH 4-CONHCH(CO2H)CH2CO2H 
23 NH2 cl CH2NH 4-CONHCH(CO2H)(CH2)2CO2H 
24 A H CH2NH 2-Cl5-CONHCH(CO2H)CH2CO2H 
25 NH2 H CH2NH 4-Cle3-CONHCH(CO2H)CH2CO2H 
26 NH2 H CH2NH 4-C1,3-CXX*)CH(CO2H)(CH2)2CO2H 
27 OH H NHCH2 4-<-ý2H. 5 
28 NH2 H NHCH2 4-CýCMCH(CO2H)(CH2)2CO2H 
29 OH H 2 NHCH 4-CONHCH(CO2H)(CH2)2CO2H 30 OH CH , 
, NHCH2 4-CCNHCH(C1D2H)(CH2)2CO2H 
P(I so 
) 
ALL 
8.00 
8.22 
8.42 
8.96 
8.59 
8.66' 
8.82 
8.40 
8.22 
4.66 
9.1 
8.89 
8,94 
8.25 
9.21 
10.05 
8.9 
8.78 
8.17 
9.07 
8.82 
9.35 
9.11 
8.52 
7.92 
6.7 
5.49 
8.00 
5.78 
6.12 
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TABLE 
I 
4.8 Calculated indicies for DHFR inhibitor by quinazoline. 
Me Q(N ) EBIND(N 3) EBIND(C4) 
E(N3-C4) MU-Y 
1 
(e) (ev) (ev) (ev) (D) 
1 -. 300184 -71.22484 -105,41615 -38.27790 0.619848 
2 -, 299987 -71.23240 -105.40618 -38.28022 1.807412 
3 -. 299805 -71.24278 -105.39846 -38.28120 0.675544 
4 -, 298598 -71.22903 -105.52671 -38.21661 -. 539148 
5 -. 302013 -71.13898 -105.50590 -38.18408 0.826308 
6 -. 300191 -71.22460 -105.41634 -38.27784 0.387875 
7 -. 302561 -71.11773 -105.52859 -38.17851 0.527160 
8 -. 299735 -71.24750 -105.39502 -38.28139 0.408157 
9 -. 299804 -71.22772 -105.40557 -38.28177 3.836345 
10 -. 288872 -71.59879 -104.89926 -38.88485 1.030471 
11 -. 299148 -71.21930 -105.41930 -38.27775 -1.45545 
12 -. 302353 -71.12025 -105.52141 -38.18182 3.966371 
13 -. 298973 -71.22537 -105.41265 -38.27903 -. 315166 
14 -. 299819 -71.21635 -105.41915 -38.27873 2.189348 
15 -. 300071 -71.22231 -105.41728 -38.27813 -. 325737 
16 -. 299261 -71.21052 -105.42835 -38.27653 -5.38324 
17 -. 302608 -71.12056 -105.52534 -38.17918 '157866 
18 -. 302651 -71.11583 -105.53019 -38.17855 -. 171872 
19 -. 303757 -71.11037 -105.53580 -38.17755 2.349499 
20 -. 301540 -71.08839 -105.54495 -38.19822 -. 664116 
21 -. 299576 -71.21375 -105.43803 -38.27024 -1.51967 
22 -. 298952 -71.21204 -105.54368 -38.21330 -1.53191 
23 -. 298999 -71.20761 -105.54833 -38.21282 -1.54528 
24 -. 300231 -71.21964 -105.43205 -38.27098 1.310289 
25 -. 299675 -71.22749 -105.41636 -38.27707 0.995671 
26 -. 299727 -71.22401 -105.41981 -38.27664 1.004502 
27 -. 286341 -71.57298 -104.89471 -38.88759 -. 171437 
28 -. 296840 -71.20197 -105.41735 -38,29577 -. 714233 
29 -. 286305 -71.57160 -104.89513 -38.88756 -. 724986 
30 -. 287190 -71.56375 -104.82748 -38.88148 -. SR0229 
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The appearance of E(N 3 -C 4)' with a positive coefficiento 
in equation 
(4.49) is very interesting as discuesed in previous section, equation 
(4.36). The appearance of, EBIND(C4) in the equation (4.50) with 
negative coefficient is difficult to interpret, as mentioned for the 
earlier series. On the other hand, the positive coefficient associated 
with EBIND(N3), in equation (4.51), suggests the reasonable hypothesis 
that drug activity increases with increasing reactivity at Ns. 
The best four two variable regression equations are obtained with p(I5O ) 
as dependent variable. All regressions are significant at the 99.9% 
levels : 
P(Iso) = 4.973(±-. 3) E(Ns-; -C 4) - 0.219(±. 04) MU-Y + 198(±14) (4.53) 
and r= . 931 ;s= . 46 ; F(2,27) = 87.89 . 
P(Iso) = -5.28(±. 4) EBIND(C 4) - 0.197(±. 05) MU-Y - 548(±47) (4.54) 
and r= . 919 ;s= . 50 ; F(2r27) = 73.39 . 
P(Iso) = 7.82(±. 6) EBIND(N, ) - 0.23(±. 05) MU-Y + 565(±, 49) (4,55) 
and r= . 912 ;s= . 52 ; F(2,27) = 67.29 . 
P(Iso = -232(±21) Q(NI) - 0.28(±.. 05) MU-Y - 61.08(±6.3) (4.56) 
and r . 909 ;s= 53 ; F(2t27) = 64.60 
It is interesting that MU-Y appears in the two variable regressions, 
this is an indication of possible electrostatic interaction between the 
drug and the receptor. 
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4.8 Inhibition of DHFR by 2,4-diamino pyrimidines 
A series of 2,4-diaminopyrimidines have been reported as inhibitors of 
DHFR from Trypanosoara equiperdum, chicken liver and rat liver in 
reference (184) and are given in table (4.9). The geometry used for 
2,4-diaminipyrimidine is extracted from the GEOMIN optimized geanetry 
for 2j4-diamino 5-benzyl-pyrimidine as explained in the next sectione 
Standard bond lengths and bond angles (110) are used for the substituent 
in the positions C. and C., 
The electronic properties are obtained by using CNDO/2'wavefunctions for 
a series of 24 substituted molecules. The calculated electronic and 
molecular indices relevant to the regression are given in table (4.10). 
The following are the regressions obtained for the three sources of the 
enzyme: 
(i) T. equiperidum 
The best four simple regression equations obtained with p(IDso) as the 
dependent variable. 7he significance levels lie between 99.75% and 
99.9% : 
PUDSO) = -0.514(i-. 08) MU-Z + 5.277(: t. 1) (4.57) 
and r= . 774 ;s= . 52 ; F(1,22) = 32.97 
PUD50) = 109.5(±. 27.5) EBIND(Hg) + 2187(+549,1) (4.58) 
and r= . 646 ;s= . 62 ; F(Ij22) = 15.77 . 
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TABLE 4.9 Observed drug activities for inhibition of DHFR by 
i 
-- 12 2,4-diaminopyrimidine. 
R2 
9 
H 
4 
NO, Substituent p(ID50) p(ID. 50) p(ID50) 
Rl R2 T. equi C. liver R. liver 
I H 4-Cl, C 
6H4 5.8239 5.0000 
5,0457 
2 CH3 4-C1 jCs Ik 5.7447 5.9908 5.5685 
3 H 2-Br, q H4 3.8538 3.7447 3.9586 
4 C2H's 4-Cl, CrH 
,4 
6.6989 6.2596 6.0969 
5 C2HS 3,4-Cl2'C6 H3 6.8538 7.6989 8.0969 
6 CH 3 -3j4-C; C6H 3 6.2218 
8.0000 7.7958 
7 0-2 3-NO2 4-Cl C6 H3 7.0000 8.1870 7.8239 
8 cA 3-NIýA-Cl, C6Eý 5.7958 5.8538 MkO 
9 CH3 4-CH3#CrH4 5.0000 6.7958 6.0000 
10 clý 3,4- (CHS 0)2 Cr H 3 3.5228 5.5528 5.1549 
11 H 4-Cl, C6H40 5.6197 3.7958 4,0969 
12 CH3 4-Cl Cs H4 0 5.6989 4.3187 4.6575 
13 H 4-CH30IC6H40 5.8239 4.6197 4.2218 
14 CH3 4-NO2fC6H40 5.1870 4,1249 4.8239 
15 H 4-Cl, C6IkCaz 5.8860 4.1366 3.6989 
16 CH3 4-Cl, C6fkCH2 5.6020 4.5686 4.3010 
17 c1h 4-NO2, C6H4CH2 6.0000 4.2757 4.9208 
18 H 3-Br A, 5- (CH 3 QI 2c6 H2CH2 6.7447 3.6020 4.3010 
19 H 2-Br , 3,4,5- (CH3 
0)3 C6 H3 Clý 6.0457 3.4559 3.6382 
20 H 2-Br j 4,5- (CH3 
0)2 C6 'ý CE6 6.0969 3.9208 4.1079 
21 CH3 3,4- (CFý 0)2 C6 H3 CR2 5.5686 3.6020 3.6020 
22 H 3p 4- (CH3 0) 2 Cr, H3 CH2 6.1549 3.8239 4.7447 
23 H 3,4 j 5- (CH3 
0) 3 Cro 1ý2 0ý2 6.0000 3.3979 4.1870 
24 H 2,4,5- (CH 30)3 q 1ý CFý 5.6989 3.4559 3.8860 
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TABLE 4.10 Calculated indic&s for DHFR inhibitor by quinazolind. 
NO, Q(NI) Q(C2) Q(N 3) Q(C4) Q(CS) 
(e) (e) (e) (e) (e) 
1 -. 240780 0.312337 -. 267272 0.252021 0,156670 
2 -. 258165 0.315099 -. 275851 0.253443 0.177840 
3 -. 240671 0.314377 -. 267404 0.257593 0.161358 
4 --. 258987 0.317521 -. 274855 0.257256 0.174118 
5 -. 257341 0.316238 -. 274462 0.254643 0.174271 
6 -, 257607 0.316610 -. 275327 0.255095 0.179484 
7 -. 256773 0.321163 -. 272432 0.260517 0.177044 
8 -. 259221 0.317117 -. 275305 -. 258031 0.174989 
9 -. 259969 . 
0.312737 -. 277362 0.250719 0.175017 
10 -. 259864 0.313091 -. 277274 0.251189 0.175488 
11 -. 232901 0.305117 -. 257618 0.219594 0.123646 
12 -. 251230 0.307917 -. 266825 0.220892 0.149348 
13 -. 234098 0.303158 -. 259129 0.218663 0.121482 
14 -. 249475 0.309751 -. 265502 0.221368 0.151554 
15 -. 242792 0.3,13140 -. 269655 0.250187 0.155548 
16 -. 259869 0.315600 -. 277930 0.251251 0.176029 
17 -. 258882 0.317077 -. 276961 0.252187 0.176883 
18 -. 243474 0.312573 -. 269691 0.249617 0.154681 
19 -. 243655 0.312441 -. 270049 0.249585 0.154590 
20 -. 243614 0.312848 -. 269722 0.250071 0.154999 
21 -. 260900 0.314232 -. 278790 0.250167 0.175352 
22 -. 243954 0.311733 -. 270410 0.249157 0.154895 
23 -. 243727 0.312075 -. 270084 0.249322 0.154697 
24 -. 244673 0.311463 -. 270733. 0.249422 0.154327 
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TABLE 4.10 Oont. 
NO, Q(Hlo) EBIIIP(C4) EB I14D (H 9) EB IND (1ý 0 FN (N 7) 
(e) (ev) (ev) (ev) (-e) 
1 0.088028 -105.03839 -19.91237 -19.91025 . 000112 
2 0.087535 -104.0759 -19-91431 -19.91372 . 000127 
3 0.088459 -105.12224 -19.92015 -19.91807 . 001319 
4 0.089001 -104.96525 -19.91006 -19.90904 . 000108 
5 0.088747 -104.95071 -19.91011 -19.91038 . 000034 
6 0.088773 -104.96315 -19.91124 -19.91068 . 000033 
7 0.092138 -104.91950 *-19.89994 -19.89998 . 000042 
8 0.088504 -105.00304 -19.91200 -19.91046 . 000087 
9 0.085741 -104.98554 -19.92062 -19.91997 . 000797 
10 0.085954 -104,99004 -19.92090 -19'. 92024 . 000803 
11 0.087454 -104.71944 -19.91119 -19.90922 . 000037 
12 0.086875 -104.66067 -19.91358 -19.91305 . 000027 
13 0.085752 -104.74759 -19.91625 -19.91398 . 000268 
14 0.088473 -104.61864 -19.90721 -19.90660 . 000017 
15 0.087691 -104.97725 -19.91476 -19.91317 . 000220 
. 16 0.087118 -104.90371 -19.91675 -19.91653 . 000182 
17 0.088509 -104.87109 -19.91082 -19.91072 . 000035 
18 0.087487 -104.96614 -19.91237 -19.91102 . 000111 
19 0.087163 -104.98189 -19.91453 -19.91369 . 000152 
20 0.087561 -104.97589 -19.91304 -19.91224 . 000396 
21 0.086022 -104.91429 -19.91975 -19.91886 . 000987 
22 0.086593 -104.98872 -19.91782 -19.91558 . 000940 
23 0.086983 -104.97936 -19.91567 -19.91379 . 000790 
24 0.086471 -105.00472 -19.91792 -19.91667 . 000147 
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TABLE 4.10 Cont. 
NO, ALPHA(Nj) ALPHA(N7) ý(CS-CO mu-z 
(KeTl) (KeTl) (ev) (D) 
1 101.419 97.251 -37.66768 -1,288007 
2 101.428 97.290 -36.66223 -0.890787 
3 101.393 97.276 -37.58001 0.8509820 
4 101.502 97.376 -36.77249 -1.629987 
5 101.501 97.345 -36.70185 -1.388725 
6 101.413 97.356 -36.64766 -1.350448 
7 101.497 97.527 -36.75934 -2.725814 
8 101.510 97.357 -36.75635 -1.484868 
9 101.411 97.194 -36.69535 0.6336940 
10 101.406 97.204 -36.69334 1.0147930 
11 101.393 97.147 -37.96876 -oo232581 
12 101.391 97.189 -36.95279 0.2452550 
13 101.395 97.064 -37.97648 -1-6058824 
14 101.408 97.269 -36.93903 1.5297960 
15 101.240 97.243 -37.88051 -0.577485 
16 101.262 97.277 -36.86606 -0.154949 
17 101.264 97.349 -36.85726 -1.230729 
18 101.237 97.235 -37.88445 -2.667001 
19 101.234 97.224 -37.88471 -1.706011 
20 101.230 97.244 -37.88217 -1.896550 
21 101.259 97.223 -36.87079 -1.786932 
22 101.234 97.189 -37.88664 -2.208051 
23 101.237 97.208 -37.88542 -2.912231 
24 101.226 97.179 -37.89473 -0.401839 
k 
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p(ID 50) = 114.7(±. 28) EBIND(HIO) + 2290(±576.5) 
(4.59) 
and r= . 645 ;s= . 62 ; F(1,22) = 15.70 . 
PUDso )= -1225(±361.5) FN(N7) + 6.173(±. l) (4.60) 
and r= . 585 ;s= . 58 ; F(1,22) = 11.48 . 
The regressions (4.58) and . 
(4.59) indicate that the greater the 
reactivity of the hydrogens of the C. -amino group, the higher the drug 
activity. This is interesting because the presence of this amino group 
is essential for enzyme inhibition, so it is likely to be in close 
contact with the receptor in the binding. ' Regression (4,57) indicates 
the relevance of a dipolar interaction, whereas (4.60) is difficult to, 
interpret because of ýhe negative slope,. 
The best four two variable regressions obtained with p(ID50) as the 
dependent variable are significant at the 99.9% level 
PUDSO) = -1050(±179) FW(N 7)-0.475(±. 
05) MU-Z + 5.65(±. I) (4.61) 
and r= . 920 ;s= . 32 ; F(2,21) = 58.62 . 
p(IDSO) = 74.4(±18) EBIND(H. ) - . 49(-ý. 07) MU-Z + 1487'(±372) (4.62), 
and r= . 878 ;s= . 40 ; F(2,21) = 35o5O * 
PUDSO) = 74.9(±20) EBIND(HIO) - 0.41(±. 07) MU-Z + 1498(±410) (4.63) 
and r- . 868 s= . 41 ; F(2.21) = 32.29 
p(IDSO) = 2.26(. ±. 8) EBIND(CO - 0.58(±. 08) MU-Z + 243(±86) (4.64) 
and r= . 839 ;s= . 45 ; F(2,21) = 25.12 . 
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The same variables appear in the regressions (4.6l)-(4.63) as in the 
simple regressions. The reappearence of EBIND(Hq) and EBIND(HIO) 
confirms the importance of the electronic structure of the C2-amino 
group. The positive coefficient associated with EBIND(C4) in the 
regression (4.64) indicates that the more reactive this position the 
higher the drug activity. 
(ii) Chicken liver 
The best simple regression equations obtained with p(ID 5 0) as 
the 
dependent variable have significance levels between 99.5% and 99.9% 
p(IDSO) = 11.18(±2) ALPHA(N, ) - 1128(±207) (4.65) 
and r= . 758 ;s=1.0 ; F(1,22) = 29.71 
p(IDSO) = 1.923(: t. 4) E(CS-Cr) + 76.6(±15.3) (4.66) 
and r= . 705 ;s=! 1.09 ; F(lp22) = 21.83 
PUDso = 10.39(±2.6) ALPHA(N7) - 1005(±256) (4.67) 
and r= . 643 ;s=1.18 ; F(1,22) = 15.54 . 
p(IDýo )= 53.19(-+16.5) Q(c. ) - 3.68(ý2.6) (4.68) 
and r= . 565 ;s=1.2 ; F(1,22) = 10.35 
The best two variable regression equations obtained with p(ID50) as 
dependent variable have significance above the 99.9% level : 
p (ID = 9.7 5 W. 7) ALPHA (N )+38.5 (±l 0) 990 (+- 17 3) (4.69) 
and r . 856 ;s- . 81 ; F(2,21) = 28.81 
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p(IDSO) = 11.05(±1.6) ATPHA(N, ) - 105(±31) Q(N3) - 1144(i-171) (4.70) 
and r= . 851 ;s= . 83 ; F(2,21) = 27.73 . 
11.1(±1.7) ALPHA(NI) + 42.2(±14.1) Q(C4) 
- 1131(+178) (4.71) 
and r= . 837 ;s= . 86 ; F(2,21) = 24.58 
I P(IDSO) = -62.3(: ý21) Q(NI) + 9.32(±1.8) ALPýA(N, ) - 956(±189) (4.72) 
and r= *835 ;s= 87 ; F(2,21) = 24.17 
The total difference of the chicken liver regression from those obtained 
for T. equiperidum is encouraging from the point of view of 
selectivity, i. e it should be possible to design a drug which is active 
against bacteria but harmless to vertebrates, e. g by choosing 
substituents which minimize both MU-Z and ALPHA(NI). All the above 
regressions, except (4.66) involve the charges and polarizabilities of 
atans in the pyrimidine ring. These may therefore be readily 
interpreted in terms of electrostatic or second order interactionst 
respectively, between the drug and receptor. 
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(iii) Rat liver 
rDL- best simple regression equations obtained with p(IDso) as the 
dependent variable have significance levels between 99.75% and 99.9% : 
p(ID50) = 9.21(+--1.9) ALPHA(NI) - 929(i-194) (4.73) 
and r= . 715 ;s= . 94 ; F(1,22) = 23.13 
p(IDSO) = 9.689(±-2.1) ALPHAM) 937.3(±212) ý(4.74) 
and r= . 687 ;s= . 98 ; F(1122) 19.75 
p(IDso) = 1.577(±. 3) E(CS-C6) + 63.79(±14.1) (4.75) 
and r= 663 ;s=1.01 ; F(1,22) = 17.28 
P(ID50) = 574.2(±162) Q(HID) - 45.3(±14.2) (4.76) 
and r= . 602 ;s=1.07 ; F(1#22) = 12.55 
With the exception of the Q(H,, ) the same variables appear as in the 
simple regressions for chicken liver. Although the standard errors for 
these regressions are higher than those obtained with other dependent 
variables, the statistical significances are still substantial, i. e 
there is a corresponding increase in the total variance of the dependent 
variables. 7he appearance of Q(H 10) in the regression (4.76) , confirms 
the importance of the structure of the C2-amino, group, indicating 
possibile electrostatic interaction with the receptor. 
The best four two variable regressions obtained with p(ID50) as the 
dependent variable are significant at the 99.9% level.: 
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p(ID50) = 6.56(±1.7) ALPHA(NI) + 6.45(1-1.9) ALPHA(NA 
- 1288(±194) (4.77) 
and r= . 824 ;s= . 78 ; F(2,21) = 22.33 
P(ID, 5c) = 8.0(±1.6) ALPHA(N, ) + 139.8(±42) Q(C2) - 850(±163) (4.78) 
and r= . 823 ;s= . 78 ; F(2,21) = 22.17 . 
p(I40 = 9.42(±1,6) ALPHA(N, ) - 0.31(±. 09) MU-Y - 949(±163) (4.79) 
and r= . 819 ;s= . 79 ; F(2,21) = 21.56 
p(ID50) = 8.02(±1.6) 'ALPHA(N, ) + 32.13410) Q(C6) - 813(±-171) (4.80) 
and r= . 810 ;s= . 80 ; F(2,21) = 20.14 
All these regressions (4.77)-(4.80) involve the polar izabil ities of 
nitrogen atcms, regression (4.77) can be interpreted in terms of second 
order interactions in the vicinities of the ring and amino nitrogens. 
The other variables appearing in regressions (4.78)-(4.80) are more 
suggestive of electrostatic interactions, 
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4.9 Inhibition of DHFR by 5-(X-benzyl) 214-diaminopyrimidine 
A series of 5-(benzyl)- 2,4-diaminopyrimidines has been shown to be 
potent inhibitors of DHFR's from bacteria and mammalian sources 
(185#186). These are given in table (4.11). The starting point 
geometry for 2,4-diamino, benzylpyrimidine is obtained from (187), This 
geometry has been optimized using the "GSOMIN" program with CNDO option. 
The 214-diamino benzylpyrimidine has two major conformational degrees of 
freedom, specified by the dihedral angles TAU, and TAU2 respectively. 
TAUý is the angle between the projection of the bonds C5-C6 and C7-C. on 
the plane perpendicular to the bond C, -C7* TAU2 is the angle between 
the projection of the bonds CS -C 7 and C. -C. on the 'plane perpendicular 
to bond C 7-C., The author 
had some doubt about the ability of GEOMIN to 
optimize these angles i. e the energy variations which occur on changing 
these angles are insufficient in terms of the GEOMIN convergance 
criterion, to make the program find accurate equilibrium point values. 
A minimum energy conformation has been obtained by varying-both TAU, and 
TAU2 in steps of 10 degrees the CNDO/2 total energy being calculated for 
each generated conformation. A minimum energy is obtained at the 
146.8357 and 324.2048 degrees for the dihedral angles TAU I' and 
TAU 
2 
respectively. 
The optimized bond lengths and bond angles are given in table (4.12). 
The calculated energies are given in table (4.13). The GEOMIN and 
manually optimized conformations are plotted in figure (4.4). 7he 
calculated indices relevant to the regressions are given in tables 
(4.14) and (4.15). 
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TABLE 4.11 Observed drug activities for DHFR inhibition by 
5-(X-benzyl) 2,4-diaminopyrimidines. 
_. __ HH 
Rl 
NO. Substituent 
Ri Rý 
1 H H 
2 H CHs 
3 H ci 
4 H OH 
5 H OCH3 
6 OCH3 H 
7 OCH3 OCH3 
8 OCH3 OCH3 
9. OCH3 OH 
10 OCH3 OCHs 
11 F H 
12 H F 
13 Br H 
14 H Br 
15 Cl H 
16 H N02 
17 H NH2 
18 CH3 H 
19 CZ H 
20 OH OH 
21 H OCFs 
22 CF3 OCH3 
23 H N(CHS)2 
24 H NIIOCH3 
25 N02 NIIOCHS 
26 OCHAH. H 
H 
R3 
H 
H 
H 
H 
H 
H 
H 
cl 
OCH 3 
OCH 3 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
H 
P(Cso 
B. 1 iver 
5.19 
4.80 
5,10 
4.92 
5.02 
5.15 
5.10 
5.33 
5.18 
5.54 
5.17 
5.47 
5.02 
4.57 
5.22 
5o53 
4.30 
4o99 
5.79 
4o76 
5,09 
5ol6 
6olO 
P(c so ) P(Cso ) 
E. coli R. liver 
5.4685 3.8239 
5.6382 4,0000 
5.6777 4.0457 
5.7447 3.7958 
5.9586 . 3.7695 6.3098 4.3665 
7.0000 4.1549 
7,3979 4.0000 
7.9586 4.0000 
8.3010 3.5850 
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TAKE 4.12 The optimized bond lengths and bond angles for 
benzylpyrmidine. 
18 19 
5 
Bond ler)gths(R) 
C2-NI 1.3493 N35 -C 4 1.3977 
N3-C2 1.3484 N14-HI6 1.0681 
C4-N3 1.3503 N14-HI7 1.0680 
C4-C, 5 1.4030 N15-Hle 1.0691 
CS-C6 1,3862 N, 5-HIq 1.0695 CS-C7 1.4669 C6-H20 1.1230 
C7-CS 1.4676 C13-H21 1.1196 
CO-Cs 1.3969 C7-H22 1.1295 
C9 -CIO 1.3830 
C7-H23 1.1277 
CIO -CII 1.3838 C9 -H24 1.1191 
CII-CI2 1.3839 Cs -H25 1.1172 
C12-C13 1.3842 CI I -H26 1.1170 N14 -C2 1.3945' CI 2 -ý 7 1.1168 
Bond angles (deg) 
N3-C2-NI 126.59 H14"C2-C3 116.69 
C4-N3-C2 115.60 Nis-C4-C3 114.48 
CS-C4-N3 124.32 H, r, -NI 4 -C2 111.62 
CB-CS-C4 112.24 HI 7 -NI4 -C2' 111.90 
C7-CS-C4 123.48 Hi e -Ni s -C4 111.15 
C8-C7-C5 119.57 Hi 9 -Ni s -, C4 110.83 
C9-`C8-C7 120.76 H2o-C6-Cs 119.53 
Ci 0 -Cq -C8 122.77 H21 -C 13 -C12 118.91 
cl I -CIO -cq 119.85 H22 -C7 -C 5 108.72 
C12 -CII -CIO 119.00 H25-C7-CS 109.19 
C23 -C12 -CI 1 120.29 H24-C9-CIO 118.34 
H23 -CI I -CIO 120.27, H26 -CI I -C 12 120.45 
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TABLE 4.13A The results of calculation of the total energy for 
benzylpyrimidine at di. fferent TAU, angles when TACý is 153.20 
NO. TAU 
(deg) 
1.1.8357 
2.11.8357 
3.21.8357 
4.31.8357 
5.41.8357 
6.51.8357 
7.61.8357 
8.71.8357 
9.81.8357 
10.91.8357 
11.101.8357 
12.111.8357 
13.121.8357 
14.131.8357 
15.141.8357 
16.151.8357 
17.161.8357 
18.171.8357 
Energy 
(a. u. ) 
-134.024573 
-134.010289 
-133.9960295 
-133.9991882 
-134.0153303 
-134.0269098 
-134.0315399 
-134.0324085 
-134.0328061 
-134.0338260 
-134.0343830 
-134.035292 
-134.0366229 
-134.038535 
-134.040850 
-134.037850 
-133.996292 
-133.821732 
NO, . TAU I 
(deg) 
19.181.8357 
20.191.8357 
21.201.8357 
22.211.8357 
23.221.8357 
24.231.8357 
25.241.8357 
26.251.8357 
27,261.8357 
28.271.8357 
29.281.8357 
30.291.8357 
31.301.8357 
32.311.8357 
33.321.8357 
34.331.8357 
35.341.8357 
36.351.8357 
Energy 
(a. u. ) 
-133.2032784 
-130.4826165 
-133.213700 
-133.653915 
-133.9197454 
-134.0135779 
-134.032171 
-134.0345771 
-134.0343172 
-134.0336860 
-134.0330615 
-134*0325890 
-134.0323877 
-134.0325280 
-134.0329981 
-134.0336168 
-134.0337442 
-134.0317115 
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TABLE 4.13B The results of calculation of the total energy for 
benzylpyrimidine at different TAM angles, when TAW is 146.8357. 
NO. TaU 2 
(deg) 
1.3.2048 
2.13.2048 
3.23.2048 
4.33,2048 
5.43.2048 
6.53.2048 
7.63.2048 
B. 73.2048 
9.83.2048 
10.93.2048 
11.103.2048 
12.113.2048 
13.123.2048 
14.133.2048 
15.143.2048 
16.153.2048 
17.163.2048 
18.173.2048 
Energy 
(a. u. ) 
-133.842244 
-133.41067 
-131.625155 
-132.274416 
-133.463587 
-133.861701 
-133.995169 
-134.031449 
-134.038379 
-134.038654 
-134.0385753 
-134.0390456 
-134,0397075 
-134.0405649 
-134. OY08621 
-134.0410202 
-134.0342514 
-134.0011766 
NO. TaU 2 
(deg) 
19.183.2048 
20.193.2048 
21.203.2048 
22,213.2048 
23.223.2048 
24.233.2048 
25.243.2048 
26.253.2048 
27.263.2048 
28.273.2048 
29.283.2048 
30.293.2048 
31.303.2048 
32.313.2048 
33.323.2048 
34.333.2048 
35.343.2048 
36.353.2048 
Energy 
(a. u. ) 
-133.886524 
-133.514766 
-131.818000 
-132.207516 
-133.492372 
-133.862251 
-133.992208 
-134.030815 
-134.038822 
-134.039004 
-134.038426 
-134.038409 
-134.038843 
-134.039659 
-134.040795 
-134.040565 
-134.030808 
-133.986254 
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TABLE 4.13C The results of calculation of the total energy for 
benzylpyrimidine at different TAU, angles, when TAU2 is 328.2048. 
NO, Tau, Energy M. Tau, 
(deg) (a, u, ) (deg) 
1, 140.8357 -134.004018134 5* 148.8357 
2. 142.8357 -134,040653137 6. 150.8357 
3. 144.8357 -134.041013024 7. 152.8357 
4. 146.8357 -13 4,0.14 1 I'S 19/6- 8. 154.8357 
. Energy 
(a. u. ) 
-7134.04093872 
-134.04013942 
-134.03846704 
-134.02919832 
TABLE 4.13D The dihedral angles (in degrees) for the GEOMIN and 
manually refined conformations. 
Dihedral angles GEOMIN Manually refined 
C4 -N 3-C2 -N, 354.71 3ý54.71 
C5 -C 4 -N 3-C2 359.70 359.70 
C6 -C 5 -C 4 -N3 4.31 4.31 
C7 -C 5 -C 4 -N3 187.70 187.70 
C 
8-C7-C57C4 91.83 146.83 
C9 -C a -C 7 -CS 153.20 328.20 
C 10 -C 9 -C 8 -C 7 175.62 175.62 
C 
11 -C 20 -C 9 -C a 
0.10 0.10 
C 
12 -C II-, 
CIO -C9 0.39 0.39 
C 
is -C 12 -C2 I -ý-C 10 359.76 359.77 
-C N 14 -C 2 -N 170.36 170.36 3 4 
NIS-C4-N, -C2 183.90 183.90 
H22-C7-C, -C4 147.37 150.65 
H23-C7-C5-C4 35.71 30.87 
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c. GWMIN optimized (viewed d. Manually refined (viewed 
down X axis) down X axis) 
-L H. 
H 
m 
a. GEOMIN optimized (viewed 
down y axis) 
b. Manually refined. (viewed 
down Y axis) 
FIGM 4.4 The GEOMIN and manually refined conformations for 2,4-diamino 
5-benzylamino pyrimidine. 
H 
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TABLE 4.14 Calculated indices for inhibition of DRFR frcm E. coli 
and Rat liver by 5-(benzyl)2,4-diaminopyrimidines. 
NO, Q(C4) Q(co EBIND(H21) E (Ce -Hs) 
. (e) (e) (ev) (ev) 
1 0.253327 -. 003111 -19.721126 -36.54007 
2 0.253241 0.002042 -19.712864 -36.532342 
3 0.253399 0.006457 -19.700626 -36.545373 
4 0.252864 0.018774 -19.724288 -36.504105 
5 0.252884 0.018338 -19.719792 -36.500963 
6 0.254028 -. 061797 -19.726395 -36.678024 
7 0.254147 -. 042655 -19.72ý102 -36.557727 
8 0.253390 -. 046315 -19.706738 -36.581921 
9 0.254679 -. 067774 '-19.810094 -36.579598 
10 0.254113 -. 069472 -19.838183 -36.595247 
NO, ALPHA(C. ) mov FE(N3) FE(CO 
(KeTý ( V) (-e) (-e) 
1 129.774 184.038 0.023387 0.138470 
2 129.747 200.599 0.027902 0.133067 
3 129.790 197.585 0.026522 0.133534 
4 129.483 192.003 0.034869 0.116995 
5 129.498 208.689 0.035508 0.111757 
6 131.078 208.837 0.018913 0.135508 
7 131.050 232.401 0.023594 0.082460 
8 131.253 243.306 0.026539 0.068198 
9 131.301 237.509 0.032872 0.053128 
10 131.274 255.996 0.030582 0.039642 
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TABLE 4.14 Cont. 
NO, FE(C 
6 
FE (C 
11) 
FE (H 
2) 
FE (H 
24 
(-ýe) (-e) (-e) (-e) 
1 0.046591 0.015ý04 0.149774 . 000500 
2 0.048742 0.037600 0.152701 . 000747 
3 0.046544 0.028071 0.148874 . 000646 
4' 0.047726 0.078552 0.145682 . 001089 
5 0.046572 0.088172 0.141636 . 001157 
6 0.043235 0.025656 0.144363 . 000153 
7 0.033807 0.180411 0.111679 . 000658 
8 0.029610 0.221276 0.094724 . 000696 
9 0.026386 0.319721 0.075181 . 001084 
10 0.020524 0.342582 0.057265 . 001053 
NO, E(NIS-H 19 Mu-Z Q(CS-H 24 AUUA(Cq-H 24) 
(ev) (D) (e) (ev) 
1 -19.58670 0.396707 -. 020834 0.102299 
2 -19.58438 0.310475 -. 016890 0.107277 
3 -19.58872 1.301630 -. 010582 0.102423 
4 -19.58345 1.027354 0.003196 0.102038 
5 -19.58349 1.015008 0.002459 0.102064 
6 -19.59109 0.316898 -. 065314 0.103407 
7 -19.58900 0.971728 -. 043608 0.103399 
8 -19.58930 0.607149 -. 043372 0.103580 
9 -19.58748 0.192138 -. 068823 0.103620 
10 -19.58779 1.783198 -. 070425 0.103613 
148 
TABLE 4.15 Calculated indices for inhibition of DHFR from Bovine 
liver by 5-(benzyl) 2,4-diaminopyrimidines, 
NO* FE(N,, ) FE (H 
21) 
FE (H 
23) E(N, 5-HIS) 
(-e) (-e) (-e) (ev) 
1 0.146818 . 002546 0.030866 -20.095723 
2 0.127179 . 001902 0.048560 -20.094064 
3 0.132824 . 001823 0.039488 -20.101251 
5 0.090201 . 000750 0.086593 -20.094207 
6 0.155929 . 001870 0.030919 -20.097892 
7 0.069590 . 000209 0.092346 -20.096968 
10 0.036251 . 000080 0.104563 -20.098285 
11 0.152577 . 001521 0.029366 -20.103114 
12 0.130850 . 001772 0.043374 -20.097914 
13 0.146349 . 002981 0.027698 -20.104462 
14 0.081076 . 00055.2 0.071691 -20.101521 
15 0.148200 . 002425 0.028091 -20.104985 
16 0.145813 . 001841 0.025958 -20.107218 
17 0.039180 . 000140 0.133773 -20.090369 
18 0.148894 . 002967 0.030117 -20.093880 
19 0.145966 . 002214 0.027048 -20.109187 
20 0.079262 . 000274 0.091599 -20.094817 
21 0.123188 . 001418 0.051056 -20.096546 
22 0.115551 . 001415 0.055061 -20.107558 
23 0.026193 . 000304 0.098360 -20.090407 
24 0.035355 . 000253 0.124065 -20.089613 
25 0.050064 . 000742 0.105612 -20.103999 
26 0.152927 . 001919 0.033228 -20.097467 
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TABLE 4.15 Cont. 
NO, E (C 7 -H2 2) 
(Imol a. IP Pi 
(ev) 
ot 
(A 
03 
(ev. A) 
1 -19.53927 26.696 252.81835 01000 
2 -19.53743 24.592 272.50869 0.560 
3 -19.54201 24.760 279.72604 0.710 
5 -19.53787 25.278 278.63905 -. 020 
6 -19.54142 25.278 280.86602 -. 020 
7 -19.54029 27.860 304.14999 -. 040 
10 -19.53884 30.442 329.44873 -. 060 
11 -19.54570 22.867 257.23342 0.140 
12 -19.54174 22.867 256.67032 0.140 
13 -19.54200 25.901 291.43672 0.860 
14 -19.54130 25.901 291.05121 0.860 
15 -19.54358 24.760 279.12764 0.710 
16 -19.54505 24.843 286.78975 -. 280 
17 -19.53501 23.891 254.39987 -1.23 
18 -19.53719 24.592 273.21885 0.560 
19 -19.54593 25.105 284.79331 0.880 
20 -19.53961 24.068 264.68529 -1.34 
21 -19.54129 25.791 288.74631 1.040 
22 -19.54429 27.687 311.57359 -. 860 
23 -19.53474 27.683 284.61771 0.180 
24 -19.53788 27.949 299.37801 -. 970 
25 -19.54884 30.096 336.47240 1.250 
26 -19.540340 34.974 388.42039 0.54 
1 .5 to 
The results are subdivided according to the enzyme sources : 
(i) col i 
The best four simple regressions obtained with p(C so 
) as the dependent 
variable, have significance above the 99.9% level 
p(C50) = -98.94(t5.4) FE(q) + 10.4L+. 2) (4.81) 
and r= . 988 ;s= . 16 ; F(1,8) = 332.67 
p (C so 
)= -29.241.8) FE(H22) + 10.11(±2.3) (4.82) 
and r= . 984 ;s= . 19 ; F(118) = 244.15 
P(C'50) = 8.10(±. 7) FE(Cll) + 5.462(±. 13) (4.83) 
and r= . 966 ;s= . 20 ; F(lr8) = 112.07 
p (Cs 0)=0.041 (+ . 002) M. V-2.369 (+ 8) (4.84), 
and r= . 964 ;s= . 29 ; F(lt8) = 107.74 
The regressions (4.8l)-(4.83) involve FE's,, the most attractive one is 
the regression (4.83), since the positive coefficient indicates that 
drug activity increases as electron donating ability at C1, increases. 
Regression (4.84) shows that p(C,, ) increases with increasing molecular 
size within this series. 
The best four two variable regressions. obtained with p(C5, ) as dependent 
variable have significance levels above 99.9% : 
P(Cso) = -25.39(±. 6) FE(CO - 5ý 
. 
54(±. 4) E(Ce-Cg) - 193(-+16) (4.85) 
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and r= . 998 ;s= . 06 ; F(2,7) = 1092 . 
P(Cso) = 7.64(±. 2) FE(Cn)ý- 5.13(±, 5) E(Ce-Cg) - 1824-19) (4.86) 
and r= . 997 ;s= . 08 ; F(2,7) = 712.33 . 
P(Cso) = -19.82(±I) FE(CO -'10.51(tl) Q(Cg) + 8.29(-±. l) (4.87) 
and r= . 997 ;s= . 08 ; F(2,7) = 707.46 . 
P(C = -20. '8(±. 9) FE(CO - 12.4(±1.2) + 8.23(±. l) (4.88) 50 
Q(C9-ýý4) 
and r . 997 ;s= . 08 ; F(2,7) = 679.68 . 
The negative coefficients associated with FE(04) and E(Ce-Cq) are 
difficult to interpret., Since the environment of the C4 site is 
critical to-enzyme inhibition, it is likely that FE(CO is surrogate for 
another property of this site. The negative coefficient of E(C. -Cq) 
indicates that the stronger this bond the higher the drug activity. The 
positive coefficient of a high electron density in the region of C9 is 
also indicated by the appearance of Q(Cg) and Q(C'9-H24) with negative 
coefficients. This is compatible with the hypothesis proposed- in 
reference (188), i. e that the electronic structure in the area between 
two rings is critical to drug activity. 
(ii) Rat liver 
The best four simple regressions obtained with p(C,, -) as the dependent 
variable have significance levels above 99.9% : 
P(C, sg = -512.2(±-163.8) FE(H24 )+4.353 (±. l) (4.89) 
and r . 742.; Sý . 15 ; F(1,8) = 9.77 . 
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P(C'50 = -28.4 (±10.5) FE(NO + 4.759 (±. 3) (4.90) 
and r . 695 ;s= . 16 ; F(1,8) = 7.50 . 
p(Cso = -52.17L+23.3) E(NIS-HIS 1018(±458.5) (4.91) 
and r . 618 ;s= . 18 ; F(1,8) 4.96 . 
P(Cso) = -0.236(±. 11) MU-Z + 4.141(±. l) (4.92) 
and r= . 557 ;s= . 19 ; F(1,8) = 3.50 
The negative coefficients of the FE'S in the regressions (4.89) and 
(4.90) are difficult to interpret. Furthermore, the direct physical 
interpretation of regression (4.91) is that the stronger the Nls-Hg 
bond, the higher the drug activity. In all of these cases, it is 
necessary to postulate covariance of the variable which appears with a 
true causal quantity, Regression (4.92) is readily interpreted in terms 
of electrostatic drug-receptor interactions, 
The best four two variable regressions obtained with p(C50) as the 
dependent variable have significance levels above 99.9% : 
p(C, so) = 397(±5) FE(Cd + 599(174) ALPHA(C. -H24). - 59.2(±7) (4.93) 
and r= . 951 s . 07 ; F(2,7) = 33.34 
P(Cso) = 37.92(±5) FE(C6) + 498(±71) ALPHA(C. ) -. 62.48(±9) (4.94) 
and r= . 936 ;s= . 08 ; F(2,7) = 25.13 . 
P(Cso) = 9.3(±1.4) FE(H 22) + 468(±70) ALPHA(C. -H 24) - 45.3(±7) (4.95) 
and r= . 935 ;s= . 08 ; F(2,7) = 24.48 .I 
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P(C. 50) = 408.4(+-+69) Q(C4) + 
5.58(+-. 9) EBIND(EýI) + 10.6(+-14) (4.96) 
and r= ,. 927 ;s= . 09 ; F(2,7) = 21.57 . 
In the regressions (4.93)-(4.95) the electron donating ability of C6 and 
the polarizability of the electrons in the vicinity of Ca both seem to 
positively affect drug activity, Regression (4.96) suggests that a high 
positive charge on C4 and the high reactivity of H21 are both favourable 
I to drug activity. 
(iii) Bovine liver 
The best four simple regressions obtained with p(C50) as the dependent 
var-iable have significance levels between 99.5% and 99.75% : 
p(Cso) = 0.329(i. 09) PI + 5.076(±. 06) (4.97) 
and r= . 602 ;s= . 311 ; F(1, ý21) = 11.98 
p(Cso) = -37.67(112) E(N, S-HIS) - 751.9t 242.6) (4.98) 
and r= . 562 ;s= . 322 ; F(1,21) = 9.97 
p(Cso) = 0.007(±. 002) a. IP + 3oll(±. 6) (4.99) 
and r= . 567 ;s= . 321 ; F(1,21) = 9.97 
p(CSO) = -59.41(±19.3) E(C7-H22) - 1156(±377.2) (4.100) 
and r= . 557 ;s= . 32 ; F(1,21) =-9.47 . 
The hydrophobic substituent constant PI appears in regression (4.97) 
with a positive coefficient indicating that hydrophobic bonding may be 
I 
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involved in the drug-enzyme interaction. The negative coefficients 
appearing with bond energies in the regressions (4.90) and (4.92) make 
it difficult to give physical meaning to them. On the other hand 
regression (4.91) indicates that' the greater the ability of the drug 
molecule for dispersive interaction (with the enzyme) the higher the 
drug activity. 
The best four two variable regressions obtained with p(C,, ) as dependent 
variable have ; significance levels above 99.9% : 
p(C5Q) = 244(±52) FE(H21) + 0.008(±. 001) a-IP + 2,46(±. 4) (4.101) 
and r= . 822 ;s = . 22 ; F(2,20) = 20.93 
p(Cso) = -6.4(±1.3) FE(H23) + . 007(±-001) a-IP + 3.26(±. 4) (4.102) 
and r= . 818 ;s= . 22 ; F(2,20) = 20.33 . 
P(CSO) = 4.91(±1.1) FE(N, 5) + 0.008(±, 001) (I. IP + 2.27(±. 5) (4.103) 
and r= . 811 ;s= . 23 ; F(2,20) = 19.34 . 
P(Cso) = 7.56(il. 4) FEW 23) + 0.086(±. Ol) + 3.63(±. 4) (4,104) 
and r= . 810 ;s= . 23 ; F(2,20) = 19.16 
The appearance of a. IP in the regressions (4JoI)-(4. (o3) tends to confirm 
the importance of London interactions between substrate and enzyme, 
while the appearance of FE's indicates that charge transfer interactions 
also play a role. The substantial covariance between a, IP and C, mol 
may account for the appearance of the latter in equation (4.10t). 01 mol 
has many possible physical significances, since it is implicated in both 
London and Debye interactions. 
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4.10 Conclusions 
In this chapter, quinazoline, pyrimidine and 2,4-diamino 
benzylpyrimidine are studied. Most of the work is devoted to a series 
of quinazolines, with activities from different sources. 7he different 
C. substituents, which characterize the five quinazoline series, were 
chosen in order to observe the effect on the electronic structure of the 
quinazoline ring. The results of the different sets of OSAR regressions 
have been obtained to explain the variation in enzyme inhibitive potency 
of each series. Some are very useful for predicting the activities of 
untested compounds. The appearance of ceartain indices, obtained from 
the CNDO/2 wavefunctions, are of particular mechanistic interest. 
AIPHA(CIO) appears with positive coefficients in-regressions, explaining 
the DHFR inhibitive potency of quinazoline and 2,4-diamino 
6-(benzylamino) quinazoline with different activities. This indicates 
that the polarizability of the electron rich centres common to benzene 
and pyrimidine rings positively affects enzyme-substrate binding. 
MU-Y appears with negative coefficients in the regressions obtained with 
2,4-diamino 6-(benzyl&nino) quinazoline analogues of pterioic and 
isopterioc acids and quinazoline analogues of glutamic acid. %ben the 
mutual drug-receptor orientation, determined by various types of 
bonding, is fixed for all molecules in the series, MU-Y might determine 
a secondary interaction with the electric field of the receptor. 
The regressions obtained indicate that the receptor dipole moment is in 
the +Y direction, in the quinazoline frame of reference, as indicated in 
figure (4.1). 
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Certain pyrimidine nitrogen properties appear in the regressions quoted 
in the sections (4.3)-(4.7). 
Q (N 
I) appears with negative coefficients 
in some of the regressions 
involving the inhibitive potency of 2,4-diamino quinazoline and 
quinazoline analogues of pterioc and isopterioc acids, indicating either 
a first order interaction with an electropositive enzyme group, or 
polarization of the enzyme charge distribution by the net negative 
charge on N,. 
The other properties are E(N, -Cg) and E(C2-N3) which have negative 
coefficients, while E(N, -C2) and -E(N3-C4) have positive coefficients 
throughout the various series. Bonds C2-N, and N, -C. are longer than 
bonds 1ý -C2 and N -C4 . i. e the former pair are likely to be single bonds 
and the latter pair likely to be double bonds, owing to a degree of : 7r 
electron localization. Any substituent which induces electron 
localization in the pyrimidine ring tend to make JE(C2-N)l and 
JE(N -C., )j smaller while making JE(N, -C2)1 and JE(N 3 -C4 
)1 larger. It 
can be concluded that 7t electron localization is unfavourable to drug 
activity. 
In the 214-diamino pyrimidine series the effect of three types 
substituents in position Cs is studied. Regressions obtained with the 
DHFR inhibitive potencies differ according to whether the enzyme source 
is bacterial or vertebrate. Inhibition of DHFR from T. equiperidum is 
very sensitive to the properties of the 2-amino group, being enhanced 
according to the ease of removal of the amino protons. There is 
evidence that the reactivity in the vicinity of the ring-carbon C4 also 
has a positive effect. Ring properties dominated the chicken liver and 
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rat liver regressions. Inhibition of DHFR for these vertebrate sources 
is positively affected by ALPHA(NI) , ALPHA(N7), Q(C6) and E(Cs-C6). It 
is likely that there is a charged enzyme group in the vicinity of N, and 
N 71 in the enzyme-substrate complex. Given the greater reactivity of 
the heteroatoms, this is a more attractive deduction than that which 
links inhibitive potency to the reactivity in the region of C6- 
For the 2,4-diamino 5-benzylpyrimidine series, charge transfer 
properties are dominant. The regressions are much affect by the enzyme 
source, High correlations are obtained with the potency of inhibition 
of E, coli DHFR and FE's. The regression coefficients appear with 
FE(CO, FE(C6) and FE(H22) are all negative. FE(CII) has a positive 
coefficient and this indicates a possibile electron donor role for the 
benzyl ring atom in the enzyme-substrate complex. 
The potency of inhibition of rat liver DHFR also appears to be 
negatively affected by FE(N3) and FE(H24), but positively affected by 
FE(C6) and FE(H22)6 ribe polarizability in, the vicinity of the phenyl 
ring atom C, may also have a positive effect. 
The hydrophobic and dispersive interaction properties may determine the 
inhibition of DHFR for bovine liver, with the appearance of PI, cmol 
and a. IP, with positive coefficients. There is 'evidence for critical 
charge transfer interactions, with donor role for atoms H21, H23 and 
N15. 
I 
In the best regressions of enzyme from mammalian sources, energies of 
bonds between N,, and H,,, H appear with negative coefficients. It is 
possible that the stabilities of binding of H18 and H19 have a direct 
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INHIBITION OF SOKE DEHYDROGENASES 
5.1 Introduction 
The drugs considered in the previous chapter are inhibitors of an enzyme 
involved with DNA synthesis, These inhibitors might be effective in the 
growth and division phase of cells when division is very fast. Many 
tumour cells are slow in dividing and hence are resistant to inhibitors 
of ENA synthesis. The inhibitors of the enzymes involved in glucose 
metabolism limit the sources of energy for these cells 
The design of antimetabolites is increasingly important for the 
treatment of cancer. Such drugs are most effective during the growth 
phase of leukemic cells in vivo,, when the division time is long. Some 
DNA must be synthesized during this time (189). Many animal and human 
solid tumour cells do not respond to treatment with inhibitors of DNA 
synthesis, since most of the tunour cells are in a resting phase, called 
the stationary phase, and not making DNA (190). 
Although resting cells are not synthesizing DNA in order. to divide, they 
are still alive and thus are using an energy source# presumably glucose, 
Scme enzyme inhibitions may interupt*the energy pathway from glucose to 
carbon dioxide, thus attacking cancer cells in the resting phase, and 
inhibiting cells in the growth phase . 
Inhibitors of enzymes involved in glucose metabolism may be useful for 
the treatment of cancer cells in the resting phase. Three dehydrogenase 
enzymes involved in glucose metabolism are glyceraldehyde phosphate, 
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lactate and malate dehydrogenases. A fourth enzyme involved with amino 
acid metabolism is glutarnate dehydrogenase. All of these enzymes are 
stulied in the present work. 
(i) Glyceraldehyde phosphate dehydrogenase (GPDH) 
This is an enzyme which is important in the glycolytic pathway where its 
function is to convert each molecule of glyceraldehyde 3-phosphate to a 
molecule of lp3-diphospho-glycerate. 
OPO'Hj H aH2. 3 ZOPO 
CHOH + mlý CHOH + NAU i 
CHO L; =u ýMj-% 
Glyceraldehyde 1,3-diphosphoglyceric 
3-Onsphate acid 
Lactate dehydrogenase (LDH) 
This enzyme is used by cells with a poor oxygen supply. The mechanism 
for conversion of MM back to NAD is not available in anaerobic 
conditions. Instead, in mammalian tissuesr the NADH reacts with the 
pyruvate under the influence of lactate dehydrogenase to give lactate in 
the glycolytic process. This makes it of interest to cancer 
chemotherapy, since many tumour cells show a high rate of glycolysis 
(191). 
OOH OOH 
+T+ 
HOH + NAD C=O + NADH +H IH3 
L3 
Lactic acid Pyruvic acid 
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(iii) Glutamate dehydrogenase (GLUDH) 
This enzyme connects the glucose energy pathway with amino acid 
metabolism. The removal of amino groups from m ost anino, acids is by the 
reaction catalysed by -glutamate dehydrogenase, in the presence of NADH 
or NND 
OOH OOH 
+f... 
=0 + NH4 - L- - 
HC-N% + H2-0 I 
H2CH2-COOH ý'; Ll il"; kl 2 -COOH 
Oxoglutaric acid glutamic acid 
(iv) Malate dehydrogenase (MM) 
This enzyme plays a role in the Krebs cycle. The malate is 
dehydrogenated by malate dehydrogenase and NADt to give oxalpacetate 
(192). 
OOH OOH 
+T+ 
IHOH 
+ NAD C=O + NAJDH +H 
CH,, ujuH 
LztWH 
Malic acid Oxaloacetic acid 
All of these enzymes are inhibited by 4-hydroxy-quinoline 3-carboxylic 
acids. ' Since quinoline is planar, it might be expected to intercalate 
with DNA in the manner of the antimalarial chloroquine (193). 
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5.2 Scope of the present study 
A series of substituted derivatives of 4-hydroxy-quinoline 3-carboxylic 
acid have been reported as having antitunour activities (189). Although 
the parent compound exists in the OH form due to hydrogen bonding 
between the 4-OH and 3-C=O groups (194), it is also possible for 
migration of a proton from 0 14 
to NI to occur to give the oxo form, 
1,4-dihydro-quinolone 3-carboxylic acid Both conformations are 
therefore considered in the present work* 
Calculations have been performed, using the oxo form, for 28 compounds 
with an unsubstituted pyridine nitrogen, and 6 compounds with a 
substituted pyridine nitrogen, as shown in table (5.1). Ebr the first 
28 compounds, calculations have also been performed using the OH 
structure, Both structures are considered to be planar. 
The geometry of the 1,4-dihydro-4-quinolone 3-carboxylic acid, i. e the 
unsubstituted oxo structure, has been initially estimated using standard 
bond lengths and bond angles (110). This geometry is optimized using 
GEOMIN with the CNDO option. The equilibrim bond lengths and angles 
are given in table (5.2). 
The geometry of 4-hydroxy-quinoline 3-carboxylic acid,, i. e the OH 
structure, has been similarly estimated using standard bond lengths and 
angles (110). 7he geometry is optimized using GEOMIN with the CNDC 
option. The optimized bond lengths and angles are given in table (5.3). 
163 
Table 5.1 Observed drug activities for quinolone. 
0 
NO, Substituent P(I so 
GLUDH 
1 H 3.3565 2.7958 3.2218 
2 8-Cl 3.5228 3.1249 3.4814 
3 8-Br 4.0000 3.0655 3.4814 
4 6-CH 3.6777 2.5228 3.0969 
5 5,, 8-Cl2 3.6989 3.4814 3.5086 
6 6j8-C12 3.8860 3.3010 3.5228 
7 5-CH 8-Cl 3.8538 3.8239 3.9586 
8 6-C4Hq 3.7958 2.9586 3.8538 
9 6-C4Hq 4.1739 3.4089 
10 6-OCsHs 4.0177 3.2757 4.1249 
11 6-CH2C6H5 3.7958 2.5838 4.2518 
12 7-Cl 3.5686 3.0604 2.7695 
13 8-CF3 3.7695 2.9208 3.2924 
14 6-CH30 3.6382 3.3372 3.3665 
15 8-CH30 4.0087 3.2596 3.2676 
16 6-NOz 3.9586 3.2596 3.6989 
17 8-CH3 3.4685 2.3279 - 
18 6-ACNH 4.0655 3.3279 - 
19 8-NO2 3.5228 2.9586 - 
20 6-Cl 3.9586 2.9586 - 
21 8-C H 3.9586 --- 3.2441 
22 8-Ch 286Hs 3.1135 3.4685 
23 7-CH2C5H6 3.9586 - 3.3279 
24 7-C6H5 3,7695 --- 
25 8-Clr5-C6Hs 4.2218 3.3979 4.4317 
26 7,8-Benzo 3.8535 3.1739 4.0043 
27 8-Cl, 5-C6, HSCH2 4.1611 3.5086 4.9586 
28 6-CrHSCH20 3.9536 3.5528 4.0132 
29 6-CH30fl-CH3 3.8239 3.4814 3.5686 
30 I-CH3 4.1307 3,2291 3.3010 
31 'l-C4H9 4.0809 3.2757 3.4202 
32 8-clpl-CH 4.2006 3*5086 3.5376 
33 8-CH 0,1-CH 4.2365 3.5228 3.4948 
34 1-CH2CGHS 4,2006 3.1079 3.5528 
P(I so 
MDH 
3.2839 
3.3872 
3.3979 
3.1549 
3.7695 
4.2006 
3.9208 
3.6020 
3.5376 
3.7695 
3.7212 
3.4814 
3.9586 
3.5850 
3.8538 
4.4814 
4.1739 
4.0315 
3.8860 
4.6575 
3,9586 
3.6989 
P(Iso) P(I so 
LDH GPDH 
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TABLE 5.2 The optimizecl bond lengths and bond angles for 
1,4-dihydro-4-quinolone 3-carboxylic acid. 
13 _-- 
IV 014 
0 11 H20 
"I - 
Cg-Ni 
c 10 -cq 
C4-ClO 
c3 -C 4 
c2 -C 3 
C8-C9 
C7-CS 
C6-C7 
C5-C6 
C3 -cil 
C 
10 -C S-N I 
C4-CIO -CS 
C3-C4-CIO 
C2-C3-C4 
c 
8-C 9-C 10 
C 
7-C 8-C 9 
c 
G-C 7-C 0 
c5 -C 6-C 7 
cI 
I-C 37C 4 
1.3955 
1.4081 
1,4460 
1.4395 
1.3623 
1.3972 
1.3776 
1.3905 
1.3773 
1.4470 
118.20 
119.53 
119.42 
117.85 
120.89 
119.64 
120.71 
119.37 
119.25 
ý -H19 
ý16 117 
H 
Bond'lerigths(R) 
012-CII 
013-CII 
014-C4 
His-CI3 
H16-C, 
H 17-C 8 
H18""C 7 
H19 -C 6 
H20 -C 5 
H21-C2 
Bond angles (deg) 
18 
1.2757 
1.3498 
1.2928 
1.0661 
L. 0661 
1.1165 
1.1174 
1.1161 
1.1181 
1.1176 
0 
12-C 11-C 3 
0 
14 -C 4-C 3 
H 15-0 13-C 11 
H Is -14 I-C 9 
H 17-CS-CZ 
H 
18-C 7-C6 
H 
19-CS-C7 
H20 -CS-C6 
0 
is -C II -C3 
125.13 
120.17 
105.19 
118.59 
121.12 
119.89 
119.96 
119.61 
117.47 
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TABLE 5.3 The optbnized bond lengths and bond angles for 
4-hydroxy quinoline 3-carboxylic acids. 
16 19 
17 
(: ý -NI 
CIO -C9 
C4-CIO 
C3 -C4 
C2 -C3 
ce -Cq 
C7 -C8 
C6 -C7 
C5 -C6 
Cl 1 -C3 
1.3791 
1.4168 
1.4226 
1.3955 
1.4081- 
1.4112 
1.3684 
1.4004 
1.3679 
1.4293 
Bond lengths(R) 
012 -CII 
013-cil 
014 -C4 
HIS -014 
H16 -012 
P27 -CS 
HIS -C7 
H19 -C6 
H20 -C5 
H21 -C2 
1.3514 
1.2864 
CIO -C9-NI 
C4 -C 10 9 
C3 -C 4 -C 10 
C2-C3-C4 
Ca -C 9 -C 10 
C7 -C 8 -C 9 
C6 -C7 -C a 
CS -C6 -C7 
C 
11 -C 3 -C 4 
123.72 
116.94 
119.89 
117.14 
118.20 
121.16 
120.77 
119.27 
116.85 
1.3496 
1.0766 
IsO320 
1.1173 
1.1179 
1.1161 
1.1178 
1.1196 
Bond angles (deg) 
014 -CII -C3 
014 -C4-C3 
HIS -014 -C4 
H 
16 -012 -C II 
Hl7-C8-C7 
H, 
a -C7-C6 
HIq -C6-C7 
H20 -CIO -C6 
0 
12 -C 11 -C 3 
123.64 
119.52 
104.55 
109.12 
120.04 
119.12 
120,42 
120.12 
118.13 
166 
-, 5.3 Method 
-A series of substituted 4-hydroxy quinoline 3-carboxylic acids are 
reported in references (189,195,196). In the present study 34 compounds 
substituted in ýthe positions 1,5p61,7 and 8 are consideredp as shown in 
table (5.1), Drug activities are given as p(I5O ), where I,, is the 
molar concentration required to produce 50% inhibition of LDH, GPDHj 
GLUDH and MDH. The substituents are positioned with respect to the 
particular parent structure using standard bond lengths and bond angles 
(110). 
In the calculations on the 1,4-dihydro 4-quinolone 3-carboxylic acids, 
eight receptor points are chosen in the molecular envirorment. These 
points are 
Point x y z 
P, -3.14 -5,04 0.0 
P2 6.22 5.540 0.0 
P3 9.28 -0.20 0.0 
P4 5.83 -5.71 0.0 
PS -0.69 -5.47 0.0 
P, 6 -2.70 - 4.50 0.0 
P7 -0.20 5.80 0.0 
P8 2.08 4.20 0.0 
The points P, -P. are chosen so as to be sensitive to the manner of 
substitution Point P, is placed on the line joinirxg N, to H 27 , at a 
distance of 5 from NI, Points P2 -P5 are placed 4R from C5, C61 C7 
and C, j respectively. The points P6-Pe are the three receptor points 
chosen to be the minimum points in the molecular el ectrostatic 
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potential. These points coincide with the minima at -135, -122 and -103 
kcal/mole in the vicinity of 012,019 and 014, respectively. The e. p 
contour map is plotted in figure (5.1a), The coordinate system used is 
indicated in this f igure 
For the 4-hydroxy quinoline 3-carboxylic acid form, eight receptor 
points are chosen in a similar manner, these points are : 
Point x y z 
Pi -0.60 -0.80 0.0 
P2 6.152 5.614 0.0 
P3 9,263 -0.11 0.0 
P4 5.860 -5.63 0.0 
ps -0.63 -5.48 0.0 
ps -2.90 3.100 0.0 
P7 -0.20 5.800 0.0 
P8 2.800 4.200 0.0 
The X and Y axes to which these corrdinates are referred are indicated 
in figure (5.1b), the Z axis being out of the plane of paper. The point 
P, corrosponds to the ep minimum at -114 kcal/mole in the vicinity of 
N, j as shown in the figure (5.1b). Points P2-Ps are positioned in 
exactly the same way as those having the same numbers for the oxo form. 
Points P 6-PS coincide with the minima at -68j -86 and -92 
kcal/mole in 
the vicinity of 0,21 0,3 and OW respectively# as shown in figure 
(5.1b). 
Calculations on both the 1,4-dihydro-4-quinolone 3-carboxylic acid and 
4-hydroxy quinoline 3-carboxylic acid series have been performed usirxg 
MOREG, with the CNDO/2 option. 
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b. 4-hydroxy quinoline 3-carboxylic acid 
-6 
a. 114-dihydro 4-quinolone 3-carboxylic-, acid 
FIGURE 5.1 CNDO/2 eep contour maps for 1,4-dihydro 4-quinolone 
3-carboxylic acid and 4-hydroxy quinoline 3-carboxylic acid. 
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5.4 ]Results and discussion 
(1) 1,, 4-dihydro 4-quinolone 3-carboxylic acids 
The calculated indices for the 34 molecules of this series# having 
activities against four types of dehydrogenases, are given in table 
(5.4). The regressions obtained for each of these enzymes are 
(i) Glyceraldehyde phosphate dehydrogenase (GPDH) 
The regressions are I based on 30 molecules for which the biological 
activities are given in table (5,1). The best four, simple regressions 
obtained with p(I,, ) as the dependent variable have significance levels 
between 95% and 99% 
p (150 -1.318 (+- . 4) V2 (Pq 1.16 1.5) (5.1) 
and r . 468 ;s= . 29 ; F(1,28) 7.86 
P(Iso -17.8(±10.04) V2 (PO - 49.42(±19.0) (5.2) 
and r . 463 ;s= . 29 ; F(1,28) = 7.66 
p(Iso) = 1.814(±. 7) E(C4-014) + 74.53(±30.1) (5.3) 
and r= . 408 ;s= . 30 ; F(1,28) = 5.61 
P(Iso) = -. 054(±. 002) EBIND(Cs) - 2.07(±2.3) (5.4) 
and r= . 395 ;s= . 30 16 F(1,28) = 5.20 
The low correlation coefficients of regressions (5.1)-(5.4) cast doubt 
on their physical interpretations. It is noticeable that high 
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polarizability at the 0,3 or 014 mintnum seems to be favourable,, as 
indicated by the appearance of V2(P. ) and V2(P7) in the regressions 
(5.1) and (5,2) respectively* 
The best four two variable regressions obtained with p(I,, ) as the 
dependent variable have significance levels of 99.9% : 
p(Iso = -5.5 (±1.3) 
E(C3-C4) - 41.09 (±B) V2 
(PO - 257 (±. 5) (5.5) 
and r . 721 ;s= . 23 ; F(2,27) = 14.62 . 
P(Iso) = 4.38(±l) E(C 2-C3) - 41.2(±8) 
V2(p6) + 70.801) (5.6) 
and r= . 678 ;s = . 25 ; F(2,27) = 11.48 . 
p(Iso) = 2.79(±. 9) E(C2-C3) - 41(±9) V2(P7) + 36.8(±32) (5,7) 
and r= . 647 ;s= . 26 ; F(2,27) = 9.72 
p (15 0=3.15 (±. 9) ALPHA (CO *+1.35 (±. 3) Ey (Pe) - 363(±108) 
(5.8) 
and r . 640 ;s= . 26 ; F(2,27) = 9.39 .* 
Second order properties appear in -each of the best two variable 
regressions. V2 (P 7) appears 
in both regressions (5.5) and (5.7)t %bile 
V2(P6) and ALPHA(C4) - appear in regressions (5.6) and (5.8), 
respectively, High polarizability of the oxygenated region of the 
molecule is clearly favourable to the inhibitive potency. The component 
of the electric field in the Y direction at point P. appears in the 
regression (5.8) with a positive coefficient, indicating that there may 
be a critical interaction with a polarized receptor fragment, located in 
the region of the 0 14 minimum point. The X and Y directions are 
indicated in figure (5, lb) . the Z direction being out of the plane of 
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the paper. 
E(C3-C4) appears in the regression (5.5) with a negative coefficientr 
which makes physical interpretation d if f icult. E (C 2-C3 appears-in 
regressions (5.6) and (5.7) with positive coefficients, indicating the 
positive effect of reactivity in the region of the C2_C3 double bond. 
(ii) Lactate Dehydrogenase (LDH) 
The best four simple regressions obtained with p(I,, ) as the dependent 
variable have significance levels of 99.9%-: 
p(I50 = 5.955(±. 1.3) Q(Nl) + 4.618(±. l) (5.9) 
and r . 605 ;s= . 21 ; F(1,32) = 18.48 
P(Iso -46.80(±-12.8) Q(C2) + 13.17(±. 2.5) (5.10) 
and r . 541 ;s= . 22 ; F(1,32) 13.28 
P(Iso -5,42(±,, Ol) EBIND(NI) - 0.78(+-1.3) (5,11) 
and r . 514 ;s= . 23 ; F(1,32) = 11.50.. 
p(T50 = 0.808(±. 25) E(N-C2) + 31.64(±-8.8) 
and r . 485 ;s= . 23 ; F(1,32) = 9.88 . 
Regression (5.9) is the most attractive of the four simple regressions. 
It involves Q (NI All simple regressions are involved with properties 
in the region of the bond NI-C2. Either a positive charge on N, or -a 
negative charge on C2 is favourable to inhibitive potency. There is a 
substantial negative covarianc*e between these two properties and it - is 
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not possible to know wbich is a causal quantity. 
The positive coefficient of E(NI-C2) appearing in the regression (5.12) 
indicates that the less stable the bond the higher the drug activity. 
The best four two variable regressions obtained with p(I,,, ) as the 
dependent variabley have significance levels of 99.9% 
P(Iso = 6.26(±1.2) Q(NI) + . 003(±. 001) M. V + 3.97(±. 2) (5.13) 
and r . 709 ;s= . 19 ; F(2,31) = 15.72 . 
p (I 
so 
6.27(±1.2) Q(NI) + . 024(t. 008) 
C' mol + 4.04(±. 2) (5.14) 
and r . 709 ;s= . 19 ; F(2,31) = 15.67 
P(Iso) = 7.55(±2.1) FE(Cs) + 1.19(±. 2) E(NI-C2) + 44.7(±B) (5.15) 
and r= . 674 ;s= . 20 ; F(2,31) = 12.91 
*21(±. 07) E(CS-C6) + 23.8 C+4.3) (5.16) P(ISO) = -58.6(±12) Q(C 2+0 
and r= . 663 ;s= . 20 ; F(2l*31) = 12.19 
In the two variable regressions (5.13) and (5.14), Q(N, ) appears with 
M. V and Olmol,, respectively. The positive coefficients associated 
with the second variables indicate that the larger the speciest the 
higher the inhibitive potency, E(NI-C2) appears with the frontier 
electron density of Cs in the regression (5.15). The positive 
coefficient of FE(Cs) indicates a possible electron donor role for this. 
atom in a charge-transfer interaction between enzyme and substrate. In 
regression (5.16) the appearance of E(CS-CO with a positive coefficient 
indicates that high reactivity in the C. -C. region is favourable to 
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inhibitive potency. 
Another interesting two variable regression is equation (4.17) which 
contains V, (P2)f provides an explaination of the high drug activity of 
molecule 25 in the table (5.1) 
p(40 = 5.91 (±1.3) Q(N 1) + . 008 (±. 005) V, (P2)" + 4.6 (. ±. l) (4.17) 
and r . 645 ;s= . 21 ; F(2,31) = 11.06 
The V, (P2) value is very large for molecule 25, wh ile. being small for 
the rest of the ser ies. Q(N, ) is able to explain the activity of the 
most active compound in the series. Molecule 33 is. 'the 'most active 
compound, and has the least negative value of Q(N, ),,,,, as. given in the 
table (5.4). 
(iii) Glutamate dehydrogenase (GLUDH) 
The best four simple regressions obtained with the GLUDH inhibitory 
potency as the dependent variable, have significance levels between 
99.75% and 99.9% : 
P(4o = 0072 (-±. 001) IP + 1.60 (±. 4) 
and r . 697 ;s= . 32 F(1,27) = 25.57 
PCýo = . 069(±. Ol) 
amol + 1.857(±, 4) (5.19) 
and r . 642 ;s= . 35 ; F(1,27) = 18.92 
P(ýo . 0093(±. 002) M. V + 1,718(±. 4) (5.20) 
and r *632 s= . 35 ; F(lp27) = 17.95 
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P(Iso) = -. 1064(±. 02) EBIND(C, ) - 6.633(±-2.8) (5.21) 
and r= . 573 s= . 37 F(1,27) = 13.25 
Simple regressions (5.18)-(5.20) indicate that the inhibitive potencý 
against GLUDH is positively affected by the moledular size# probably via - 
enhancement of the dispersive interaction between enzyme and substrate. 
The negative coefficient appearing with EBIND(Cs) , 
in the regression 
(5,21) irdicates that the more strongly Cs binds to the rest of the 
molecule,, the higher the drug activity, It may be that the sun of the 
electron densities of atom Cs and its neigbbouring atoms is critical to 
drug activity. 
The best two variable regressions obtained with p(I50) as thý 
variable have significance levels above 99.9% : 
P(Iso) = -. 07(±. 02) EBIND(Ct) + . 005(±. Ool) a IP - 4.7(±2.2) (5.22) 
and r= . 781 ;s= . 29 F(2,26) = 20.45 
P(Iso = -. 084 (±. 02) EBIND(C. ) + . 007 (±. 001) M. V - 6.1 (-ý2.2) (5.23) 
and r . 771 ;s= . 29 ; F(2,26) = 19.15 
p (ISO = . 006 (±-. 001) a. IP - 25.9 (±10) V2 (PO - 47.3 (±19) (5.24) 
and r . 764 ;s= . 30 ; F(2,26) = 18.22 
P(Iso) = *007(±. 001) a. IP + . 62(±. 2) VI(P8) + 4.35(±1.2) (5.25) 
and r= . 760 ;s= . 30 ; F(2,26) = 17.83 . 
Regressions (5.24) and (5.25) contain properties observed at the 01, and 
I l: ) 
014 minima, respectively, as well as a. IP. The second order 
interaction energy at point P.; appears with a negative coefficient in 
regression (5.24), indicating that high polarizability in the oxygenated 
part of the molecule is favourable to enzyme inhibition. The appearance 
of V, (Pe) in regression (5,, 25) indicates that an electronegative 
receptor moiety might be, in this vicinity. The more shallow the 0,4 e, p 
minimume the higher the enzyme-substrate interaction energy. 
(iv) Malate dehydrogenase (MUH) 
The data base for these calculations is waller than for the previous 
three enzymes. In particular,, only, one N, substituted molecule is 
included, because of the lack of reliable drug activity data. 
The best four simple regressions obtained with p(I. 0) , as 
the dependent 
variable have significance levels between 99.5% and 99.75% 
P(Iso) = 0.0052(t. 001) a IP + 2,27(±. 4) (5.26) 
and r= . 643 ;s= . 29 ; F(1,20) = 14,09 
P(I50) = 0.0552(i-. 01) mol + 2.425(±. 4) (5.27)f 
and r= . 601 ;s= . 30 F(1,20) = 11.31 
P(Iso) = 0.288(±. 08) PI + 3.385(±. l) (5.28) 
and r= . 585 ;s= . 30 ; F(1,20) = 10.42 
P(Iso) -. 0065(±. 002) M. V + 2.432(±. 4) (5.29) 
and r . 572 ;s= . 31 ; F(1#20) = 9.74 
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Regressions (5.26)-(5.28) are very similar to those obtained for GLUDH, 
indicating that the molecular size plays a major role in determining the 
drug activity. The appearance of PI with a positive coefficient in 
regression (5.28), may be due either to its covariance with substituent 
size, or indicative of hydrophobicity being favourable. 
The best four two variable regressions obtained with p(I50) as the 
dependent variable have significance levels above 99.9% 
p(I5o) = 4.06(i-1.2) EBI14D(C2) + . 077(±. Ool) 
amol + 388(±115) (5.30) 
and r= . 774 ;s= . 24 F(2,19) = 14.20 
p(Iso )=3.29(1-11.1) EBIND(C2) + . 006('±. 001) (x IP + 316(±110) (5.31) 
and r= . 767 '; s= . 25 ; F(2,19) = 13.59 . 
p (1 50 
)=0.006(+-.. 001) a. IP - 2.0.9(±. 7,4) V2(P6) - 53.4(±19) (5.32) 
and r= . 765 ;s= . 25 ; F(2119) = 13.47 
p(Iso . 004(+. Ool) aip - 25.1(±9.7) V2(P7) - 45.3(±18) (5.33) 
and r . 751 s =.. 25 ; F(2,19)'= 12.33 
The appearance of EBIND(C2), with positive coefficients in regressions 
(5.30) and (5.31), indicates that reactivity in the vicinity of C., may 
'be critical'for inhibitive potency, as indicated for the MH series. 
Regressions (5.32) and (5.33) contain V2(P6) and V2(P7) with negative 
coefficients, indicating high polarizability in the oxygenated region, 
where there are lone pairs of electronst to be favourable in the 
enzyme-substrate interaction. 
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Table 5.4 Calculated indices for inhibition of some dehydrogenases 
by 1,4-dihydro 4-quinolone 3-carboxylic acids. 
NO, PI Q(NI) 0 (C 2) EBIM(N, ) EBIND(C2)WHA(C4) FE(C5) 
(e) (e) (ev) (ev) (KeV") (-e) 
1 0,00 -. 12650 0.19976 -84.6580 . 1! 1195.3387 
116.129 . 010727 2 0.71 -. 12465 0.19984 -84.7823 -95.2835 116.177 . 014744 3 0.86 -. 12689 0.19979 -84.6488 -ý95.2778 116.175 . 022339 4 0.56 -. 12588 0.19941 -84.6333 -95.1545 '116.191 . 024706 5 1.42 -. 12400 0.19953 -84.7944 -. 95.2ý98 . 116.279 . 018982 6 1.42 -. 12360 0.19957 -84.8452 -95.2182 116.242 021991 
7 1.27 -. 12342 0.20153 -84.8472 -95.302-2 115.902 . 044561 8 1.90 -. 12596 0.19943 -84.6313 -95.3547 116.10 424578 
9 1.96 -. 12537 0.19963 -84.6203 -95.3608 116.219 031942 
10 2.08 -. 12473 0.19956 -84.6074 -95.3580 '-116.275 . 052529 11 2.01 -. 12566 0019951 -84.6412 -95.3517 116.184 , . 024426 12 0.71 -, 12595 0.20004 -84.6861 -95,2812 116.223 .. 007808 13 0.88 -. 16748 0.20361 -84.1865 -95.3282 116,157 -.. 005404 
14 -. 02 -. 12462 0.19958 -84.6138 -95.3608 116*. 270 . 047758 15 -. 02 -. 17154 0.20141 -82.9920 -95.3803 116#184 041101 
16 -. 28 -. 12538 0.19908 -84.8233 -95.1773 116.245 .. 
004999 
17 0.56 -. 13190 0.20013 -84.4812 -95.3674 116.167 '. 022364 
18 -. 97 -. 12479 0.19942 -84.6022 -95.3499 116.295 . 079743, 19 -. 28 -. 15391 0.20250 -84.5009 -95.2694 116.168 . 003614. . 20 0.71 -. 12580 0,19950 -84.7298 -95,2688 116.207 018191 
21 1.96 -. 12849 0.20011 -84.5279 -95.3647 116.188 . 029332'. 22 2.01 -. 23945 0.20485 -81.3873 -95.4547 116.102 . 018572 23 2.01 -. 12737 0.19937 -84.6419 -95.3477 116.093 . 008600 24 1.96 -. 12736 0.19909 -84.6550 -95.3460 116.046 . 007373 25 2.67 -. 12416 0.19994 -84.8107 -95.3021 116.090 . 026691 26 1.32 -. 12540 0.19356 -84.6986 -95.3158 116.212 . 059466 27 2.72 -. 12422 0.19965 -84.7978 -95.3019 116.198 . 025791 28 0,54 12452 0.19965 -84.6033 -95.3680 116.258 . 050001 29 0.54 09061 0.19423 -90.7967 -95.3519 116.212 . 044282 30 0.56 -. 09333 0.19433 -90.8217 -95.3329 116.196 . 010834 31 1.90 -. 10003 0.19212 -90.9051 -95.2740 116.206 . 003727 , 32 1.27 -. 08652 0.19321 -90.8584 -95.2518 116.241 . 015658 33 0.54 -. 08576 0.19377 -90.9067 -95.3385 116.266 . 043610 34 2.01 -. 09534 0.19203 -90.8725 -95.2303 116.218 . 001378 
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Table 5.4 Cont. 
NO, a mol M. V Ey (pe) VI (P e)- V2(pe) V2(p7) 'V2(p6) 
(ý 3) (R 3) volt/R volts (ev/e 
2) (ev/e2) (ev/e 2) 
1 19.273 156.956 -. 20338 -4.6197 -3.22725 -1.88624 -2.64591 
2 21.337 169.796 -. 12160 -4.4056 -3.25543 -1.89065 -2.65738 
3 22.478 173.867 -. 11614 -4.3798 -3.26038 -1.89343 -2.65991 
4 21.169 173.513 -. 21670 -4.6449 -3.24327 -1.88764 -2.64631 
5 23.401 182.306 -. 12867 -4.7034 -3.76907 -1.90758 -2.66790 
6 23.401 183.305 -. 01682 -4.2179 -3.28558 -1.89604 -2.66903 
7 23.233 184.574 1.01006 -3.8795 -3.61839- -1.89970 -2.65863 
8 26.857 222.973 -. 22457 -4,6526 -3.25527 -1.88952 -2.64658 
9 28.969 228.013 -. 21550 -4.6349 -3.26262 -1.89039 -2.64839 
10 29.655 236.286 -. 19785 -4.6854 -3.27276 -1.89050 -2,64936 
11 30.865 244.357 -. 20051 -4.5956 -3.25643 -1.88920 -2.64734 
12 21.337 170.057 -. 11673 -4,4062 -3.27561 -1.89232 -2.65731 
13 21.682 185.620 -. 12767 -4.4209 -3.23888 -1.88490 -2.65368 
14 21.855 181.769 -. 15331 -4.4532 -3.26091 -1.88736 -2.64701 
15 21.855 178.466 -. 21052 -4.6207 -3.24291 -1.88659 -2.64649 
16 21.420 179.184 0.03047 -4.2087 -3.26163 -1.89130 -2.66665 
17 21,169 172.545 -. 21381 -4.6511 -3.23770' -1.88734 -2.64660 
18 24.526 200.518 -, 16696 -4.4866 -3.27285 -1.88989 -2.65024 
19 21.420 177.428 -. 06142 -4.2292 -3.25072 -1.88714 -2.66412 
20 21.337 170.062 -. 08993 -4.4147 -3.25975 -1.89174 -2.65824 
21 28.969 227.688 -, 21449 -4.6541 -3.24971 -1.89052 -2.64942 22 30.865 240.182 -. 28706 -4.8130 *-3.22523 -1.88638 -2.64239 
23 30.865 244.229 -. 23122 -4.6720 -3.23203 -l'. 89047 -2.64678 
'24 28.969 227.953 -. 25200 -4.7133 -3.22563 -1.89234 -2.64666 
25 31.033 240.311 -. 00646 -4.1419 -3.41325 -1.89828 -2.65950 
26 25.597 199.220 -. 30987 -4.8084 -3.28209 -1.90268 -2.65967 
27 32.929 256.496 -. 05777 -4.2975 -3.42348 -1.90347 -2.66i83 28 31.551 248.658 -, 21114 -4.7075 -3.26438 -1.88898 -2.64757 
29 23.751 197.734 -. 18059 -4.5073 -3.27017 -1.88981 -2.65163 
30 21.169 172.903 ý-. 22622 -4.6664 -3.23802 -1.88873 -2.65028 
31 26.857 218.094 -. 24108 -4.7048 -3.24520 -1.89042 -2.65100 
32 23.233 183.500 -, 14279 -4.4258 -3.26495 -1.89350 -2.66227 
33 23.751 196.464 -. 23001 -4.6925 -3.25918 -1.88953 -2.65357 34 30.865 238.914 -. 21966 -4.6478 -3.25412 -1.89617 -2.65888 
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Table 5.4 Cont. 
NO. EBIND(Cs) VI(P2) a. IP E(Nj-C2) E(C3'IC4) E(C -C E(C -C 
32 3) 5 6) (ev) volts (R. ev) (ev) (ev). (ev) (ev) 
1 -95.842 -. 2888 215.4132 -34.3887 -32*8681 -40.4584 -38.8855 
2 -95.728 -. 1939 242.0603 -34.3252 -32,8766 -40.4772 -38.7749 
3 -95.705 -. 1777 254.0785 -34.3113 -32.3976 -40.4817 -38.7513 
4 -95.393 -. 2867 233.0290 -34.4334 -32.8841 -40.4260 -38.1558 
5 -96.952 -. 3909 268.0699 -34.2672 -32.8651 740.5073 -37.9582 
6 -95.455 -. 2306 268.5091 -34.2502 732.8633 -40.5083 -37.9105 
7 -103.42 -. 1657 261.1404 -34.3944 -32.9503 -40.4256 -37.9164 
8 -95.265 -. 2864 295.2070 --34.4387 -32.8849 -40.4238 -38.2234 
9 -95.323 -. 2635 317.4733 -34.4618 -32.8975 -40.4054 -37.8833 
10 -95.199 -. 4155 322.5623 -r34.4910 --t32.9144 -40.3797 -38.3172 
11 -95.244 -. 2541 340.1072 -34*. 4296 -ý32.8847 -40.4278 -38.2027 
12 -95.826 -. 2151 243.0039 -34.3368 -32.8626 -40.4755 -38.8755 
13 -95.759 -. 1897 246.4739 -34.4305 -32.9227 -40.4427 -38.7405 
14 -95.038 -. 1401 238.1250 -34.4990 -32.9186 -40.3744 -38,2728 
15 -95.753 -. 2934 237.5872 -ý34.5954 -32.9607 -40.3123 -38.8652 
16 -95.137 '-. 4532 250.9532 -34.1837 -32.8273 -40.5545 -38.0915 
17 -95.784 -. 3045 234,1443 -34.4521 -32.8865 -40.4245 -38.8312 
18 -95.079 -. 1936 263.4352 -34.5032 -32.9225 -40.3671 -38.0807 
19 -95.641 -. 0933 247.2496 -34.3370 -32.9216 -40.4676 -38-6036 
20 -95.568 -. 3227 241.5122 -34.3069 -32.8539 -40.4933 -38: 0147 
21 -95.781 -. 3102 319.7802 -34.4564 -32.8855 -40.4194 -38.8627 
22 -95.786 -. 3391 329.5173 -34.7679 '-33.0354 -40.2326 -38.8314 23 -95.788 -. 2932 343.4359 -34.3690 -32.8486 -40,4786 -38.9866 
24 -95.800 -. 3042 322.0549 -34.3466 -32.8383 -40.4963 -39.0577 
25 -103.51 40.831 349.7867 -34.3222 -32.8673' -40,4893 -37.6337 26 -95.745 -. 3438 273.0800 -34.3562 -32.8638 -40,4631 -40.2119 27 -103.12 -. 0791 370.8098 -34.3311 -32.8654 -40,4852 -37.9768 
28 -95.212 -. 4021 342.6609 -34.5008 -32.9166 -40.3754 -38.3103 29 -95.034 -e1521 253.0073 -34.2357 -32.9572 -40.3349 -38.2837 
30 -95.841 -. 2994 231.1995 -34.1233 -32.9025 -40.4224 -3a. 8941 
31 -95.827 -. 3168 276.0839 -34.0325 -32.8959 -40.4329 -38.9273 
32 -95.728 -. 2042 257.1808 -34.0500 -32.9112 -40.4332 -38.7853 
33 -95.743 -. 2985 253.6629 -34.2701 -32.9727 -40.2935 -38.8689 
34 -95.821 -. 3004 283.6242 -33.9497 -32.8562 -40.4805 -38.8918 
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(2) 4-Hydroxy quinoline 3-carboxylic acids 
The calculated indices for the 28 molecules of this seriest having 
activity against four types of dehydrogenases, are given in table (5.5). 
The regressions obtained for each of these enzymes are : 
(i) Glyceraldehyde phophate dehydrogenase (GPDH) 
The best four simple regressions obtained with p(IO ), as the dependent 
variable have significance levels between 99.0% and 99.9% : 
p(ISO) = -63.35(±14.3) V2(P6) - 74.63(±17.5) (5.34) 
and r= . 686 s= . 25 ; F(lr22) = 19.56 
p(Iso -30.16(±7.3) V2(p7) - 78.16(±19.7) (5.35) 
and r . 660 ;s= . 26 ; F(1,22). = 17.02 
p(ISO) = -, 857(±, 2) DELTA + 13.63(±2.9) (5.36) 
and r= . 604 ;s= . 28 ; F(1,22) = 12.63 
p(Iso -1.342(±. 4) V2(p8) + 0.24(±. 9) (5.37) 
and r . 558 ;s= . 29 ; F(lr22) = 9.49 
The negative coefficient of V2 at the points 6,, 7 and 8 in the 
regressions (5.34) j 
(5,35) and (5.37) respectively,, suggests that there 
is a charge entity in the vicinity of P6, P7 and P. in the drug enzyme 
complex. The ease with which this charge polarizes the drug molecule 
determines the drug activity. ' In regression (5.36), the appearance of 
DELTA with a negative c6efficient indicates that the greater the ease of 
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electronic excitation,, the higher the drug activity. 
The best four two variable regressions obtained with p(I, O) as the 
independent variable have significance levels above 99.9% 
p(40 = 133r-. 25) Q(C3) - 0.103(±. Ol) EBIND(q) + 16.2(±-3.8) (5.38) 
and r 818 ; s. = . 21 ; F(2,21) = 21.30 . 
lj(40 346(tý60) Q(Iýs + 12.5(±2) E(C4-014) + 317(±51) (5.39) 
and r . 800 ;s = . 21 F(2,21) = 18.67 
56 
13,3 (+24) (5.40) p (1 0 
2.17 (-" . 7) E (C4 -0.14. ) -70.5 12) V? (P 
and r . 798 ;s= . 22 ; F(2,21) = 18.46 . 
p(Iso) = 5.27(±1.2) FE(Cs) + 7.45(±1.3) EBIND(HIS + 167(±29) (5.41) 
and r= . 781 ;s= . 22 ; F(2,21) = 16.49 
All of the independent variables appearing in the above regressions 
involve properties of the oXygenated region of the moleculee' The 
appearance of Q(C, ) and Q(H,, ), with positive coefficientsy in 
regressions (5.38) and (5.39),, indicates that the enzyme fragment 
present in the region(-6FC3 and H,, may have a net negative charge. 
The appearance of EBIND(H Is),, with a positive coefficient, 
in regression 
(5.41), indicates that the ease of migration of H., s may positively 
affect drug activity. The appearance of E(C4-0,4) in regressions (5.39) 
and (5.40) is indicative of the positive effect of general reactivity in 
this region. However, the C4-0,4 bond is unlikely to be broken in the 
drug-enzyme interactions 
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Lactate dehydrogenase (LDH) 
The best four simple regressions obtained with p(I,, ),, as the dependent 
variable have significance levels between 99.5% and 99.9% 
P(Iso 2.593(j. 7) FE(Cs) + 3.273(±, l) (5.42) 
and r . 567 ;s= . 21 F(1,26) = 12.35 
PU50) = -1.857(±. 5) FE(Ni) + 4.477(t. l) (5.43) 
and r= . 566 ;s= . 21 ; F(lp26) = 12.26 
P(Iso -. 024(4.009) E. F 2 (PI) + 3.908(±. 05) (5.44) 
and r . 466 ;s= . ý3 F(lt26) =1 7.21 
P(Iso )=-. 146(+. 05) E. F(PI) + 4.078(±. l) (5.45) 
and r . 439 ;s= . 23 ; F(1,26) = 6.22 . 
Regression (5.42) indicates that Cs may be the donor atm in a charge 
transfer interaction between enzyme and substrate. The 'negative 
coefficients appearing in regressions': (5.43)-(5.45) make their direct 
physical interpretation difficult. The negative coefficients-appearing 
in (5.44) and (5.45) indicate that the lower the facility for 
interaction with an induced or permanent dipole, in the vicinity of N,, 
the higher the drug activity. The direct physical interpretation of the 
regression (5.43) is that there may be a charge transfer process which 
reduces inhibitory potency. 
The best four two variable regressions obtained with p(1ý0 ) as the 
dependent variable have significance levels above 99.9% : 
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P(Iso = -43.7 (±9) FEW 17) + . 032(±. 008) 
Clnx)l + 3.02(±. 2) (5.46) 
and r . 746 ;s= . 17 ; F(2,25) = 15.76 . 
p(Iso) = -43.3(±9.1) FE(H17) + . 004(±. 001) M. V + 2.9(±, 2) (5.47) 
and r= . 738 ;s= . 18 F(2#, 25) = 15.01 
P(Iso = -40.9 (t9.2) FE(H 17) + . 003(t. 0007) a. IP + 3.01(t. 2) ' (5.48) 
and r . 728 ;s= . 18 ; F(2,25) = 14.16 . 
p (ISO 2.59 (t. 6) FE (CO + . 002 (±. 0008) IP + 2.62 (±. 2) (5.49) 
-6§6 s= . 19 ; F(2,25) = 11.74 and r0 
The negative coefficient associated with FE(Hj7) in regressions 
(5.46)-(5.48) indicates that the charge transfer interaction, in which 
H17 acts as the donor atcm, may reduce inhibitory potency. 7he second 
independent variable appearing' in each of regressions (5.46)-(5.49) 
indicates that inhibitory potency is positively affected by molecular 
size, or capacity for dispersive interaction between enzyme and 
substrate, The most attractive regression is (5.49),, since this can be 
explained in terms of a charge transfer and a dispersive interactions 
between the enzyme and substrate. 
(iii) Glutamate dehydrogenase (GUJDH) 
The best four simple regressions obtained with p(I5, ý as the dependent 
variable have significance levels between 99.5% and 99.9% : 
P(Iso )= . 0071(±. 001) a. IP + 1.633(±. 4) . 
(5.50) 
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and r= 672 ;s= . 37 ; F(1,21) = 17.29 . 
p(Iso . 0728(±. Ol) mol + 1.79(±. 4) (5.51) 
and r . 663 ;s= . 38 F(1,21) = 16.54 
P(ISO) = . 0097(±. 002), M. V. + 1.663(i-. 5) (5.52) 
and r= . 651 ;s= . 38 ; F(1,21) = 15.49 
p (I 
so = -. 
0035(±. 001) 
, 
B, E + 2.185(±. 4) (5.53) 
and r . 593 ;s= . 41 ; F(1,21) = 11.41 
Regressions (5.50)-(5.53) indicate that. molecular size and properties 
related to- the dispersive interaction positively influence the drug 
ac tiv ity. 
The best two variable regressions obtained with p(I,, ) . as the dependent 
variable have significance levels of 99.9% : 
P(Iso-) = -. 077(+-. 02) EBIND(CS) + . 006'(±, ý001) ct. IP - 5.5(±2.4) (5.54) 
and r= . 786 ;s= . 32 ; F(2,20) = 16.25.. 
P(Isg) -'-. 081(±. 02) EBIND(Cs) + . 008(±. 002) M. V - 5.9(i. 2.4) (5.55) 
and r= . 784 ;s= . 32 ; F(2,20) = 16.01 . 
P(Iso = -. 077 (±. 02) EBIND(Cs) + . 061 L+ . 01) 
Olmol - 5.4 (-+2.4) (5.56) 
and r . 781 ;s= . 32 ; F(2,20) = 15.72 
P(Iso 1.34(±. 5) EBIND(Cqo) + . 006(±-*001) a, IP + 141(±53) , (5.57) 
and r . 769 s= . 33 ; F(2,20) = 14.49 
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It is interesting that EBIND(C. ) appears in regressions (5.54)-(5.56) 
with a negative coefficientp tending to indicate that the more reactive 
the Cs site the lower the drug activity. It is likely that EBIND(C, 5) is 
surrogate for a true causal quantity. The appearance of EBIND(C, O) with 
a positive coefficient tends to confirm that reactivity in this region 
of the molecule is critical to drug activity,, without giving sufficient 
evidence of the mode of interaction. The only clue is that size and 
dispersive properties have a critical positive effect, since such a 
property appears in each of the two variable regressions (5.54)-(5.57). 
(iv) Malate dehýdrogenase (MCH) 
The best four simple regressions obtained with p(Iso as the dependent 
variable have significance levels between 99.5% and 99.75% 
P(Isc = . 0051(±. 001) CI. IP + 2.3(±. 4) (5.58) 
and r . 627 ;s= . 30 F(1,19) = 12.31 
P(Iso = 0.3017(±. 09) PI + 3.358(±. l) (5.59) 
and r . 591 ;s= . 31 ; F(1,19) = 10.23 
PUSO) = 0.0499(t. 01) Cýwl + 2.478(±, 4) (5.60) 
and r= . 590 ;s= . 31 ; F(1,19) = 10.14.. 
P(Iso) = . 0062(±. 002) M. -V + 2.489(±. 4) (5.61) 
and r= . 563 ;s= . 32 ; F(lF19) = 8.83 
Simple regressions (5.58)-(5.61) are very similar to those obtained with 
GLUDHj, except for the appearance of PI instead of B*E , The direct 
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physical interpretation of regression (5.59) is that the more lipophilic 
the substrate, the higher the drug activity. 
The best four two variable regressions obtained with p(I5O as the 
dependent variable have significance. levels of 99.9% 
p(Iso )= 70.3 (±12.7) Q(C2) + 009 (-±. 001) M. V - 9.5 (±2.2) (5.62) 
and r= . 864 ;s= . 20 ; F(2,18) = 26.50 . 
P(Iso) = 60.08(+-12.4) Q(C2) + . 006L+. 001) a. IP - 7.87(±2.1) (5.63) 
and r- 858 ;s= . 20 ; 'F(2,18) = 25.16 
p(Iso 65.3(±12) Q(Cý) + . 071(±. Ol) 
C'mol 
- 8.64(±2.1) (. 5.64) 
and r 858 ;s= . 20 ; F(2,18) = 25.12 . 
P(Iso = 76.01(±14) Q(C2) - . 003(±. 0006) B, E - 10.06(±2) (5.65) 
and r . 826 ;s= . 22 ; F(2,18) = 19.37 . 
In all of the two variable regressions, the appearance of Q(C2) with 
positive coefficient contrasts with its appearance with a negative 
coefficient in the regressions (5.10) ana (5.16) for the oxo form. The 
enzyme is different in the'two cases. 7he second variable in each of 
the two variable regressions confirms the positive influence of the size 
and dispersive properties. 
5.5 Conclusions 
Indices calculated for two structures are used to explain the variation 
in the inhibition of three types of enzymes involved in glucose and 
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amino, acid metabolisms. A substantial improvement in correlation occurs 
on going from the oxo to the OH form for GPDi inhibitory potency. For 
the other three enzymes, the correlation coefficients obtained for the 
OH form are very similar to those obtained for the oxo form. 
The mechanistic conclusion which may be drawn, from the regressions 
obtained with GPDH inhibitory potency is that the more polarizable the 
oxygenated region, the higher the drug activity. For the remaining 
three inhibitory potencies, the conclusion may be drawn that the larger 
the molecule, the higher the drug activity. It should also be pointed 
out that second order interaction energies observed at receptor points 
close to the oxygen atoms may appear,. with negative coefficients$ in the 
oxo regressions with GLUDH and MDH inhibitory potencies. 
It is dif f icult to draw f irm, deductions about which tautomer is the 
active substrate from the statistics of the above regressions. The 
relative stability of the two tautomers can be obtained by comparing the 
calculated total - energies. The CNDO/2 total energy for 
lt4-dihydro-quinolone 3-carboxylic acid is -321.38 e. v t whereas the 
value for 4-hydroxy-quinoline 3-carboxylic acid is -322.66 e. v . Hencer 
the latter is expected to be more stable than the former. This can be 
explained by the polarization of electrons towards the oxygenated region 
in the oxo form which is much greater than 'in the OH form. The 
calculated dipole moments are 10.32 D and 0.733 D, respectively* 
Th design a more potent inhibitor, with the same basic structure, it is 
necessary to increase the polarizability in the oxygenated region, and 
to increase molecular size as much as possibile, without introducing any 
significant steric interference to intercalation. 
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Table 5.5 Calculated indices for inhibition o 
by 4-hydroxy'quinoline 3-carboxylic 
NO, Q(C3) 0 (C2 Q(H, 5 FE(NI) 
(e) (e) (e) (-e) 
1 -. 174691 0.161123 0.260639 0.438901 
f some dehydrogenases 
acids. 
a. ip B, E 
0 
(Mev) (ev) 
218.1208 -322.6637 
2 -. 172260 0.163161 0.262819 0.355207 242.0177' -323.1646 
3 -, 172859 0.164284 0.262834 0.245711 249.2276 -325.0298 
4 -, 173176 0.157999 0.259769 0.394110 235.1532 -356,6962 
5 -. 170313 0.165243 0.263477 0.301147 265.3425 -323.7403 
6 -. 170698 0.166527 0,265081 0.321232 268.6320 -323.5742 
7 -. 173050 0.164077 0.258294 0.301827 257.0196 -357.1732 
a -. 173452 0.158035 0.259729 0.395664 298.1494 -458.2515 
9 -. 171591 0.156431 0.259651 '0.371495 320.0717 -489.7984 
10 -. 169309 0.153527 0.259641 0.310140 322.5482 -499.4591 
11 -. 173118 0.158550 0.260106 0.392557 343.8612. -523.5740 
12 -. 171248 0.162662 0.262299 0.428161 246.2711 -323.1095 
13 -. 172563 0.166040 0.263714 0.446447 254.8071 -36 3.5728 
14 -. 169760 0.153111 0.259380 0.333165 238.9223 -366.2626 
15 -. 168617 0.150624 0.259843 0.312195 233.2213 -366.3030 
16 -. 172124 0.170843 0.266177 0.442030 256.6193 -355.9943 
17 -. 173350 0.158886 0.259967 0.382306 233,5165 -356.7043 
18 -. 168945 0.152361 0.259588 0.231573 261.4055 -408.0793 
19 -, 171153 0,168326 0.265472 0.435546 255.9444 -356.0266 
20 -. 173026 0.164838 0.263108 0.371818 243.9383 -323.1051 
21 -. 172050 0.158402 0.259982 0.359270 318.2398 -489.8205 
22 -. 172214 0.155826 0.260601 0.529261 324.4700 -523.7018 
23 -. 177276 0.162903 0.260586 0,435875 346.8659 -523.5795 
24 -. 179185 0.164514 0.260671 0.437449 325.3341' -489*8569 
25 -. 174897 0.165770 0.262120 0.292959 341,8665 -490.4345 
26 -. 172005 0.162306 0.257785 0,162779 . 278.4863 -432,5889 
27, -. 173678 0.164385 0.261341 0.305527 364.8685 -524.1360 
28 -. 167464 0.155208 0.261442 0.294046 368.4656 -515.9304 
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Table 5,5 Cont. 
NO, FE(Cs) EBIND(Cio 
(-e) (ev) 
1 0.185138 -103.716 
2 0.199173 -103.7ý1 
3 0.193914 -103.679 
4 0.227718 -103.672 
5 0.187323 -103.542 
6 0.213022 -103.727 
7 0.215666 -103.383 
8 0.226408 -103.663 
9 '0.243236 -103.662 
10 0.279444 -103.805 
11 0.224265 -103.666 
12 0.169625 -103.669 
13 0.156868 -103.717 
14 0.276554 -103.772 
15 0,266550 -103.770 
16 0.150927 -103.812 
17 0.233457 -103.683 
18 0.297378 -103.755 
19 0,142059 -103.782 
20 0.203180 -103.726 
21 0.245985 -103.672 
22 0.008025 -103.689 
23 0.177299 -103.664 
24 0.169012 -103.656 
25 0.207317 -103.293 
26 0.231412 -103.511 
27 0.206938 -103.332 
28 0.283889 -103.802 
EBIND(Cs) 
(ev) 
-95.73305 
-95.63657 
-95.61886 
-95.25624 
-96.85180 
-95.35707 
-103.3538 
-95.13682 
-95.17444 
-95.02228 
-95.11910 
-95.73146 
-95.68372 
-94.86533 
-95.59747 
-95.02905 
-95.66147 
-94.88257 
-95.59053 
-95.45537 
-95.65029 
-95.66261 
-95.68705 
-95.70158 
-103.4558 
-95.64230 
-103.0370 
-94.96451 
EBIND (H is 
(eV) 
-22.20750 
-22.17209 
-22.17088 
-22.21250 
-22.13054 
-22,13772 
-22.04840 
-22.21405 
-22.20953 
-22.20660 
-22.20943 
-22.16844 
-22.15703 
-22.20606 
-22.19672 
-22.12441 
-22.20890 
-22.19793 
-22.12879 
-22.17105 
-22.20277 
-22.20092 
-22.21750 
-22.22301 
-22,14661 
-22.20447 
-22.13688 
-22.17988 
E(C4-014) DELTA 
(ev) (ev) 
-32.17377 12.62246 
-32.20299 12.29735 
-32,21010 12.02290 
-32.14180 12,43008 
-32,21455 11.85962 
-32.25130 12.15747 
-32.01053 12,07021 
-32.13895 12.44258 
-32.12783 12.32819 
-32.10662 12.08980 
-32.14583 12.43609 
-32.18852 12.33357 
-32.22940 12.58929 
-32.09315 12.16599 
-32.12778 11.91198 
-32,29788 12.65827 
-32.15734 12.32970 
-32.08980 11.82394 
-32.25933 12.31280 
-32,22585 12.45304 
-32.15065 12.25580 
-32.16866 11.73244 
-32.18309 l2e54554 
-32.19248 12.63550 
-32.16324 12.067ý1 
-32.06449 12.12575 
-32.15541 12.05301 
-32.13098 11.87278 
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Table 5.5 Cont, 
NO. ol mol M. V V2 (P 8) V2 (PO V2 (PO EF(PI) E2 (PI) P2 
(A3 (PA? (ev/eý (ev/e2 (ev/e 2) voltýA vol? /OA2 
1 12.273 156.646 -4.01099 -2.68420 -1.21982 1,81446 3.292291 
2 21.337 169.648 -3.80798 -2.69189 -1.22698 1.36022 1.850209 
3 22,478 173.857 -3.77386 -2.69391 -1.23026 1.11972 1.253777 
4 21.169 173.225 -4.05311 -2.68695 -1.22271 1.81463 3.292907 
5 23.401 182.217 -4.25303 -2.71652 -1.23357 1.30100 1.692611 
6 23.401 183.150 -3.63027 -2.70141 -1.23456 1.29758 1.683737 
7 23.233 184.633 -3.19910 -2.70515 -1.22926 1.37691 1.895882 
8 26.857 222.708 -4.05249 -2.68848 -1.22353 1.81795 3.304966 
9 28.969 227.718 -4.04405 -2.69044 -1.22637 1.81167 3.282167 
10 29.655 236.017 -4.12802 -2.69259 -1.22674 1.78826 3.197886 
11 30.865 244.128 -3.99266 -2.68899 '-1.22399 1.80866 3.271255 
12 21.337 169.853 -3.82483 -2.69981 -1.22943 1.70863 2.919437 
13 21.682 186.633 -3.76109 -2.68920 -1.22427. 1.19511 1.428310 
14 21.855 181.513 -3.58974 -2.68944. -1.22462 1.77922 3.165639 
15 21.855 179.921 -3.98035 -2.69315 -1.22828 3.43619 11.80745 
16 21.420 178.886 -3.63117 -2.69729 -1.22737 1.67475 2.804807 
17 21.169 172.856 -4.04541 -2.68695 -1.22269 1.79480 3.221335 
18 24.526 200.235 -3.93145 -2.69339 -1.22860 1.77672 3.156734 
19 21.420 178.202 -3.57658 -2.69295 -1.22937 1.79459 3.220565 
20 21.337 169.825 -3.82044 -2.69393 -1.22755 1.74186 3.034087 
21 28.969 227.518 -4.03867 -2.69154 -1.22640 1.79870 3.235326 
22 30.865 241.935 -3.99460 -2,69176 -1.24191 5.17526 26.78341 
23 30.865 243.993 -4.02569 -2,68856 -1.22350 -1.85468 3,439870 
24 28.969 227.677 -4.04254 -2.68836 -1.22348 1.87722 3.523955 
25 31.033 240.206 -3.45802 -2.69916 -1.23109 1.38452 1.916900 
26 25.597 199.428 -4.12053 -2.70589 -1.22608 1.78861 3.199141 
27 32.929 256.439 -3.67219 -2.70632 -1.23224 1.37567 1.892482 
28 33.615 261,840 -ý. 94888 -2.69794 -1.23309 104128 1.799051 
CHAPrER SIX 
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THE MUrAGENIC AND ANTITUMOUR ACTIVITIES OF ACRIDINES AND DIACRIDINES 
6.1 Introduction 
Nucleic acids are biologically important receptors. Molecules capable 
of binding to nucleic acid templates and interferring with processes in 
which nucleic acids participate are important in both, antibiotic and 
cancer chemotherapy (197). Some drugs bind to nucleic acias Dy 
intercalation i. e the insertion of a flat molecule between the base 
pairs of the double helix (198). 
Various molecules are thought to form intercalation complexes with DNA,,. 
e. g the acridine, ethidium bromide (199). In such complexes, the 
molecules lie flat, sandwiched between the successive base -pairs which 
join the two strands of the DNA double helix. In the case of 
316-diamino acridine (proflavine), the N1. protonated molecule links 
opposite phosphate anions in each helical chain. This link is 
maintained by stabilizing Van der. Waals interactions between . the 
proflavine molecule and purine-pyrimidine base pairs between which it 
lies (200), Intercalation may be studied by observing the effect of 
substituents on the acridine ring. Such substýituents might prevent 
intercalationt or once the molecule is intercalated, they might delay 
de-intercalation. Consequently,, ring substituents determine not only 
the specificity of binding but also the strength of binding. ' 
Intercalation causes distortion of the nucleic acid polymer. In the 
case of FNA, this may inhibit cell growth. In the case of DNA , this 
may inhibit mitosisp or even produce mutation by confusing the 
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recognition of the distribution of bases. 
In an attempt to develop new antitumour compounds, a series of 
symmetrically substituted diacridines have been synthesized and tested 
(201). These comPOunds consist oftwo acridine rings connected through 
their 9-Amino positions by hydrocarbon chains of various lengths. These 
compounds might bind more strongly than monoacridine to DM and rM, if 
double intercalation occurs, The length of the connecting chain 
determines the ability of these diacridines to act ýs single or double 
intercalators (202). 
The intercalation of one acridine ring into DNA will automatically bring 
the second acridine ring into close proximity to the DNA thus inducing 
it to intercalate in neighbouring positions. r1he expectation is that 
the diacridine molecule would act as a "staple" within the DNA molecule 
as is shown in figure (6.1a). The DNA could only be free of the 
diacridine if both acridine rings were to de-intercalate at the same 
time, Such a DNA staple would intercalate with the DNA molecule at 
positions whose limits would be defined by the length of the chain 
connecting the two acridine rings. It is also possible that the 
diacridine might crosslink adjacent strands of DNA, as indicated in 
figures (6, lb) and (6.1c). The length of the chain and the diacridine 
conformation is then constrained by the-relative positions of the two 
strands. 
In the present work a series of substituted 9-anilinoacridine and 
diacridines have been studied, having mutagenic and antitunoUr' 
activities 
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c. Cross linkage, diacridine 
has a centre of symetry 
a. Staple (stacked), diacridine b. Cross linkage, diacridine 
has a plane of symetry has a plane of symmetry 
I 
FIGURE 6.1 Schematic representation of the different possible 
modes of double intercalation. 
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t 
6.2 Ilbe mutagenic activity of 9-anilinoacridine 
6.2.1 Method 
N 
A series of substituted 9-Anilinoacridines have been tested for 
mutagenicity and growth inhibition using Salmonella lyphimuriun strain 
TA 1537,, and are given in reference (203). The 38 substituted ccmpounds 
considered in the present work have two measured activities : bacterial 
growth inhibition and mutagenic effectiveness. Bacterial growth 
inhibition is expressed as p(D5'O),, where Dso is the molar concentration 
of drug required to produce 50% growth inhibition. Mutagenic 
effectiveness is expressed as pC? where C is the lowest molar 
concentration of drug required to provide a constant proportion * of 
revertant colonies (chosen as 50 per 109 bacteria). The molecules and 
their biological activities are given in table (6.1). 
The X-ray geometry (204) -for neutral 9-anilinoacridine is optimized 
using program "GECMIN" with the CNDO option. The acridine ring is 
protonated at Njo using the standard bond distance 'Of 1.01 The 
protonated form is considered in the calculation, since SCF convergance 
is very slow with neutral form 4-(9-acridinylamino) 
methansulfonanilide (campound 1 in table 6.1) in its neutral form 
requires 42 iterations to produce SCF convergence, the CNDO/2 total 
energy being -237.711052 Hartrees. By contrast the same compound in its 
protonated form requires 30 iterations and has a CNDO/2 total energy 
-238*296089 Hartrees. The SCF convergence criterion is 0.000001 
Hartrees in calculated total energy. 
The optimized bond lengths and bond angles are given in table (6.2). 
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The substituents on the acridine and 9-phenyl ring are positioned using 
standard bond lengths and bond angles (110). No receptor points are 
chosen,, because the parent molecule is large. This makes the 
calculation of the second order interaction energy . expensive in 
computing time. 
1 
6.2.2 Results and discussion 
Electronic and molecular indices are obtained. using I'MOREG" with the 
CNDO/2 option The electronic indices and molecular properties 
obtained-# relevant to the regressions, are given in table (6.3). The 
following regressions are obtained with pC as the dependent variable. 
The best four simple regressions have significance levels between 97.5% 
and 99.75% : 
PC = 0.241(±. 06) PI + 4.579(±. 09) 
and r= . 540 ;s= . 33 ; F(lj3l) 12.81'. 
PC = 3.270(±1.0) ALPHA(C 14 
)+0.402 (±-. 1) (6,2) 
and r= 471 ;s= . 35 ; F(1,31) = 8.86 
PC = 0.006(±. 002) a. IP +'0.584(±1.4) (6.3) 
and r= . 432 ;s= . 35 ; F(lt3l) = 7.14 
PC = 132.3(±53.5) Q(C6) 6.420(±4.3) (6A) 
and r= . 405 ;s= . 36 F(1,31) = 6.11 
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Table 6.1 Observed drug activities for 9-anilinoacridine. 
NO. Substituents P(D 50) 
PC 
xY 
1 4-NHS(ýCH3 H 3.96 4.29 
2 4-NHS02CH2CH3 H 4.09, 4.62 
3 4-NHS02 (CH2)2 CH3 H 4.50 4.62 
4 4-NHS02 (CH2) 3 CH3 H 
4.31 4.92 
5 4-NHS02 (CH2. )4 CH3 H 4.81 5.12 
6 4-NHS02CH3 -3-NH 2 3.36 3.68 
7 4-NMO2. CH3 3-NWH3 3.52 3.61 
8 4"ýNHS02CH3 3-NWOCH3 3.55 3.95 
9 4-NM02CH3 3-NHCOOCH3 3.64 4.07 
10 4-NM02CH3 3-N02 5.27 4.39 
11 4-NHSOZCH3 3-CH3 3.88 4.66 
12 4-NHS02CH3 3-40CH 3 3.79 
4.45 
13 4-NHS02CHS 3-Cl 3.88 4.64 
14 4-NHS02CH3 3-Br 4.33 4.60 
15 4-NHS%CH3 3-CN 3.37 - 
16 4-NHS02CH3,3-CH3 H 3,47 4.44 
17 4-NMO2. CH3 2-CH3 H 3.62 3.88 
18 4-NHSOICH3 2-Clý 3.96 4.31 
19 4-NHS%CH3 4-CH3 3.93 4.60 
20 4-NHS%CH3,3-OCHs H 3.39 3.79 
21 4-NHS02 CH3 p 2--OCH3 H 3.60 4.70 22 4-NHS02CH3 1-OCH 3 3.68 4.64 23 4-NHSCýCH3 2-OCH 3 3.84 
4.64 
24 4-NHSOýCH3 4-OCH 3 3.59 
4.37 
25 4-NM(kCH3j3-Cl3 H 3.56 4.38 
26 4-NHSCýCH3,2-Cl3 H 4.19 -- 
27 4-NHS02CH3 1-cl 3.47 3.94 
28 4-NHSOzCH3 2-Cl 4.13 4.60 
29 4 -NHS(ý CH3 4-Cl 3.81 4.06 
30 4 -NHS(k CH3 3-NOz H 3.91 4.54 
31 4-NHS(ýCH3,2-M H 3.46 -- 
32 4-NHSCý CH3 2-NO2 3.44 -- 
33 4-NHS(ý CH3 3-Mij H 3.90 4.38 
34 4-NMýCH3,2-NH2 H 3.50 3.55 
35 4-NHS(ý CH3 2-NH2 3.68 3.78 
36 4-NHS(kCH3 4-NH2 3.88 4.10 
37 4-NHSCýCH 2-CCNH2 3.39 --- 38 4-NHS02 C3 H3 4-CCNH 2 3.87 4.60 
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TABLE 6.2 The optimized bond lengths and bond angles for 
9-anilinoacridine. 
U30 
2 2 
%2 28 
q 
21 2 
19 
20 1 H 16 3 kH "21 
1 34 18 
H 
9 
13 2 
17F 
42 35 
H 
3,3 16 29 36 
Bond lengths(A) 
C2-Cj 1.3601 H35-CS 1.1179 
C3-C2' 1,4102 H36-C4 1.1176 
C4-C3 1.3594 Hlr, -Cs 1.1175 
C12-C4 1.4227 H17-C6 1.1177 
CII-cl 1.4209 H18-C7 1.1167 
c9-cII 1.4083 H19-C8 1.1201 
C13-C9 . 1.4099 H2o -N Is 1.0757 
C14-CI3 1.4245 H21-NIS 1.4133 
CS-C14 1.4226 C22-C21 1.3952 
C6-cs 1.3594 C23-C22 1.3831 
C7-C6 1.4097 C24-C23' 1.3853 
C8-C7 1.3602 C25-C24 1.3833 
NIO -C12 1.3552 C26-CZS 1.3826 
NIS -C9 1.3958 
H27-C22 1.1177 
H33 -CI 1.1226 H26-C23 1.1172 
H -, C 34 2 1.1168 H 31-C25 1.1172 
H29 
-NIO 1.0099 
H30 -C24 1.1159 
Bond angles (deg) 
C3-C2-C1 119.42 H36 -C4-C3 120.34' 
C4-CVý'C2 120.45 H, 6-C5-C6 120.32 
C12 -C4 -C3 121.45 H 17 -C6 -C7 118.86 
cl I -Ci -, Cý 122.31 
HI8-C7-C6 119.60 
. 
C-9-CU -C72 117.83 H19 -C8-C7 118.77 
1 
C1 
3 -CW -4CI 119.63 H20 -NIS -C9 110.50 
C14 -C23 "CP. 117.83 C2.1 -NIS -q 123.74 
CS -Cl 4 -Cl 3 118.49 C22 -C21 -NIS 125.05 
C6 -CS -4ql 4 121,47 C2 3 -C22 -C2 1 120.89 
C7 -C6 -CS 120.35 C24 -C23 -C22 120.44 
CS-. -C7 -C6 119.51 C25 -C24 -C23 119.43 
1ý10 -CI2. -ýC 12 123,22 C26 -C25 -C24 120.01 
Iii S -Cý -C I'l 121.01 
H27-C22-C23 119.70 
H33 -C1 -C2 120.60 H28-C23-C24 119.98 
43 4 -C2 "q3 119.44 H31-C25-C24 120.17 
4" -C3 -C4 120.61 H32-C26-C25 119.63 
H30 -C24 -C25 119.50 H29 -NI 0 -C 12 120.00 
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Table 6.3 Calculated indices for 9-anilinoacridine. 
NO. Pi WO Q(H29 ) ALPHh(C14) ALPHA. (H29 a IP 
(e) (e) (KeV') (Kell) (ev. 93 
1 -1.18 . 081780 . 162020 -121.657 -31.086 592.4810 2 -. 680 . 081749 . 161975 -121.670 -31.088 614.4318 3 -. 180 . 081658 . 161698 -121.659 -31.091 633.9055 4 0.680 . 081633 . 161646 -121.660 -31.092 657.7156 5 1.180 . 081622 . 161619 -121.660 -31.093 681.7500 6 -2.41 . 079521 . 159308 -121.812 -31.127 605.8028 7 -1.15 . 079172 . 158246 -121.830 -31.147 631.7062 8 -1.15 . 077994 . 154466 -121.799 -31.253 628.9812 9 -1.15 . 079570 . 160994 -121.773 -31.109 672.9311 10 -1.46 -. 084481 . 166929 -121.636 -30.997 633.5880 11 -0.52 . 080810 . 160421'- -121.724 -31.114 617.4114 12 -1.20 . 080463 . 15870 -121.770 -31.144 627.7717 13 -0.37 . 081773 . 162897 -121.685 -31.067 622.3601 14 -0.32 . 082249 . 163008 -121.697 -31.071 640.6928 15 -1.75 . 082146 . 162625 -121.689 -31.075 627.0160 16 -0.62 . 081669 . 161792 -121.657 -31.090 610.5017 17 -0.62 . 081615 . 161930 -121.674 -31.089 614.6051 18 -0.62 . 080952 . 161104 -121.718 -31.104 618.2397 19 -0.62 . 081375 . 162880 * -121.663 -31.062 617.8908 20 -1.20 . 081773 . 162081 -121.656 -31.085 610.5933 21 -1.20 . 081536 . 161516 -121.674 -31.096 618.9148 22 -1.20 . 082024 . 162847 -121.653 -31.057 596.7401 23 -1.20 . 080384 . 160048 -121.739 -31.119 624.5058 24 -1.20 . 081186 . 168583 -121.623 -30.949 626.9417 25 -0.47 . 081915 . 162335 -121.659 -31.081, 617.1116 26 -0.47 . 081883 . 162204 -121'. 663 -31.083 621.4594 27 -0.47 . 082395 . 163360 -121.689 -31.068 523.1016 28 -0.47 . 081962 . 162697 -121. '695 -31.075" 622.5841' 29 -0.47 . 081884 . 165774 *-121.689 -31.004 623.1121 30 -1.46 . 082881 . 164250 -121.651 -31.049 643.5697 31 -1.46 . 082932 . 163683 -121.661 -31.057 646.9422 32 -1.46 . 084561 . 166458 -121.687 -31.007 631.8419 33 -2.41 . 081597 . 161796 -121.668 -31.091 575.5846 34 -2.41 . 081333 . 161419 -121.670 -31.096 587.0772 35 -2.41 . 079252 . 159320 -121.807 -31.132 600.0726 36 -2.41 . 081104 . 158534 -121.645 -31.100 604.3377 37 -2.67 . 082342 . 162505 -121.700 -31.080 636.1370 38 -2.67 . 080841 . 226310 , -121.644 -29.079 639.5239 
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Table 6.3 Cont. 
NO. EN (C 3) FN (CO FN (C6) ' FN (Cg) FN (C14) 
(-e) (-e) (-e) (-e) (-e) 
1 0.168567 . 038350 0.166723 0.612634 0.149608 
2 0.169290 . 038363 0.167279 0.610765 0.150053 3 0,168851 . 038378 0.166978 0.611905 0.149529 4 0.168871 . 038353 0.167043 0.611809 0.149526 5 0.168893 . 038351 0.167070 0.611748 0.149522 6 0.142499 . 014555 0.179369 0.617919 0.158364 7 0.141969 . 013981 0.179250 0.616119 0.157685 8 0.137993 . 019217 0.178699 0.612834 0.152852 9 0.149863 . 021596 0.174749 0.612457 0.153955 10 0.215459 . 092805 0.123177 0.513610 0.116894 11 0.168793 . 032253 0.168138 0.606858 0.149726 12 0.152352 . 020733 0.175877 0.617096 0.156735 13 0.171053 . 036890 0.164989 0.607942 0.148365 14 0.184457 . 059876 0.144639 0.566274 0.132267 
15 0.186873 . 050862 0.151671 0.582054 0.138084 16 0.168695 . 038352 0.166930 0.612142 0.149492 17 0.169178 . 038294 0.167393 0.610057 0.149927 18 0.171473 . 041211 0.165254 0.606540 0.147792 
19 0.165724 . 039163 0.166633 0.608556 0.148263 20 0.168407 . 038198 0.166755 0.612894 0.149590 21 0.169531 . 038559 0.167508 0.609428 0.149830 22 0.161929 . 022978 0.174155 0.619166 0.153934 23 0.184473 . 046505 0.158759 0.597424 0.141220 24 0.154536 . 039863 0.162368 0.606495 0.142500 25 0.168530 . 038298 0.166646 0.612911 0.149899 26 0.168191 . 038295 Oil66125 0.612542 0.149481 27 0.172849 . 043227 0.160369 0.600937 0.146716 28 0.169364 . 037518 0.166847 0.611465 0.150429 29 0.168784 . 041265 0.165561 0.610681 0.148790 30 0.167621 . 038533 0.164739 0.616468 0.150576 31 0.167894 . 039365 0.163282 0.614245 0.149754 32 0.163826 . 051953 0.159166 0.604597 0.151529 33 0.169152 . 038127 0.167655 0.610793 0.149988 
34 0.168792 . 038281 0.167343 0.610161 0.149268 35 0.187562 . 046396 0.157745 0.594110 0.139131 36 0,144971 . 035984 0.165017 0.609017 0.143349 37 0.159765 . 041155 0.168007 0.613493 0.153517 38 0.212630 . 056051 0.153864 0.581042 0.141370 
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The low correlation coefficient obtained for the simple regressions 
makes their physical interpretation difficult. In a system, where the 
acridines are introduced into the fluid surrounding the bacterial cell 
culture, it is possible that the partition coefficients appear to be 
relevant to activity. The hydrophobic substituent constant PI, appears 
in the regression (6.1) with a positive coefficient, indicating that. 
ease of passage into the biQphase has a positive effect on mutagenicity. 
The appearance of ALPHA(C14) ard Q(Cr, ) with low correlation coefficients 
in the regressions (6.2) and (6.4) respectivelyl are quite distinct 
molecular properties, which have a positive effect on drug-receptor 
interaction. 
The best four two variable regressions obtained with pC as the dependent 
variabl6l have significance levels above 99.9% : 
pC = 2.66 (t, 9) ALPHA(CIO '+ 0.21 (ti06) PI + 329(tll7) (6.5) 
and r= . 659 ;s= . 30 ; F(2,30) = 11.56 . 
pC = 3.43(±. 9) ALPHA(C14) + e006(+-. 001) a. IP + 4.18(±116) (6.6) 
and r = . 657 ; s= . 30 ; F(2,30) = 11.40 
PC = 12.33(+-4.9) Q(H29) + 0.28(--h. 06) PI + 2.6L+. 7) (6.7) 
and r= . 643 ;s= . 30 ; F(2,30) 10.59 
PC = 0.4(+-, l) ALPHA(H29) + 0.29( ±. 06) PI + 17.1(t5) (6.8) 
and r= . 641 ;s= . 30 ; F(2,30) = 10.47 
It is noticeable that PI appears in all of the two variable regressions 
except (6.6) vbere a. IP appears. This may be due to a high covariance 
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with PI. The appearance of ALPHA (CI 4) in regressions (6.5) and (6.6),, 
indicates a possible role for ALPHA(C, 4), quite independent from PI. 
The variables Q(H29) and ALPHA(Fýq ) appear in the regressions (6.7) and 
(6.8), showing that a positive charge or high polarizability in the 
vicinity of atom H 29 may 
be favourable to drug-re*ceptor interaction, 
The best four simple regressions obtained with p(EýO ) as the dependent 
variable, have significance levels between 99.5% and 99.9% : 
p(Dso) = -12.02(+3.0) FN(Cq) + 11.10(±1.8) (6.9) 
and r= . 549 ;s= . 34 ; F(1,36) = 15.58 
p(Dso -30.31(+7.7) FN(C14 )+8.31(±1.1) (6.10) 
and r . 547 ;s= . 34 ; F(1,36) = 15.37 
p (Dso = -21.7 (±5.8) FN (CO + 7.405 (±. 9) 
and r . 524 ;s= . 35 ; F(1,36) = 13.66 
p(Dso 11.85(±3.8) FN(C3) + 1.831(±-. 6) (6.12) 
and r'= . 458 ;s= . 36 ; F(1,36) = 9.58 
The appearance of the FN "s with negative coefficients in the simple 
regressions (6.9)-(6.11) make their physical interpretations difficult. 
]Regression (6.12) indicates that the greater the ability of C3 to act as 
an electron acceptors, the greater the growth inhibitive potency. 
The best four two variable regressions obtained with p(D5O* as the 
dependent variable have significance levels above 99.9% : 
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p (D so = -13.33(-±2.4) 
FN(Cq) + . 24(±. 05) PI-+ 12.1(±1.4) (6.13) 
and r . 751 ;s= . 27 ; F(2,35) = 22.73 
p(Dso) = -32.2(±6.3) MCIO + . 227(±, 05) PI + 8.84(±. 9) (6.14) 
and r= . 732 ;s= . 28 F(2,35) = 20.21 
P(Dso) = -22.9(-+-4.9) ýN(C6) + . 224(±. 05) PI + 7.86(±. 8) (6.15) 
and r= . 711 ;s= . 29 ; F(2,35) = 17.89 
p(Dso) = 16,54(±3.6) FN(C4) + 0.21(±. 05) PI + 7.4(±. l) (6.16) 
and r= . 702 ;s= . 29 ; F(2,35) = 17.07 
In the two variable regressions, the correlation coefficients are 
improved. Frontier electron densities for nucleophilic attack appear in 
each of the best four two variable regressions, along with the 
hydrophobic substituent constant PI, Pegression (6.16) suggests the 
combined relevance of PI and FN(C4). 7he former might determine the 
concentration of acridine at the receptor site, whilst the latter 
probably determines the drug-receptor interaction through charge 
transfer. 
In conclusion, the above regressions might shed some light on the 
mechanism of the acridine action. Taking a broad view of the two 
variable regressions obtained with both pC and p(Dso ), it is evident 
that drug activity is determined by hydrophobicity and by electronic 
properties of acridine ring atoms, which may be relevant to 
intercalation. 
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6.3 The antitumour activity of diacridines 
6.3.1 Method 
A series of diacridines, connected at the 9-amin'o position of the 
acridine ring by alkyl chains of varying length, and with various 
substituents on the acridine ring, are reported in reference (205)l as 
having antitunour activity. They are potent inhibitors of growth of 
P388 ascites cells in yitro and in mice. The biological activities are 
expressed as 
MI so# the molar concentration required to produce 50% inhibition of 
the cell growth in vitro, 
(ii) M,,, the in vivo toxicityp this being the molar concentration. 
required to kill 10% of animals, 
(iii) T. I, the ratio of M,, to I., . The T. I values obtained ar'e, only 
relevant to the true therapeutic value of the drugs, if there is a close 
parallel between tunour cell growth inhibition in vitro with tunour cell 
growth inhibition in vivo. 
27 substituted diacridinesp each with an alkyl chain containing an even 
nunber of carbon atoms,, are considered in the present study, and are 
given in table (6.4), along with their biological activities. 
7he starting point geometry for acridine is obtained from reference 
(206). 7his geometry is optimized using program "GEOMIN" with the CNDO 
option, to get more reliable estimate of the conformation in solution. 
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The optimized bond lengths and bond angles are given in table (6.5). 
Standard bond lengths and bond angles (110) are used for the 9-amino 
group, the alkyl chain, and for any ring substituents. The conformation 
of the entire diacridine, is determined by the type of sýmm etry selected. 
Calculations are performed on the diacridines in their neutral form, as 
opposed to that protonated at N7, for reasons of stability and speed of 
calculation . compound one in the table (6.4) in its neutral form 
requires, 49 iterations to achieve* SCF convergencep the CNDO/2 total 
energy being -262.4622 Hartrees. The same compound in its diprotonated 
form requires 89 iterations and has a CNDO/2 total energy -261.905292 
Hartrees, The latter is-less stable due to coulombic repulsion between 
the two acridine groups. 
Two types of planar conformations are selectedo 'planar-mirror and, 
planar-inversion. ribese sýwetries are relevant to cross linkage. The 
third type conformation is stacked-mirr'Or, which is relevant to 
stapling. In, this conformation one 'acridine molecule is stacked 
directly above and parallel to the other, Since only mirror and 
inversion sýumetries are considered,, the appropriate transformation 
matricies are T.. and T. respectively Rurr inv 
+1 0000 
T0 +1 0 T. 0 -1 0 
rraxr inv 
1- 
0o -1 
0o 
-1- ý 
The three different conformations of compound one in table (6.4) are 
plotted in figure (6e2)., 
205 
Table 6.4 Observed drug activities for diacridines, 
H7).. H. HH 
H , HH 7 
HH H 
,HH 
14 H 
NO, Substituent IC P(I50) p(LD10) log (T. I) 
1H25.8477 4.9840 0.8637 
2H45.5670 4.6045 0.9625 
3H66.4202 4.7184 10018 
4 3-amino 6 6.6777 
5, '4-ethyl 6 6.6382 4.5207 2.1175 
6 3-nitro 6 6.3187 -- -- 
7 2-imethoxy 6 6.4948 4.7903 1.7045 
8 3-propoxy 6 6.4948 4.9359 1.55ý9 
9 4-methoxy 6 6.7212 4.6279 2.0933- 
10 3-methoi; y 6 6.6197 4.7487 . 1,8710 
11 H86.4948 4.5674 1.9274 
12 4-ethyl 8 6.6382 4.6649 1.9733 
13 2-methoxy 8 6.7212 4.9690 1.7522 
14 4-methoxy 8 6.5376 4.6168 '1.9208 
15 3-chloro 8 6.6382 
16 3-bromo 8 6.6777 
17 3-nitro 8 6.4814 
18 3-methylthio 8 6.4317 4.8683 1.5634 
19 4-methylthio 8 6.0655 -- 
20 3,5-dimethoxy 8 6.3767 4.6775 1.6992 
21 3-methoxy, 7-Cl 8 6.7958 4.9525 1.8433 
22 3-propoxy 8 6.6777 5.0484,1.6293 
23 H 10 6.4202 4.8764 1.5438 
24 4-ethyl. 10 6.8239 4.6516 2.1723 
25 H 10 6.4948 4.9296 1.5652 
26 4-butoxy 6 6.4436 4.9758 1.4678 
27 4-butoxy 6 6.7212 4.9273' 1.7939 
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TABIE 6,5 The optimized bond lengths and bond angles for acridine. 
Ic 
IGH- I, IG 
19 
Bond lengths(R) 
C27C 
1 1.3584 
C13 -C12 1.4120 
c3 -C 2 1.4121 
C14 -CI3 1.3580 
C4-C3 1.3584 H15 -C4 1.1183 
CS -C4 1.4230 H19 -CID 1.1200 
C6 -cs 1.4266 1122 "CI 1.1174 
N7 -C6 1.3540 1'6 -C2 1.1175 
CS -N7 1.3545 H 24 -C 3 1.1169 
CS -Ce 
. 
1.4262 H 
16 -C 11 
1.1184 
(; 0 -C9 1.3933 H19 -C12 1.1169 
Ci I -,; 1.4233 
"6 -CI 3 1.1175 
C12 -CII 1.3584 1ý 1 -C14 1.1151 
N 
17 -CID 1.3996 H18 -JN 27 1.0078 
Bond angles (deg) 
C 
3-C 2-C 1 120.52 C 12"Ci 121.69 
c4 -C 3 -C 2 119.94 c -C -C 13 12 11 119,94 
c5 -C 4 -C 3 121.60 C14 -C13 -C 12 120.24 
C6-CS-C 
4 118.25 H 15 -C 4-C3 120.18 
N7-C6-CS 122.65 H 19 -Cis -CS 118.72 
Ca -N7 -C6 118.76 H16 -mo-11 -CI2 120.09 
CS --c8 -1ý 123.07 1ý2 -Cj -C2 120.43 
c 10 -C 9 -ce 116.33 
H 
23 -C 2 
-C3 118.73* 
cl 
I -cs -C8 118.26 
H24-CS -C 2 119.06 
H 
19 -C 12 -C is 
119.01 H 20 -C 13 -C 12 119.10 
N 
17 -C 20 -C 9 
119.89 HIB-N 17 -CIO 120.20 
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c. Stacked-mirror. 
vI 
b. Planar-inversion. 
a, Planar-mirror. 
FIGURE 6.2 The three different conformations of diacridines. 
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The diacridines are large molecules, the smallest having 54 atoms and 
150 basis functions, so it is not possibile for program MOREG to handle 
these calculations. It is necessary to use the symmetry to simplify the 
MO calculations. The method of. symmetry adapted orbitals is used. This 
method is described in appendix B. For the calculation of reactivity 
indices, MOREG has been modified to make use of this method by the 
author. Three sets of CNDO/2 calculations are performed on the three 
types of conformations. For each set of calculations, the input data 
for the MOREG program has consisted of the coordinates of half the 
particular diacridine molecule. The remaining half is generated using 
symmetry according to the particular type of conformation considerea. 
It was intended to calculate a few points in the molecular enviromenti 
relevant to the intercalation. Unfortunately, the great size''of the 
molecules makes it impossible to calculate receptor point properties. 
Indices included in the regressions are the properties of the atoms and 
bonds of each acridine group and those of the molecule as a whole. 'The 
varying length of the alkyl' chain makesýit impossible to include the 
properties of the individual atoms in the chain. The length of this 
chain (NC), in CH2 groups,,. i, s used in the regression analysis as an 
additional variable. 
I 
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6.3.2. Pesults and discussion 
The electronic and molecular indices obtained for planar-mirrort 
planar-inversion and stacked-mirror diacridine conformations, relevant 
to the regressions, are given in tables (4.6), (4.7) and (4.8) 
respectively. The regressions obtained for the three conformations are 
(i) planar-mirror 
The following regressions are obtained with p(I5O as the dependent 
variable, having significance levels between 99.75% and 99.9% : 
P(Iso -. 001 (±, 0001) B. E + 5.323 (±. 2) (6.17) 
and r . 739 ;s= . 19 ; F(1,25) = 30.16 
p (I so )= -9.6 83 (+- 1.8) FE (C2) + 6.714 (+- ,0 5) (6.18) 
and r= . 720 ;s= . 19 ; F(1,25) = 26.92 
p(I. 50 12.82(.: R. 7) Q(C4) + 6.52L+. 04) (6.19) 
and r . 685 ;s= . 20 ; F(lt25) 22.18 
P (Is o 0.0 67 (±. 01) ALPHA (C3 2.19 (+ 1.8) (6.20) 
and r e679 ;s= . 21 ; F(1,25) = 21.48 . 
The negative coefficient associated with B. E in the regression (6.17) 
indicates that the more stable the molecule the higher the drug 
activity. This may arise through a tendency for drug activity to 
increase with increasing alkyl chain length or molecular bulk. The 
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I molecular volume is also correlated with p(Iso) in -the following 
regression : 
P(Iso) = 0.002(±. 0008) M. V + 5.03(±-. 4) (6.21) 
and r= . 574 ;s= . 23 ; F(lt25) = 12.29 
Regression (6,18) indicates that the less ready C2 is to donate 
electrons, the higher the drug activity. This is difficult to explain, 
if the drug activity is determined by the stability of the drug-receptor 
complex. If charge transfer is to occur in such a complex, it should 
have a stabilizing effect and thus lead to a positive coefficient in the 
observed regression. 
Regression (6,19) and (6.20) are readily interpreted in terms of 
coulombic or second order interactions of the drug-receptor in the 
vicinity of C4 and CV respectively. 
The best four two variable regressions obtained with p(Iso ) as the 
dependent variable, have significance levels of 99,9% : 
P(Iso) = -9.73(il. 4) FE(C2) - 2.14(! -. 4) E(Nl7-Hl8) 37.6(+-10) (6.22) 
and r= . 856 s= 15 ; F(2,24) = 33.07 
P(Iso) = 13.13(±2.0) Q(C4) - 2,22(±. 5) E(N17-Hle) - 39.6(-+10) (6.23) 
and r= . 838 ;s= . 15 ; F(2,24) = 28.44 . 
P(Iso) = 0.068(. ±. Ol) ALPHA(C3) - 2.17(±., 5) E(N17-Hle) - 47.6(±11) (6.24) 
and r= . 827 ;s= . 16 ; F(2,24) = 26.10 . 
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p (I so=6.86 (±l. 1) E ((ý- -H 15 )-2.18 (±. 5) E (Nl 7 -H, 8+ 97.8 (-+ 26) (6.25) 
and r . 816 ;s= . 17 ; F(2,24) = 23.99 . 
It is interesting that E (N 17 -H18) appears in the regressions 
(6.22)-(6.25), with a negative coefficient. This indicates that the, 
more stable the N, 7-H,, bond the higher the drug activity. The strength 
of this bond is expected to affect the relative ease of stapling with 
respect to cross linkage intercalation-with the DNA. Stapling requires 
the N17-Hj, to be rotated out of the plane of the rest of the acridine 
group, thus producing steric interference with the DNA base pair above 
or below. The negative coefficient indicates that the more 
energetically favourable cross-linkage is, the higher the growth rate 
inhibition. 
The positive coefficient associated with E(C4-Hj5 ), in regression (6.25) 
indicates that the weaker the C4-Hjs bond the greater the cell growth 
inhibition. This is reasonable, since this bond may be required to bend 
in the intercalation process. 
For further. investigations, the regressions are obtained -with M,, and 
log(T. I). These are obtained for 21 molecules,, because of-the lack of 
toxicity data for some of the molecules given in table (6.4). 
The best four simple regressions obtained with p(LD jo) as the dependent 
variable, have significance levels between 97.5% and 99.0% : 
p(LD, Q) = -. 217(±. 07) ALPHA(C. .)+ 
31.33(±8.9) (6.26) 
and r= . 561 ;s= . 13 ; F(1,19) = 8.75 
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p(LDIO) = -. 389(±, l) EBIND(C6) 35.85(±13.8) (6.27. ) 
and r= . 559 ;s= . 13 ; F(1,19) = 8.63 
P(LDIO) = 1.84(±. 6) FE(N17) + 4.611(±. 07) (6.28) 
and r= . 538 ;s= . 14 F(1,19) = 7.74 
p(LDIO) = 3.0(±1.1) FE(Cl) + 4.603(t. 07) (6.29) 
and r= . 536 ;s= . 14 ; F(1,19) = 7.68 
The negative coefficients which appear in the regressions (6.26) and 
(6.27), make them unattractive, but it is possible that the inertness of 
C6 has a direct positive effect on in vivo toxicity by improving the 
chances of the molecule reaching its receptor site without being 
metabolized. Regressions (6.28) and (6.29) can be readily explained in 
terms of charge transfer interactions between the molecule and its 
receptor. The electron donation by C, or N17. to the adjacent receptor 
may have a critical effect on drug activity. 
The best four two var iable' r egress ions obtained with p(LDIO ) a4' the 
dependent variable, have significance levels^between 99.5% and 99.9% 
p(LDIO = -61.8 (±. 17.6). Q(N17) + . 001(±. 0003) a. IP - 8.77(±3.7) (6.30) 
and r= . 737 ;s= . 11 ; F(2118) = 10.71 . 
P(LDIQ = -81.42L+19.5) Q(N 17) + 015(±. 004) 
clrnol; '- 13.1(±4.2) (6.31) 
and r . 734 ;s= . 11 ; F(2,18) = 10.54 
P(LDIO )=0.864C+-. 2) EBIND(N, 7) + . 015(±. 004) 
(1mol + 73(±. 20) (6.32) 
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and r= . 671 ;s= . 12 ; F(2,18) = 7.37 . 
p(LD10) = 1.17(±. 4) E(N17-HIS) +. 001(±. 0003) a. IP + 28.3(±-9) (6.33) 
and r= . 668 ;s= . 12 ; F(2,18) = 7.25 
The regressions (6.30)-(6.33) indicate that the reactivity of NI, is 
critical to the drug activity. The negative coefficient of the Q(N17) 
indicates that the accumulation of electrons in the reactive lone pair 
region of N17 is favourable to toxicity. The appearance of either a Mol 
or a. IP in each of the regressions indicates that the greater the 
facility for Van der Waals interactions, the greater the toxicity. 
The best four simple regressions obtained with log(T. I) as the dependent 
variable, have significance levels between 99.5% and 99,9% : 
log(T. I) = 167.9(±32) Q(N17) + 36.59(±6.6) (6.34) 
and r= 769 ;s= . 21 ; F(1,19) = 27.48 
log(T. I) = -1.84(±. 3) EBIND(NI. 7) - 146.2(±32) (6.3 5) 
and r= . 727 s . 23 ; F(1,19) = 21.37 
log(T. I) = -7.209(-+-2,0) FE(C3) + 2.146(±. 13) (6.36) 
and r= . 632 s= . 26 ; F(1,19) = 12.68 
109(T, I) = 2.348(±. 6) FE(NO + 1.125(±. l) (6.37) 
and r= . 611 ;s= . 26 ; F(1,19) = 11.33 
It is noticeable that Q(N27) and EBIND(N17) appear in regressions (6.34) 
and (6.35) with coefficients of opposite sign to those in regressions 
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(6.30) - (6.33) . This trend is readily explained by the negative 
relationship of log(T. I) with p(LDID The negative coefficient 
associated with FE(C3) in regression (6.36), cannot be explained via a 
pogitive relationship between p(Mýo and FE(CO, because there is 
litýle correlation between these two quantities, as indicated in the 
following regression 
p(LDIO) = 1.919(±1.2) FE(C3) + 4.675(±. 08) (6.38) 
and r= . 338 ;s= . 15 ; F(lpl9) = 2.45 . 
'Regression' (6.37) indicates the positive influence of the electron ANQ-Ij 
donating ability of N7 towards the P. 388 cell receptor. 
I 
The -best four two variable regressions obtained with log (To I) as the 
dependent variable, have significance levels above 99.9% : 
109(T, I) = 187.2(+-25) Q(N17) - 12.29(-+3.3) 1/DELTA + 41. BL+5) (6.39) 
and r= . 875 ;s= . 16 ; F(2,18) = 29.49 
log (T. I) = -2.17 (±. 6) Q (C3) + 157 (+--25) Q (N17 + 34A (+- 5) (6.40) 
and r= . 867 s= . 17 ; F(2,18) = 27.44 
109(T. I) = 041(-±. Ol) ALPHA(C 3) + 154(+-26)'Q(N 17) + 28.4 (±5) (6.41) 
and r= . 865 ;s= . 17 ; F(2,18) = 26.93 
log(T. I) = 2.34(±-. 4) FE(N7) - 2.76ft. 6) E(N -4'18) - 56.1(±12) (6.42) 17 
and r= . 842 s= . 18 ; F(2,18) = 22.01 . 
The I/DELTA appearing in regression (6.39) with a negative coefficient 
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indicates that the greater the first excitation energy the higher the 
drug activity, The most attractive regression is (6.41) , in which 
ALPHA(C3) appears with a positive coefficient,, as in the p(I50) 
regressions (6.20) and (6.24). Converselyr Q(N17) appears. with a 
coefficient of opposite sign to that in regression (6.30) and (6.31), as 
expected from the negative relationship between p(LDIO) and log(T. I). 
Regression (6.41) therefore confirms that it is possible to separate 
cancer cell inhibition from toxicity and hence aim to maximize the 
former and minimize the latter in the design of more effective drugs. 
(ii) Planar-irmersion 
The best four simple variable regressions obtained with p(I,, ) as the 
dependent variable,, have significance levels between 99.0% and 99.75% : 
P(Iso) = . 0028(±. 0008) M. V + 5.03(±. 4) (6.43) 
and r= . 574 ;s= . 23 ; F(1,25) = 12.32 
p(I, 50) = -. 0014(±. 0004) B. E + 4.85(±. 4) 
(6.44) 
and r= . 560 ;s= . 23 ; F(1,25) = 11.42 
P(Ir, o) = . 023(±. 007) 
(1 mol + 4.916(±. 4) (6.45) 
and r= . 542 ;s= . 24 ; F(1,25) = 10,42 
PUSQ 0.074 (±. 02) NC + 5.94 (6.46) 
and r . 513 s= . 24 ; F(1,25) = 8.95 
ReIressions (6.43)-(6.46) reflect the increase in cell growth inhibition 
with increasing molecular bulk. Regression (6.46) indicates that p(I., 
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increases by 0.074 for each CH2 group added to the alkyl cross linkage. 
The best four two variable regressions obtained with p(I50) as the 
dependent variable, have significance levels between 99.5% and 99.75% : 
P(ISO) = 12.7(±7.1) Q(C4) + 0.003(±. 0007) M. V + 4.92(±. 4) (6.47) 
and r= . 639 ;s= . 22 ; F(2,24) = 8.31 . 
PU50) = -5.84(±3.7) Q(N7) + 0.002(±. 0007) M. V + 3.6(±-l) (6.48) 
and r= . 625 ;s= . 22 ; F(2,24) = 7.70 . 
p (Iso 0.17 (t. 1) ALPHA (N 17) + 002 (±,, 0008) M. V - 12.7 (±-Il) (6.49) 
and r . 625 ;s= . 22 ; F(2,24) = 7.69 
P(I, 50) = . 215(±. l) EBIND(N7) + . 002(±-. 0007) M, V + 20.1(±10) - (6,50) 
and r= . 623 ;s= . 22 ; F(2,24) = 7.61 . 
The two variable regressions (6.47)-(6.50) each contain an electronic 
index as well as a size index. From the appearance of the electronic 
properties of N7, in regressions (6.48) and (6.50), it is possible that 
there may be a receptor fragment located in this vicinity, in the 
drug-receptor complex. From regression (6.49)j, the polarizability of 
the amino nitrogen may have a positive effect on activity. 7his may be 
related to the ease of cross linkage. 
The best four simple regressions obtained with p(LDIO) as the dependent 
variable, have significance levels between 95.0% and 97.5% 
P (LDIO )= -1.065 (t . 3) FE (NO + 5.058 (ts 09) (6.51) 
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and r= . 539 ;s= . 14 ; F(1,19) = 7.78 . 
p(LDIO) = 0.323(±. l) ALPHA(C3) - 36.91(117.3) (6.52) 
and r= . 483 ;s= . 14 ; F(1,19) = 5.80 . 
p(LD10) = -. 201(±. 08) E(C6-N7) - 2.322(±2.9) (6.53) 
and r= . 480 ;s= . 14 ; F(1,19) = 5.71 . 
p(LDIO) = . 0012(j. 0005) a. IP + 4.027(±. 3) (6.5.4) 
and r= . 457 s= . 14 ; F(1,19) = 5.03 
The appearance of negative coefficients with FE(NO and E(C6-N7) in 
I 
regressions (6.51) and (6.53) makes it necessary to consider processes 
having a negative effect on drug activity. It is possible that a high 
frontier electron density or bond energy might be favourable to a 
reaction wbich prevents the diacridine from reaching the site of its 
toxic action, or prevents intercalation. ALPHA(C3) and a. IP appear 
with positive coefficients in regressions (6.52) and (6.54), indicating 
that polarizabilty at atom C, or facility for dispersive interactions, 
respectively, might positively affect toxicity. 
The best four two variable regressions obtained with p(LDIO) , as the 
dependent variable have significance levels above 99.0% : 
p(LD, g) = -. 218(±. 07) E(C6-N7) + . 0008(±. 0003) S. A - 3.43(±2.7) (6.55) 
and r= . 635 ;s= . 13 ; F(2,18) = 6*08 
P(LDIO) = -. 896(±. 3) FE(NA + -0009(±-0005) a-IP + 4.43(±. 3) (6.56) 
and r= . 634 s= . 13 F(2,18) = 6.06 
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P(LDIO) = -. 221(±. 07) E(C6-N7) + . 001(±. 0004) M. V - 3.59(±2.7) (6.57) 
and r= . 627 ;s= . 13 F(2,18) = 5.85 
P(LDio) = -1.59(±. 4) FE(N7) + 23.3(±13) E(N17-HIB) + 489( -279) (6.58) 
and r= . 626 ;s= . 13 ; F(ý, 18) = 5.79 
The negative coefficient associated with E(C6-N7) in the regressions 
(6.55) and (6.57) indicates that the stronger the C6-N7 bond the-higher 
the toxicity, It is evident from the second independent variable 
appearing in regressions (6.55)-(6.57) that the larger the molecule, the 
higher the toxicity. The second independent variable appearing in 
regression (6.58) indicates that a low stability of the N, *7-H*,, bond is 
favourable to toxicity. This is-reasonable if distorsion of this bond 
is necessary in the intercalation processe 
The best four simple -regressions obtained with log(T. I) , as the 
lependent variable have significMce levels above 97.5% 
log(T. I) = 0.453(±. l) E(HCMO) + 5.845(±1.5) (6.59) 
and r= *533 ;s= . 28 ; F(1#19) = 7.55 . 
log(T. I) = . 396(±. l) ALPHA(N17) - 37.9(±14.6) (6.60) 
and r= *526 ;s= . 28 ; F(lpl9) = 7.29 
109(T, I) = . 795(±. 3) E(N7-C + 29.9(±10.6) (6.61) 
and r= . 519 s= . 28 ; F(I. 19) = 7.00 
109(T, I) = . 414(+--, l) E(C6-N7) + 16.39(±5.9) -(6.62) 
and r= . 493 ;s= . 29 ; F(1,19) = 6.12 . 
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It is interesting that the regressions obtained for log(T. I),, are very 
different from the regressions obtained with p(Iso ),, r1be variation of 
log(T. I) is complicated by its dependence on p(LD,, ). In spite of low 
correlation coefficients associated with the regressions (6.61) and 
(6.62), the positive coefficients are an. indication that weak bonds 
between the atcms N7 and C6 or C, are favourable to the therapeutic 
index. Regression (6.62) is probably explined by the negative influence 
of E(C. -N 7) on p(LDIO), as indicated by regression (6.53) . 
The best two variable regressions obtained with log(T, I) as the 
dependent variable have significance levels between 99.75% and 99,5% : 
log(T. I) = 1.12(±. 2) ALPHA(N17) + 3.8(±l) EBIND(NI7) 
+ 197(±74) (6.63) 
and r= . 735 ;s= . 23 ; F(2,18) = 10.58 . 
log(T, I) = 680(±. l) ALPHA(N17) - 20.92(±6.6) EBIND(Hig) 
487.6 U143., 7) (6.64) 
and r= 730 ;s= . 23 ; F(2,18) = 10.27 
log(T., I) = -147.1(±49.4) Q(1417) + 1.38(±. 3) E(N7-CS) + 20.3(-+9) (6.65) 
and r= s714 ;s= . 24 ; F(2,18) = 9.38 . 
109(T, I) . 791(t, l) EBIND(N7) - 70.64(±23)E(NI7-HIS) 
1408 (±470) (6.66) 
and r= . 703 ;s= . 24 ; F(2,18) = 8.79 
Regression (6.63) indicates a combined role for the polarizability and 
energy of binding of atom N17 0 It is possible that both these 
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quantities might positively affect the ease of intercalation. 
ALPHA (N 17 ) also appears in regression (6.64). The secorx3 variable , 
appearing with a negative coefficient, has a similar implication in 
terms of the relative ease of cross linkage and stapling as E(N, 7 -HIO), 
which appears in-regressions (6.22)-(6.25), as well as'in (6.66). 
EBIND(N 
7) appears with a positive coefficient in regression (6.50),, with 
p (40 ) as the dependent var iable, while *E (NI 7 -H, 9) appear s with a 
positive coefficient in regression (6.58),, with p(LDIO ) as the dependent 
var iable. EBIND (tý ) and E (N I j-H, a) are 
both appear in regression (6.66) 
the . expectation being that one of the variables determines p(I., ) and 
the other determines p(LIý, )* 
Stacked-mirror 
The best four simple regressions obtained with p(I50) , as the dependent 
variable have significance levels between 99.5% and 99.75% : 
P(ISO) = . 002(±. 0005) S. A + 5.289(±, 3) (6.67) 
and r= *569 ;s . 23 ; F(1,25) = 12.02 
P(Tso . 0026(±. 0008) M. V + 5.10(±. 4) (6.68) 
and r *557 ;s= . 23 ; F(1,25) = 11.29 
P(Iso = -. 0014(±. 0004) B. E + 4.909(±. 4) (6,69) 
and r . 553 ;s= . 23 ; F(1,25) = 11.06 
P(; o = . 023(±. 007) olmol + 4.916(±. 4) 
. 
(6.70) 
and r . 542 ;s= . 24 ; F(1,25) = 10.42 
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Frm the above regressions (6.67)-(6.70), the p(I5O ) is predominantly 
determined by the size, of the molecule. The larger the molecule, the 
higher the activity. 
The best four two variable regressions obtained with p(I,,, ) as the 
dependent variable have significance levels between 99.75% and 99.9% : 
p(]ýo = 45.62(-±9,8) FN(Ce) + 2.92(±., 7) Q(C13) + 5.27(±*2) (6.71) 
and r . 692 ;s= . 21 ; F(2,24) = 11.07 . 
ý'P(Iso )= -4.23(+--2.3) Q(N 7) + . 0023(±-. 0005) S. A + 
4.19C+. 6) (6.72) 
and r= . 638 ;s= . 22 ; F(2,24) = 8.27 . 
P(Iso = 1.28(t. 7) FE(N7) + . 002(-+. 0005) S. A + 4.98(-±. 3) (6.7 3). 
and r . 637 ;s= . 22 ; F(2,24) = 8.21 
POýo -4.272(±2.3) Q(N7) + . 0031(±. 0008) M. V + 3.96(+-. 7) (6.74) 
and r . 628 ;s= . 22 ; F(2,24) = 7.85 
Regression (6.71) can be interpreted in terms of charge transfer and 
electrostatic -4ruteraction between drug and receptor, In regression 
(6.72)-(6.74), a rnolecular size index appears together with electronic 
properties of the pyridine nitrogen. Either the charge or the electron 
donor capability of N7 seems to affect drug activity, 
The best four simple regressions obtained with p(LDjO) as the dependent 
variable have significance levels. between 95.0% and 99.0% : 
P(LDIO) = 3.759(±1,3) FE(r%4) + 4.502(--+. l) (6.75) 
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and r= . 546 ;s= . 14 ; F(1,19) = 8.11 . 
p (Lrý 0)=-. 3 50 (-+.. 1) EBI14D (C6) -31.8 3 (±. l 3.8) (6.76) 
and r= . 520 ;s= . 14 ; F(1,19) = 7.04 
P(Llho = -. 196(±-. 08) E(C6-N7) - 2.174(+-3.0) (6.77)- 
and r= . 465 ;s= 14 ; F(1,19) = 5.26 .- 
p(LD, g = -. 361 (±. l) E(N 7-CS) - 8.033C+-5.5) (6.78) 
and r= . 465 ;s= . 14 ; 
'F(1,19) = 5.24 
I"gression (6,75) ", can be interpreted in terms of drug-receptor 
interaction. This regression suggests that CI, 4 acts as an electron 
donor in a charge transfer in - teraction. Fran regressions (6.76)-(6.78), 
it seems that the stability of intramolecular bonding in the vicinity of 
the pyridine nitrogen positively affects toxicity. 
The best four two variable regressions obtained with p(LD, O as the. 
dependent variable have significance levels of about 99.9% 
p(LDjo = 0.28(-+. 06) 'ýý(CO + . 0016(±. 0003) a. IP - 33. le+8) (6.79) 
and r= . 761 ;s= . 11 ; F(2,18) = 12.42 . 
P(LDjo )=-. 48(-+, l) EBIND(C. ) + . 013C+. 003) a. IP - 46.5(±11) (6.80) 
and r. = . 741 ;s= all ; F(2,18) = 10.95 
P(LDjo = -. 48C+:. 1) EBIND(C6) - . 0007(+-. 0002) B. E - 46.9c+12) - (6.81) 
and r . 725 ;s= . 11 ; F(2,18) = 9.98 . 
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P(LDIO -. 465(±. I) PIND(Cr) + . 0013(±. 0004) M. V - 44.4(±12) (6.82) 
and r= . 718 ;s= . 12 ; F(2,18) = 9.61 
It is noticeable that EBIND(C. ) appears with a negative coefficient in 
the regressions (6.80)-(6.82), suggesting that toxic effects may be 
prevented by high reactivity at this centre. The second index in the 
two variable regressions' indicites a positive influence of the ability 
for dispersive interaction or size on the toxicity. 
The best four simple regressions obtained with log(T, I) as the dependent 
variable have significance levels between 99.0% and 99.5% : 
log(T, I)'= -. 433(±. l) ALPHA(CS) + 55.45(±16.1) (6.83) 
and r= . 606 s= . 26 ; F(1,19) = 11.04 
log(T, I) = -6.267(±2.1) FE(CI) +2.121(±. l) (6.84) 
and r= . 566 ;s= . 27 ; F(1,19) = 8.97 . 
109 
* 
ýT. I) = 0.565(±. 2. ) EBIND(C. ) + 60.75(±21.1) (6.85) 
and r= . 540 ;s= . 28 ; F(1,19) = 7.83 
log(T, I) = 0.729(±. 2) EBIND(C6) + 77.9(±-27.3) (6.86) 
and r= . 538 ;s= . 28 ; F(1,19) = 7.74 . 
In the regression (6.83)t the negative coefficient associated with 
ALPHA(Cs) indicates that the lower the polarizability at Cs, the higher 
the T. I, but it is not clear whether ALPHA(Cs) has a negative effect on 
activity or a positive effect on toxicity. The positive coefficients 
associated with EBIND(Ce) and EBIND(C6) in the regressions (6.85) and 
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(6.86), respectively, are in agreement with the deductions made from 
regressions (6.76)-(6.78), i. e the more stable the situation in the 
vicinity of N 71 the higher the toxicity. 
The best four two variable regressions obtained with log (T. I) r as the 
dependent variable have significance levels above 99.9% : 
log(TeI) = 2.135(i. 4) EBIND(Ce) - 1.556(±-. 4) E(Cs-CI4 
+ 171.3ý36.1) (6.87) 
and r= *757 ;s= . 22; F(2tlB) = 12.14 . 
log(T, I) = -4.97tE-1.7) FE(CI) - 358(i-115) ALPHA(Cs) + 46.4(±, 14) (6.88) 
and r= . 747 ;s= . 23 ; F(2,18) = 11.39 . 
log(T. I) = 57. lL+12.1) FN(Ce) + 2.95(±. 8) Q(CI3) + . 206(±. 3) (6.89) 
and r= . 745 ;s= . 23 ; F(2,18) = 11.27 . 
log(T, I) = -, 931(-+. 2) ALPHA(C5) + 24.89(±9) 1/t)ELTA 
114.9(±25.6) 
and r= . 745 ;s= . 23 ; F(2,18) = 11.23 . 
(6.90) 
Regressions (6,87), (6.88) and (6.90) may not be readily explained in a 
terms of the effects of the variables appearing on either p(I50) or 
p(LDIO ). Fegression (6.89) bears an astonshing similarity to regression 
(6.71)0, obtained with p(I50) as the dependent variable. The improved 
correlation coefficient of (6.89) is probably the result of the smaller 
data base used for these regressions. The second index of the 
regression (6,90) indicates that the lower the excitation energy the 
higýer the drug activity. 
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Table 6.6 Calculated indices for planar-mirror diacridines. 
NO. FE(Cl) Q(C3) Q (CO Q (N 17) FE (C 2 FE (N 7 
' (-e) (e) (e) (e) (-e) (-e) 
1 *082113 -, 018119 -. 000197 -. 212399 0.022592 0.240610 
2 . 105420 0.257291 -. 071294 -. 208658 0.022436 0.000191 
3 . 081917 -. 019596 0.000301 -. 207828 0.022486 0.244579 
4 . 083416 -. 025143 0.004205 -. 208313 0.015897 0.261746 
ý5 . 004785 -. 021654 0.004404 -. 205024 0.001733 0.405183 ý 
6 . 084378 -. 013345 -. 001696 -. 206097 0.022259 0.237127 
7 . 070060 -. 016722 -. 003064 -. 208164 0,027122 0.216562 
8 . 084606 -. 023519 0.003337 -. 207959 0.018358 0.258140 
9 . 067327 -. 016270 -. 002634 -. 207965 0.023460 0.214604 
10 . 084820 -. 023349 0.003404 -. 207825 0.018187 0.258150 
11 . 081866 -. 019946 0.000490 -. 207766 0.022270 0.244694 
12 . 004792 -. 022068 0.004470 -. 205051 0.001735 0.405345 
13 . 069957 -. 017121 -. 002851 -. 208114 0.026888 0.216665 
14 . 067404 -. 016543 -. 002592 -. 208056 0.023338 0.214971 
15 . 083202 -. 017812 0.000056 -. 206950 0.021313 0.243880 
16 . 081562 -. 017148 -. 000627 -. 207090 0.020374 0.241907 
17 -. 014039 -. 001380 --ý. 205899 0.021959 0.237430 
18 1'079975 -. 0M50 0.000245 -. 207688 0.019098 0.243524 
19 . 066065 -. 018735 0.000257 -. 207141 0.020282 0.206ý10 
20 . 086476 -. 000244 -. 026553 -. 208269 0.043071 0.222424 
21 . 067267 0.045965 0.012624 -. 206714 0.002309 0.183496 
22 . 084658 -. 023731 0.003200 -, 208180 0.018303 0.258414 
23 . 081797 -. 019992 0.000537 -. 207841 0.022204 0.244757 
24 . 004789 -. 022060 0.004309 -. 205343 0.001724 0.405807 
25 . 081805 -. 020035 0.000397 -. 207942 0.022226 0.244922 
26 . 067184 -. 016586 -. 002606 -. 208117 0.023558 0.2148 39 
27 . 067291 -. 016794 -. 002744 -. 208381 0.023510 0.215281 
Täble 6.6 Cont. 
NO FE(N 17 ) 
CLMOl 
(-e) (A 
03) 
1 . 133772 49.888 
2 . 000239 53.680 
3 . 131292 57.472 
4 . 104819 59.862 
5 . 006127 65.056 
6 . 139937 61.766 
7 : 130175 62.636 
8 . 117021 70.220 
9 . 116555 62.636 
10 . 116844 62.636 
11 . 132121 61.264 
12 . 006127 68.848 
13 . 130875 66.428 
14 . 117150 66.428 
15 . 132651 65.392 
16 . 127976 67.674 
17 141487 65.558 
18 . 119337 71.810 
19 . 107547 71.810 
20 . 103861 71.592 
21 092390 70.556 
22 . 117461 74.012 
23 . 132417 65.056 
24 . 006107 72.640 
25 . 132414 68.848 
26 . 116685 74.012 
27 . 117064 77.804 
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FE (C3) 
(-e) 
. 071527 
. 1171$6 
. 071350 
. 081083 
. 001473 
. 072197 
. 055797 
. 078846 
. 056546 
. 079157 
. 079157 
, 001469 
. 055897 
. 056681 
. 073084 
. 072745 
. 072332 
. 073036 
. 056309 
. 077424 
. 090736 
. 078851 
. 071597 
, 001462 
. 071558 
. 056468 
. 056527 
Q (N 17) 
(e) 
-. 212399 
208658 
-. 207828 
-. 208313 
-. 205024 
-. 206097 
-. 208164 
-. 207959 
-. 207965 
-. 207825 
-. 207825 
-. 205051 
-. 208114 
-. 208056 
-. 206950 
-. 207090 
-. 205899 
-. 207688 
-. 207141 
-. 208269 
-. 206714 
-. 208180 
-. 207841 
-. 205342 
-. 207942 
-. 208117 
-. 208381 
E(C4-HIS) E(N17-H, 8) EBIND(NI7) 
(ev) (ev) (ev) 
-19.9062 -20.4258 -79.8218 
-20.0206 -20.7396 -80.1073 
-19.9076 -20.7419 -80.2195 
-19.9025 -20.7392 -80.2334 
-19.9017 -20.7375 -80.4157 
-19.9149 -20.7417 -80.3446 
-19.9095 -20.7422 -80.1138 
-19.9040 -20.7398 -80.2450 
-19.9104 -20.7443 -80.1620 
-19.9045 -20.7396 -80.2572 
-19.9076 -20.7439 -80.2164 
-19.9016 -20.7397 -80.4139 
-19.9094 -20.7445 -80.1097 
-19.9103 -20.7464 -80.1567 
-19.9106 -20.7436 -80.2866 
-19.9110 -20.7441 -80.2700 
-19.9148 -20.7441 -80.3522 
-19-9085 -20.7439 -80.2303 
-19.9089 -20.7430 -80.2412 
-19.9215 -20.7461 -80.1883 
-19.8252 -20.7417 -80.3320 
-19.9042 -20.7422 -80.2369 
-19.9081 -20.7438 -80,2186 
-19.9023 -20.7397 -80.4100 
-19.9082 -20.7441 -80.2140 
-19-9099 -20.7446 -80.1496 
-19.9099 -20.7468 -80.1418 
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Table 6.6 Cont, 
NO, 1/DELTA M. V B. E ALPHA(C3) a IP AJPHA(C6) 
0 A3) (ev) (KeVl) 
R) 
(ev . (KeV') 
1 0,094303 369.690 , -856.6994 128.769 473,4629 121,546 
2 0.144036 387.286 -261.8441 114.533 322.7081 122,609 
3 0.093957 437.160 -992.7066 128.771 541.3831 121.530 
4 0.093660 459.634 -1032.855 128.759 522.9263 121.376 
5 0.107320 495.612 -1123.547 128.675 546.5724 122.327 
6 0.098633 482.084 -1059.301 128.829 618.7572 121.505 
7 0.095977 485.318 -1079.416 128.793, 577.6939 121.763 
8 0.093513 553.702 -1215.897 128.756 656.5766 121.412 
9 0.095631 485.058 -1079.513 128.789 574.3523 121.728 
10 0.093582 485.158 -1079.663 128.756 588.2094 121.405 
11 0.093955 470.684 -1060.515 128.773 574.2267 121.530 
12. 0.107276 529.118 -1191.359 128.677 575.8246 122.323 
13 0.095990 518.602 -1147.226 128.796 608.8158 121.764 
14 0.095631 518.616 -1147.320 128: 0792 606.2648 121.725 
15 0.095005 499.102 -1060.545 128.792 631. '2626 121.502 
16 0.096204 506.126 -1065.026 128.819 650.6358 121.522 
17 0.098699 515.690 -1127.122 128.832 654.9055 121,503 
18 0.095379 541.396 -1135.970 '128.804 675.7587 121.519 
19 0.096440 541.100 -1136.120 128.760 667.3233 121.583 
20 0.095895 566.570 -1234.212 128.697 648.0768 122., 869 
21 0.108869 540.064 -1154.637 131.893 639.4143 121.612 
22 0.093530 586.790 -1283.705 128.760 688.3662 121.408 
23 0.093960 504.258 -1128.318 128.769 610.3249 121.529 
24 0.107364 562.684 -1259.163 128.674 606.6851 122.317 
25 0.093973 537.858 -1196,120 128.770 644.3095 121.526 
26 0.095547 587.160 -1283.533 128.789 675.6164 121.736 
27 0.095553 620.190 -1351.341 128.792 707.0319 121.731 
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Table 6.7 Calculal 
NO, NC Q(C4) 
(e) 
12 . 000211 
24 . 000395 
36 *000559 
46 . 004299 
56 . 004507 
66-. 00141 
76-. 00278 
86 . 003297 
96-. 00252 
10 6 . 003365 
11 8 . 000560 
12 8 . 004335 
13 8 -. 00292 
14 8 -. 00252 
15 8 . 000259 
16 8 -. 00040 
17 8 -. 00153 
1.8 8 . 000461 
19 8 . 000328 
20 8 -. 02666 
21 8 012818 
22 8 001489 
23 10 . 000429 
24 10 . 004358 
25 12 . 000441 
26 6 -. 00266 
27 8 -. 00250 
ýed indic( 
Q (N 7) 
(e) 
-. 23130 
-. 23311 
-. 23443 
-. 25043 
-. 25088 
-. 21986 
-. 22616 
-. 24591 
-. 21384 
-. 24605 
-. 23478 
-. 25043 
-. 22591 
-. 21418 
-. 22987 
-. 22757 
-. 21981 
-. 23370 
-. 22629 
-. 22642 
-. 24477 
-. 23705 
-. 23440 
-. 25071 
-. 23452 
-. 21373 
-. 21472 
I 
?s for plan 
EBIND(N7) 
(ev) 
, 70.0258 
-70.0070 
-69.9960 
-69.8963 
-69.0383 
-70.1059 
-70.0127 
-69.9399 
-70.0651 
-69.9501 
-69.9906 
-69.0405 
-70.0090 
-70.0603 
-70.0410 
-70.0224 
-70,0988 
-69.9788 
-70.1225 
-70.0079 
-70.0093 
-69.9649 
-69.988ý7 
-69.0388 
-69.9886 
-70.0609 
-70.0546 
ar invrsic 
E8 IND ('ý 7 
(ev) 
-80.3052 
-80.2248 
-80,2225 
-80.2331 
-80.4174 
-80.3511 
-80.1164 
-80.2441 
-80.1625 
-80.2564 
-80.2202 
-80.4124 
-80.1120 
-80.1605 
-80.2887 
-80.2730 
-80.3450 
-80.2347 
-80.2448 
-80.1897 
-80.3692 
-80.2415 
-80.2167 
-80,4108 
-80.2157 
-80.1477 
-80.1483 
)n diacridines. 
ALPHA(C3) a mol 
(Kev-1) 
128.773 49.888 
128.772,53.680 
128.770 57.472 
128.759 59.862 
128.674 65.056 
128.829 61.766 
128.793 62.636 
128.757 70.220 
128.789 62.636 
128.756 62.636 
128.770 61.264 
128.674 68.848 
128.793 66.428 
128.789 66.428 
128.789 65.392 
128.816 67.674 
128.830 65.558 
128.800 . 71,810 
128.757 71.810 
128.697 71.592 
129.111 70.556 
129.825 74.012 
128.770 65.056 
128.674 72.640 
128.770 68.848 
128.790 74.012 
128.789 77.804 
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Týible 6.7 Cont. 
NO, EE(N7) E(C7-C8) 
(-e) (ev) 
1 0.245250 -35.5657 
2 0.244293 -35.5630 
3 0.244663 -35.5619 
4 0.261982 -35.5828 
5 0,405036 -34.9539 
6 0.237261 -35.5959 
7 0.216413 -35.5162 
8 0.258452 -35.6035 
9 0.214765 -35.5089 
10 0.258471 -35.6093 
11 0.244772 -35.5619 
12 0.405646 -34.9551 
13 0.216737 -35.5168 
14 0.215004 -35,5085 
15 0.243799 -35.5905 
16 0.241836 -35.5468 
17 0.237496 -35.5966 
18 0.243512 -35.5410 
19 0.206505 -35.6209 
20 0.222690 -35.5954 
21 0.245094 -35.5236 
22 0.011125 -35.5482 
23 0.244921 -35.5628 
24 0.405738 -34.9548 
25 0.244940 -35.5628 
26 0.215069 -35.5086 
27 0.215231 -35.5071 
E (N 27 -His 
(ev) 
-20.7357 
-20.7441 
-20.7441 
-20.7418 
-20.7398 
-20.7440 
-20.7448 
-20.7424 
-20.7466 
-20.7423 
-20.7440 
-20.7399 
-20.7449 
-20.7466 
-20.7434 
-20.7440 
-20.7441 
-20.7438 
-20.7431 
-20.7464 
-20.7430 
-20.7468 
-20.7442 
-20.7399 
-20.7441 
-20.7470 
--20.7468 
E(C8-C14) 
(ev) 
-34.35143 
-34.35303 
-34.35388 
-34.76341 
-33.87856 
-34.38965 
-34.25492 
-34.65139 
-33.72648 
-34.64498 
-34.35403 
-33.87858 
-34.25490 
-33.72670 
-34.23928 
-34.3359 
-34.38932 
-34.33280 
-33.49862 
-34.61956 
-34.69683 
-34.6535 
-34.35367 
-33.87903 
-34.35370 
-33.71643 
-33.71748 
E (C 6 -N 7) ALP"h 
(CS) 
(ev) (KeV') 
-35.58622 123,794 
-35.58187 123.798 
-35.57849 123.798 
-35.55117 123.759 
-34.48073 123.754 
-35.52466 123.980 
-35.59659 123.867 
-35.55142 123.759 
-35.55984 123.864 
-35.54866 123.757 
-35.57713 123.799 
-34.48080 123.754 
-35.59633 123.867 
-35.55876 123.864 
-35.54366 123.862 
-35.58475 123.933 
-35.52338 123.981 
-35,56011 123.883 
-35.51412 123.785 
-35.47748 123.856 
-35.66112 123.734 
-35.56591 123.399 
-35,57712 123.798 
-34.47997 123.754 
-35.57666 123.798 
-35.56331 123.864 
-35.56150 123.864 
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Table 6.7 Cont. 
NO, B. E a IP M. V E(HCMO) ALPHA (N17) S. A 
(ev) (ev. 93)' ( 
R3) 
(ev) (Keýý) 
0 
2) (A 
1 -857.257 474.5386 371.732 -9.51208 99.345 . 409.3627 
2 -925.117 506.9761 387.642 -9.44441 99.740 413.8909 
3 -992.927 540.6628 438.581 - 9.40741 99.852 495.5814 
4 -1033.07 . 
551.9099 461.098 -9.21970 99.853 526.4249 
5 -1123.76 545.8130 497.076 -8.38989 100.734 560.4546 
6 -1059.52 618.1909 483.548 -10.0085 100.152 549.2315 
7 -1079.63 576.2953 486.774 -9.20070 99.461 551.7051 
8 -1216.11 655.6848 555.166 -9.33758 99.896 641.6542 
9 -1079.73 573.6457 486.522 -9.15840 99.561 550.7087 
10 -1079.88 587.3908 486.622 -9.37784 99.931 551.6959 
11 -1060.73 574.9840 471.040 -9.38535 99.896 539.4327 
12 -1191.57 575.4335 529.476 -8.35802 100.784 604.3190 
13 -1147.44 609.7969 518.958 -9.17972 99.496. 595.2276 
14 -1147.53 607.0734 518.976 -9.13881 99.603 593.9926 
15 -1060.76 031.2078 499.458 -9.65267 100.079 573.7025 
16 -1065.27 650.5985 506.482 -9.61371 100.035 580.2418 
17 -1127.34 653.6774 516.046 -9.97097 100.215 592.7209 
18 -1136.18 676.3170 541.754 -9.41814 99.926 625.4013 
19 -1136.33 668.1277 541.460 -9.30410 99.980 623.0984 
20 -1234.42 648.9492 566.926 -9.06455 99.672 650.0094 
21 -1148.69 673.4871 540.420 -9.54542 100.467 610.1084 
22 -1295.27 631.0425 594.534 -8.52621 99.842 697.4103 
23 -1128.53 609.6742 504.614 -9.37153 99.912 582.3054 
24 -1259.38 606.0795 563.040 -8.34360 100.815 647.1785 
25 -1196.33 644.6160 538.214 -9.36288 99.924 626.1566 
26 -1283.75 674.8720 588.624 -9.11841 99.525 683.6485 
27 -1351.55 708.0638 620.554 -9.10060 99.573 727.3028 
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Table 6.7 Cont. 
NO, FE (C 1) 
(-e) 
1 . 081088 
2 . 081768 
3 . 081701 
4 . 083208 
5 . 004782 
6 . 084185 
7 . 069685 
8 084444 
9 . 067189 
10 . 084655 
11 . 081717 
12 . 004785 
13 . 069783 
14 . 067263 
15 . 083173 
16 . 081542 
17 . 084198 
18 . 079880 
19 . 065930 
20 . 086322 
21 . 078920 
22 . 045241 
23 . 081752 
24 . 004790 
25 . 081762 
26 
-. 
067066 
27 . 067135 
EN (C 8) 
(-e) 
. 003516 
. 003413 
. 003386 
. 006731 
. 020649 
«004994 
. 000049 
. 005875 
. 000150 
. 006044 
. 003384 
. 020610 
. 000055 
. 000153 
. 004390 
. 004650 
. 005013 
. 004609 
. 000584 
. 009663 
. 005891 
. 006015 
. 003409 
. 020613 
. 003409 
, 000142 
. 000140 
Q(C13) 1/DELTA 
(e) (eql) 
. 031711 . 093974 
. 031700 . 093949 
. 031710 . 093948 
. 180718 . 093652 
. 016399 . 107315 
. 055236 . 098673 
-. 01241 . 095988 
. 209202 . 093523 
-. 05514 . 095636 
. 211924 . 093591 
. 031686 . 093957 
. 016295 . 107375 
-. 01247 . 096001 
-, 05513 . 095638 
. 104932 e094999 
. 077888 . 096199 
. 055093 . 098733 
. 043014 . 095369 
. 043159 . 096443 
. 209176 . 095895 
. 214642 . 094580 
. 209112 . 141590 
. 031627 . 093971 
. 016305 . 107348 
. 031618 . 093974 
-. 05282 . 095559 
-. 05270 . 095553 
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Table 6.8 Calculated indices for stacked mirror diacridines, 
NO. FE (C ) EN (C Q (N 
7) 
Q (C 
13 
) EBIND (C 
6 
E (C 
6-N 7) I 
(-e) (-e) (e) (e) (ev) (ev) 
1 . 089745 . 014695 -. 231767 0.031703 -104.7340 -35.53658 
2 . 096372 . 020863 -. 202698 0.026185 -104.4914 -35.62950 
3 . 063657 . 021193 -. 230420 '031206 00 -104.5615 -35.57496 
4 . 068104 . 013625 -. 246301 0.180097 -104.6025 -35.54784 
5 . 004828 . 032589 -. 246924 0.015838 -103.9493 -34.47852 
6 . 062747 . 025825 -. 216544 0.055375 -104.4910 -35.52699 
7 . 055208 . 027770 -. 222377 -. 012876 -104.5352 -35.58701 
8 . 067391 . 015184 -. 242393 0.208835 -104.5876 -35.54828 
9 . 054409 . 030901 -. 209146 -. 055954 -104.5338 -35.55400 
10 . 067486 014910 -. 242596 0.211591 -104.5835 -35.54590 
11 . 096152 . 021083 -. 204621 0.026509 -104.4943 -35.62981 
12 . 004686 . 032607 -. 220723 0.011400 -103.9075 -34.59055, 
13 
. 078859 . 027469 -. 183209 -. 017553 -104.4620 -35.60967 
14 . 071785 . 030259 -. 195513 -. 061146 -104.4603 -35.58899 
15 . 097537 . 021741 -. 198956 0.099521 -104.4693 -35.61144 
16 . 091682 . 023537 -. 196517 0.072673 -104.4651 -35.61385 
17 . 101443 . 023475 -. 188977 0.050366 -104.4290 -35.60245 
18 . 083936 . 022591 -. 203816 0.037850 -104.4867 -35.61708 
19 . 063213 . 015216 -. 195538 0.037522 -104.4709 -35.57521 
20 . 096897 . 011720 -. 196750 0.204635 -103.9620 -35.57537 
21 . 087462 . 020181 -. 217201 0.210532 -104.4423 -35.69601 
22 . 095288 . 015678 -. 217662 0.204977 -104.5250 -35.61219 
23 . 064189 . 021173 -. 231111 0.031241 -104.5626 -35.57332 
24 . 004861 . 032549 -. 248287 0.016083 -103.9547 -34.47737* 
25 . 096006 . 021024 -. 204296 0.026484 -104,4953 -35.63034 
26 . 054344 . 031063 -, 209745 -. 053416 -104.5367 -35.55655 
27 
. 071640 . 030405 -. 183152 -. 058798 -104,4636 -35.59004 
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Table 6.8 Cont. 
NO. E (N 
7 -ce) 
FE (C 
14 
EBIND(C 
6) a. 
ip FE (N7') a mol 
(ev) (-e) (ev) (ý3 . ev) (-e) 
N 
1 -35.53011 104399 -104.7534 370.1675 0.222228 49,886 
2 -35.59208 . 083415 -104.4898 534.4954 0.223933 53.680 
3 -35.56531 . 064477 -104.5676 537.6987 0.226941 57.472 
4 -35.52808 . 105002 -104.7373 549.2015 0.248612 59.862 
5 -34.96191 . 034230 -103.9418 543.1890 0.399615 65.056 
6 -35.59001 . 051670 -104.5203 615.1584 0.215316 61.766 
7 -35.52513 . 056778 -104.4490 573.5815 0.203311 62.636 
8 -35.60639 . 086283 -104.7267 652.3361 0.242248 70.220 
9 -35.51882 . 069521 -104.0049 571.1860 0.204064 62.636 
10 -35.61141 . 086432 -104.7153 584.4912 0.242158 62.636 
11 -35-59034 . 083852 -104.4922 609.7677 0.225623 61.264 
12 -35.05237 . 036416 -103.8689 592.5137 0.402018 68.848 
13 -35.58077 . 070740 -104.3700 647.1124 0.191471 66.428 
14 -35.57003 . 087033 -103.9343 640.6387. 0.185954 66.428 
15 -35.60443 . 084243 -104.4538 667.5358 0.223944 65.392 
16 -35.55905 -. 092710 -104.3663 686.2099 0.217789 67.674 
17 -35.58766 . 067947 -104.4590 692.6339 0.217851 65.558 
18 -35.56314 . 107192 -104.3969 710.9597 0.211619 71.810 
19 -35.63976 . 084443 -104.5411 699.6962 0.163271 71.810 
20 -35.59974 . 087521 -104.6067 680.5614 0.193309 71.592 
21 -35.57641 . 112145 -104.6034 708.8500 0.221800 70.556 
22 -35.63194 . 118019 -104.6518 726.4095 0.238954 74.012 
23 -35.56506 . 064897 -104.5685 608.2885 0.228398 65.056 
24 -34.96158 . 034137 -103.9457 605.9570 0.399956 72.640 
25 -35.59098 . 084172 -104.4932 685.0740 0.226393 68.848 
26 -35.51746 . 069611 -103.9991 672.0148 0.204383 74.012 
27 -35.57113 . 087182 -103.9282 747.3027 0.186409 77.804 
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Table 6.8 Cont. 
NO. B, E AIýPHMCO S, A M. V ALPHA(Cs) 
(ev) (KeýT) (R2) (R 3) (KeNfl) 
1 -848.4383 130.938 333.88528 350.004 126.116 
2 -924.9525 128.741 460.88442 406.036 124.037 
3 -984.3855 128.738 499.69132 436.638 123.971 
4 -1024.531 128.755 530.48828 459.032 123.932 
5 -1115.209 128.658 564.88555 495.036 123.930 
6 -1050.961 128.774 553.37578 481.564 124.153 
7 -1071.105 128.747 555.58193 484.484 124,036 
8 -1207,574 128.744 645.66663 553.204 123.932 
9 -1071.194 128.740 5ý4.89447 484,476 124.035 
10 -1071.341 128.743 555.73803 484.556 123.932 
11 -1061.361 128.742 545.12940 474.104 124.030 
12 -1192.109 128.670 609.83427 532.490 124.036 
13 -1148.132 128.752 601.10346 522.028 124.044 
14 -1148.202 128.742 599.80746 522.108 124.026 
15 -1061.380 128.762 579.86141 502,478 124.084 
16 -1065.878 128.788 586.42552 509.528 124.. 143 
17 -1127.949 128.795 598.95939 519.172 124.154 
18 -1136.816 128.776 631.35073 544*884 124.121 
19 -1136.964 . 128.729 628.81159 544.716 124.014 
20 -1235.072 128.634 656.06632 570.020 124.048 
21 -1149 . 242 129.166 633.16334 
ý49.024 124.063 
22 -1284.532 128.746 691.29411 590.694 124.068 
23 -1119.993 128.737 586.41527 503.458 123.970 
24 -1250.825 128.654 651.60950 561.904 123.927 
25 -1196.964 128.742 631.85334 540.872 124.031 
26 -1275.215 128.741 687.88161 586.498 124.034 
27 -1352.225 128.743 733.40017 624.132 124.027 
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6.4 Conclusions 
Pegressions pertaining to the mutagenic and bacteriostatic activities of 
the 9-anilino acridines make use of hydrophobicity,, a. IP and various 
electronic properties obtained from the CNDO/2 wavefunctions. 7he first 
and second order properties of 1ý9 may be relevant to the intercalation 
process. It is noticeable that the frontier electron density of C61 C9 
and C14 appear with negative coefficients, while C3 and C4 appear with 
positive coefficients. Transfer of electrons from receptor to C3 or C4 
may produce stabilization of the drug-r. eceptor complex. 
The three sets of regressions obtained for the diacridines are relevant 
to three different po . ssible mechaniEms of intergalatione 7he most 
attractive electronic indices appearing in planar-mirror-regressions as 
independent variables are those involving atoms N7 and N17. The 
appearance of E(N, 7 -HIS ) in sane of the p(I,, ) and p(LD,, regressions, 
with coefficients of opposite sign in the two cases, indicates that the 
facilities for cross linkage, and stapling may parallel the inhibition of 
ascites cell growth and toxicity to mice, respectively. Predictably, 
E(Njj-Hj8) appears with a negative coefficient in log(T. I) regressions. 
Some properties have a positive relationship with molecular*size and a 
positive effect on both p(I. 0 ) and p(LD,, The molecular size, is 
irrelevant to log(T, I), 
The only pyridine nitrogen property appearing in the best regressions is 
FE(N7)4 ribe net charge of N17 negatively affects toxicity and 
positively affects the T. I* There may be an interaction with an 
electropositive portion of the receptor for toxic action. 
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As with the planar-mirror regressions, molecular size has positive 
effects on both p(I,, and p(LDIO ) in the planar-inversion regression. 
Molecular size is therefore irrelevant to therapeutic index. Properties 
for the atom N7 and bonds with neighbouring atoms appear in the 
regressions obtained using the planar-inversion conformation. The 
general reactivity in the vicinity of N7 positively affects both 
and log(T. I), uhile negatively affecting p(LD,, ). The polarizability of 
N7 positively af fects both p(ISO) and log (T. I) . E(N17-H 18) positively 
affects p(LD,, ) and negatively affects log(T. I), supporting the 
deduction that an increase in the ease of stapling relative to cross 
linkage increases toxicity. 
In the stacked-mirror regressions, the size indices play a similar role 
as for the other conformations, High reactivity of the pyridine 
nitrogen appears to be favourable to p(I., FN(CO and Q(Cjs 
positively af fect both p (150 ) and log (T. I) . 'The stability of binding in 
the vicinity of N7 positively affects p(LAo ) and negatively affects 
log (T. I) . 
Canparing the correlation coefficients for the best regressions obtained 
with each of the three conformationsr the planar-mirror regressions are 
generally more significant than the stacked-mirror regressions which are 
in turn more significant than the planar-inversion regressions. The 
following mechanistic conclusions can be drawn : 
(i) The molecular size positively af fects the inhibition of P388 ascites 
cell growth in vitro and toxicity in mice. ' Cancelation of the size 
effect leads the T, I to be independent of size. The alkyl chain length 
is irrelevant to clinical utility. 
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(ii) The stability of bonding in the vicinity of N7 positively affects 
p(LDIO) and thus negatively bkffects log(T. I). 
Fran the calculations on planar conformations, it can be observed 
that the strength of the N 17 -H,, bond negatively affects toxicity and 
positively affects p (150 ) and - log (T, I) This may be interpreted in 
terms of the ease of rotation of the rest of the molecule about the 
C,, -N, 7 bond of one intercalated acridineo, when the entire molecule is 
in an essentially planar conformation. 
The electronic properties appearing in the regressions for the mutagenic 
and bacterostatic activities of t he 9-anilino acridine are very 
different from those appearing in the regressions for the antitumour 
activity of the diacridines. However the dispersive interaction 
capability (a. IP), which appears in r egressions explaining the. 
mutagenic activity of 9-anilino acridines , also appears in the 
regressions explaining the in vivo toxicities of the diacridine. 
I 
CHAPTER SEVEN 
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IMPLICATIONS OF THE PRESENT WORK TO DRL)G DESIGN 
In the present work, pbarmacological LFER's are produced using molecular 
properties obtained by empirical and semiempirical M. 0 metbods . The 
electronic properties are'determined from CNDO/2 and INDO wavefunctions. 
7he basic structure of the molecules of a given series is the 
equilibriun geometry for the parent molecule, obtained using a method 
which is compatible with that used to calculate the electronic 
properties, All of the M. 0 methods used are based on the ZDO 
approximation. This approximation allows the molecule to be divided 
into zones, in each of which the basis functions associated with only 
one atom are non zero. The division of the molecule into atanic zones 
makes possible the theoretical justification of single centre indices 
in terms of the perturbation energy associated with a hypothetical 
probing potential, which is meant to represent the coulombic effect of a 
receptor fragment in the-vicinity of a given atom. 
For determining observable molecular properties, ab initio, calculations 
employing minimal or larger basis sets are more reliable than the MO 
methods used in the present work. The proper account taken of 
differential overlap in ab initio method means that simple indices such 
as net atomic charge loose their theoretical justification i. e a probing 
Potential taking a constant value over the region of the orbitals of a 
given atom is no longer confined to that atom, A new set of indices 
need to be generated to specify localized properties. 
7he present work is confined to receptor point properties, In some of 
the series studied, a few points in the molecular environment were 
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chosen as being of particular relevance to modes of drug-receptor 
interaction. If more compu ting time were available, the systematic 
probing of a whole mesh of points in the molecular environment is 
possible. This may provide a more reliable description of local 
interaction energies than that obtained from the single centre indices. 
MOREG searches a large set of independent variable to find regressions 
capable of explaining the variation in drug activity. It is possible to 
obtain some chance correlations when employing such a procedure 
(207j208). In the present work, the F test is' used to determine the 
statistical significance of regressions. A significance level of 99.9% 
associated with a given regression implies that there is one chance in a 
thousand of the given degree of correlation arising randomly. If a 
thousand indices are involved in simple regressions for correlation with 
drug activity, 
- 
then one correlation of significance level 99.9% or 
better can be expected to occur randomly. None of the regression 
analyses performed in the present work consider as many as two hundred 
independent variables. With two hundred independent variables,, there 
are 19900 distinct pairs of independent-variables. The. distinct pairs 
are not necessarily independent pairs, The intercorrelations rise when 
a given variable appears in many, pairs. The implications for the 
probability of observing chance two variable regressions are 
negligiable. 
In the present work, the author chose conformations' of molecules 
according to their stability in the ground statep in isolation from any 
other species. Future calculations might be based on the equilibriun 
geometry of the molecule in solution as determined by surrounding it 
with water molecules. These water molecules might affect the calculated 
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indices. In some cases, it' might be more relevant to attempt 
calculations on the molecule in a lipid environment. 
The set of electronic indices used in the present work can not be 
regarded as comprehensive. The local probing potential, which is only 
non-zero over one atomic zone, has limited relevance to real 
interactions. In some cases, it would be more relevant to take a 
potential wbich is non-zero and constant over the zone of a given atom 
and extending over neighbouring atom zones. Such a potential would 
generate new first and secondorder interactions. The first order term 
would be the magnitude of-the potential times the sum of the charges on 
the atom and its neighbours. The sun of charges is the index designed 
to account for coulombic interactions. 
In the present work four types of drugs have been studied, to observe 
the variation of the activity with structure on a quantitative basis. 
The electrostatic potential maps have been plotted for some of these 
drugs. These maps may be useful in understanding the mechanian of 
interaction with the receptor. QSAR's have been obtained by regression 
analysis. Some good correlations between drug activities and calculated 
indices have been observed, these may be useful in the design of new 
compounds, Communucation between the author and workers in theý drug 
industry might be useful, by making use of these regressions to predict 
more potent compounds, 
In conclusion the calculated indices described in the present work and 
additional related indices provide a description of molecular mechanisrn 
and the prediction of drug activity. The e. p contour and solid maps are 
valuable for the purpose of drug-receptor interactions. 
APPENDIX A 
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APPENDIX A 
Linear Regression Analysis 
For a given value, x. , of the independent variable x, the corresponding I 
value of y is observed, As well as being functionally dependent on x. 
the observed value of y is subject to additional random fluctuations. 
If the functional. dependence is assumed to be linear, then we have : 
Y. =a+ax. + E:. for i=1 to n 
-0 
yi Y6alt ': i (A, 1) 
wbere y 
cal : 
i: ao + a, x (A. 2) 
For a given set of data (x.,, y where i =' 1 to n,, the-' best estimates 
of a, and a', are determined by the least squares procedure i. e to find 
n 
the values which make c2a minimum . The corresponding expressions 
for these parameters, determined by calculus (209),, are 
-a., X2 Xy) X2 _ rjR 
2) (A. 3) 
and 
of a, and a', are determined by the least squares procedure i. e to find 
n 
the values which make c2a minimum . The corresponding expressions 
for these parameters, determined by calculus (209), are 
a, =(X xy -n 7y- )/(J. x; -n 32 ) (A. 
where all smmations are carried over the n data points 
and 
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If =I 
'9 =I 
When a, and a, are determined by (A. 3) and (A. 4)1 respectively, equation 
, (A. 2) is referred to as the regression of y on x. 
In the case for two independent variabes, x, and x2, where a linear 
dependence , is assuned : 
" a, + a, x, +a (A. 5) Ycal '4 2X2 
If each observed value'of y differs from y 
cal. 
by a random error cp 
then for a set of n observation, the value s of a,,, a, and a2 which makes 
IC2a minimum are given by : 
[( jx21 X2 _) 
2] jy +( JX ix 2) a, d =12Q X1X2 1X2 
j X2 -y -XI 2 
I Xly +( XXIX2 IXI -I X2 
I X12) I X2Y 
(A. 6) 
2) 1X 2_ (I X2)2 Xly aid I XIX2 I X2 -7 Xly X2 Iy+[n22 
x, 2 -nI X*IX2) X X2Y (A. 7) 
-a2d =( JXI YXIX2 - JX2 I X12) I y'+ (I xi I x2 -n I XIX2) 
I XiY +[ njxj 2_ (I XI )211 X2Y 
(A, 8) 
wher e 
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d2=n IX 2 X2 -n )2 +2 
JXI XX2 XXIX2 
22 
JXIX2 
Ix 
1)2 
1 X2 2_7 X12 ( JX2 )2 (A. 9) 
The standard deviation (s) of- points about a regression line is a 
measure of the spread (or dispersion) of the seto 
C2/(n (A. 10) 
where n is nunber of data points and m is the nunber of regression 
coefficients (+I for constant term) to be determined. (n-m) is the 
number of degrees of freedom to deviate. 
7be multiple correlation coef f icient (r) is given by : 
)2 '7 ") 2 
cal 
A value of r close to unity indicates a good regression line, while a 
value of zero indicates a random distribution of points. 7hus defined, 
r is the correlation coefficient between y and y. For the case of cal 
the simple regression, (A. 2). it is related to the correlation, r- XY 
between x and y: 
XY 
I 
wbere 
r. =11 
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r always takes the same sign as the slope, a 
XY 
The variance ratio, F, is defined by : 
y )2/ S2 (y n -m (A., 12) 
cal 
F is related to the Gaussian probability distribution in-a similar way 
to the t distribution. 
With reference to the simple regression (A. 2) . the estimated standard 
errors (s. e. ) in the intercept-and slopes are : 
s. e. (a JX2/ nX )2 S 
s. e. (a I)=S/ 
[j( X_X )2 ]1 
(A, 13) 
(A, 14) - 
With reference to the two variable regression (A. 5) . the estiMated 
standard errors in the intercept and coefficients are 
2 
s. e. (a 0) xI X2 XI X2 2ýIIs 
s. e. (a nX X2 X2)2 
)Is 
2 
. s. e. (a2) =, (nI x2 -(I xj] 
is /d 
where d is defined by equation (A. 9) 
(A. 15) 
(A, 16) 
(A, 17) 
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APPENDIX B 
Method of symetry adapted orbitals 
The M. 0's are expressed as linear combinations of-2n. A. 0's, where' n is 
the number of basis functions. The sýmetry of the system allows the 
A, O's to be divided into two sets, ý and 
(X#, YFZ) 2-- VOxtyrz) where V =lton (B, 1) p 
where (X, Y#Z) = (x,, ylz) T 
'where T is a diagonal transformation matrix? defined by the symmetry of 
the system. 
The Sý=etry adapted orbitalso and X of even and odd 
symmetriesp respectively (210), can be defined by 
X+1 //2- + (B. 2) 
X- 
P=1 
/Y"2-- (0P-01P) (B. 3) 
The one electron Fock operator -P , acts'upon a M. 0 to give the 
eigenvalue (equation 2,20), %ben applied to basis functions, the 
elements of the Fock Hami-Itonian matrix are generated 
ý 
11 F. 
1ev 
liv 
Fis constrained to have the symmetry appropriate to the molecular 
sYstem. 7he Fock matrix for the sýmmetry adapted orbitals can be 
el 
246 
Aefined as : 
liv 
(B. 4) 
-'and 
F 
11V < X7 11 
FI X- v> 
-Using equation (B, 2), equation (B. 4) becomes 
(B. 5) 
F+ 1/2 <>+ IF I>+< IF I> 
)IV vvV. 
+<> (B. 6) 
v 
Fran the symetry of the systeml it follows-that 
<>>=F (B. 7) 
and 
<v> 
11 
Fv> Fpv (B, 8) 
-ý 
F+ 
liv =F 11V +F PV II 
(B, 9) 
, 
Similarly using equation (B. 3), equation (B. 5) becomes 
F 
]IV 
=F 
11V -F liv 
(B, 10) 
Using equations (B. 2), ard (B. 3)0, (B. 7) and (B. 8)0, it follows 
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<X III Fl Xv>=<Xlll P IXV>=O (B. 11) 
In employing the CNDO/2 approximation in a given SCF. cycle, F 11V 
and 
F 
11VI 
are evaluated using equations (2.22) and (2.23).. It is then 
necessary to constitute F+ - and F- using equations (B. 9) and. (B. 10). 
The result of diagonalizing F+ - is a set of coefficients, D+ , relating 
the M, O's of even symmetry to the basis function of even symmetry 
n 
I D+ X+ (B. 12) 
P=l P1 v 
By applying equation (B. 2) in (B. 12),, we get : 
(B. 13) 
Expanding M. 0 as a linear combination of 2n A. 0's for'the case when 
the A. 0 function is related to A, O function 1 ... n) by a 
symmetry element of the system, the expression becomes 
nn +I 
C4 (B e 14) ýj = 
11 
11 cpi ý11 + 
lz--l 
Canparing equation (B. 13) with equation (B. 14), we observe that 
C'11i = cf. 42- IJ+ 
The result of diagonalizing P-is a set of coefficients D-F relating the 
M, O's of odd symmetry to the basis functions of odd symmetry : 
(B. 15) 
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Applying equation (B. 3) in (B. 15), we get : 
D7 x 1//7 (B, 16) 
Expanding M, O in terms of the origi, nal A. 0 basis gives 
n 
c+ Cl (B. 17) 
'pi P pi 11 
Ccmparing equation (B. 18) with equation (B, 17), we observe that : 
co (B, 18) 
The eigenvectors of both symetries can be then used to produce a 
complete set in ascending order of eigenvalue. It -is only necessary io 
store the coefficients of the unprimed A. 0's, the remainder being 
syrmnetry related. Using the relationships 
P 
liv = P, v 
pv pV 
and 
p 
11V I=Pp 
Jv=p 
v 
I,, =P 
V11 
I 
The nuTLber of bond order matrix elements which it is necessary to 
evaluate and store is reduce from (2n)2 to n(n+l). Similar equalities 
may be used in evaluating and storing the overlap, core Hamiltonian and 
Fock Hamiltonian matrix, referred to the A. 0 basis, 
The F 
11V and 
F,, 
Vj may 
then be redetermined from equations (2.14) and 
(2.15) to complete the SCF iterative cycle. 
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